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Abstract 
Interferons (IFNs) are an integral part of the innate immune response to viral 
infection. As well as possessing important anti-viral properties, they possess 
immunomodulatory, cytotoxic and anti-tumoural functions. As a consequence, the IFNs 
(mainly type I IFN) have been utilised for the treatment of human disease where they 
represent important therapies, most commonly in the treatment of chronic hepatitis C virus 
(HCV). However, there is now emerging evidence of an association between type I IFN drug 
treatment and the development of severe and at times irreversible pulmonary arterial 
hypertension (PAH). Through the course of this PhD I have investigated potential 
mechanisms for type I IFN induced PAH and have identified the IFN regulated protein IP10 
and the promitogen and vasoconstrictor endothelin (ET)-1 as important candidate 
mediators. It is well established that autoimmune conditions such as systemic sclerosis, 
where PAH is a common complication, are typified by chronic activation of type I IFN 
pathways. I have used the observation that IFN drug treatment may cause PAH, as a 
platform to hypothesise that endogenous type I IFN production may be important in the 
pathogenesis of systemic sclerosis associated PAH. Through a comprehensive approach 
utilising in vitro cell culture models, in vivo animal models of disease and patient samples, I 
have demonstrated that endogenously produced type I IFN plays an important role in the 
development of systemic sclerosis associated PAH and also idiopathic PAH. I have also gone 
on to show that other facets of the immune system appear to have pathogenic relevance in 
this devastating and still under-characterised disease. I conclude that a dysregulated and 
chronically active innate immune system plays a pathological role in the development of 
pulmonary arterial hypertension. 
 5 
 
Publications 
1. Proteome-wide analysis and CXCL4 in systemic sclerosis.  
George PM, Wort SJ, Mitchell JA.  
New England Journal of Medicine 2014 Apr 17;370(16):1561-2. 
 
2. Use of IFN beta in the treatment of ARDS: proceed with caution. 
George PM, Wort SJ, Mitchell JA.  
The Lancet Respiratory Medicine 2014 Apr, 2(4):e2. 
 
3. Evidence for the Involvement of Type I Interferon in Pulmonary Arterial 
Hypertension. 
George PM, Oliver E, Dorfmuller P, Dubois OD, Reed DM, Kirkby NS, Mohamed NA, 
Perros F, Antigny F, Fadel E, Schreiber BE, Holmes AM, Southwood M, Hagan G, Wort 
SJ, Bartlett N, Morrell NW, Coghlan JG, Humbert M, Zhao L, Mitchell JA  
Circulation Research 2014 Feb 14;114(4):677-88. 
 
4. Evidence that pulmonary vascular pathology explains the decline in lung function 
associated with interferon α based therapies for chronic hepatitis C virus. 
George PM, Mitchell JA.  
The Journal of Viral Hepatitis 2013 Aug;20(8):592. 
 
5. Endothelin-1 as a mediator and potential biomarker for interferon induced 
pulmonary toxicity.  
George PM, Cunningham ME, Galloway-Phillipps N, Badiger R, Alazawi W, Foster GR, 
Mitchell JA.  
Pulmonary Circulation 2012 Oct;2(4):501-4. 
 
 
 
 6 
 
6. Viral Toll Like Receptor activation of pulmonary vascular smooth muscle cells results 
in endothelin-1 generation; relevance to pathogenesis of pulmonary arterial 
hypertension.  
George PM, Badiger R, Shao D, Edwards MR, Wort SJ, Paul-Clark MJ, Mitchell JA. 
Biochemical and Biophysical Research Communications 2012 Oct 5;426(4):486-91. 
 
7. Pharmacology and therapeutic potential of pattern recognition receptors. 
Paul-Clark MJ, George PM, Gatheral T, Parzych K, Wright WR, Crawford D, Bailey LK, 
Reed DM, Mitchell JA. 
Pharmacology and Therapeutics 2012 Aug;135(2):200-15. 
 
8. Pharmacology and therapeutic potential of interferons. 
George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. 
Pharmacology and Therapeutics 2012 Jul;135(1):44-53. 
 
 
 
 
 
 
 
 
 
 7 
 
Presentations 
1. Type I Interferon – a novel inflammatory target in the treatment of pulmonary 
arterial hypertension 
Peter M George 
Oral presentation, 9th International Workshop on Cardiovascular Biology and 
Translational Medicine, Royal College of Physicians, London, Sep 2014 
 
2. Evidence for the involvement of interferon in the pathogenesis of pulmonary arterial 
hypertension; role of ET-1 and IP10. Peter M George, Eduardo Oliver, Peter 
Dorfmuller, Olivier D Dubois, Daniel M Reed, Nicholas S Kirkby, Frederic Perros, 
Fabrice Antigny, Elie Fadel, Benjamin E Schreiber, Alan M Holmes, Mark Southwood, 
Guy Hagan, Stephen J Wort, Nathan Bartlett, Nicholas W Morrell, John G Coghlan, 
Marc Humbert, Lan Zhao, Jane A Mitchell.  
Oral presentation, American Thoracic Society Meeting, San Diego, May 2014 
 
3. Evidence that Type I interferon drives pulmonary arterial hypertension. George PM, 
Oliver E, Schreiber BE, Holmes A, Southwood M, Wort SJ, Bartlett N, Dorfmuller P, 
Morrell NW, Coghlan G, Humbert M, Zhao L, Mitchell JA 
Oral presentation, British Thoracic Society meeting, London, Dec 2013 
 
4. Type I interferon mediates ET-1 and IP10, but not KC release induced by LPS in vivo. 
PM George, N Bartlett, NS Kirkby, JA Mitchell.  
Poster presentation, British Pharmacological Society meeting, London, Dec 2013 
 
5. Modulation of endothelin-1 release by TNFα and interferons from human lung 
alveolar type I versus alveolar type II epithelial cells. PM George, EF Smith, H 
Gashaw, TD Tetley, AJ Thorley, JA Mitchell. 
Poster presentation, British Pharmacological Society meeting, London, Dec 2013 
 
6. Novel insights into the mechanisms behind interferon induced pulmonary 
hypertension; relevance of ET-1 and IP10. PM George, P Dorfmuller, NS Kirkby, N 
 8 
 
Galloway-Phillipps, KA Veselkov, M Southwood, SJ Wort, W Alazawi, GR Foster, AM 
Holmes, BE Schreiber, JG Coghlan, NW Morrell, M Humbert, JA Mitchell. 
Poster presentation, 5th World Symposium on Pulmonary Hypertension, Nice, Feb 
2013 
 
7. Endothelin-1 is a potential biomarker and therapeutic target for lung toxicity 
associated with interferon. PM George, ME Cunningham, N Galloway-Phillipps, R 
Badiger, W Alazawi, GR Foster, JA Mitchell. 
Poster presentation, Keystone Symposium, Monterey, Sep 2012 
 
8. Pharmacology of IFNα and IFNλ in hepatocytes and human lung microvascular 
endothelial cells; relevance to pulmonary inflammation secondary to Hepatitis C 
therapy. George PM, Price JA, Gashaw H, Galloway-Phillips N, Mitchell JA. 
Poster presentation, British Pharmacological Society meeting, London, Dec 2012 
 
9. Effect of interferon α preparations on IP-10 and ET-1 release by human pulmonary 
artery smooth muscle cells. Badiger R, Manigold T, Gashaw H, Hinton HJ, Singer T, 
George PM, Hansel TT and Mitchell JA. 
Poster presentation, European Respiratory Society meeting, Amsterdam, Sep 2012 
 
10. Effects of type I, II and III interferons on endothelin-1 release by human pulmonary 
artery smooth muscle cells. George PM, Badiger R, Gashaw H, Galloway-Phillipps N, 
Hansel TT, Mitchell JA. 
Poster presentation, European Respiratory Society meeting, Amsterdam, Sep 2012 
 
 
 
 9 
 
Prizes 
1. GSK Sparrows national abstract and presentation competition winner – Dec 2014  
2. British Pharmacology Society Schachter Award – August 2014 
3. American Thoracic Society International Trainee Scholarship award – May 2014 
4. American Thoracic Society Pulmonary Circulation board scholarship – May 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10 
 
Abbreviations 
In order of mention in this thesis: 
IFN    Interferon 
PAH    Pulmonary arterial hypertension 
ET-1    Endothelin-1 
IP10    Interferon gamma inducible protein 10 
TLR    Toll like receptor 
PDC    Plasmacytoid dendritic cell 
JAK-STAT   Janus-kinase-signal transducers and activators of transcription 
PAMP    Pathogen associated molecular pattern 
PRR    Pattern recognition receptor 
TIR    Toll/interleukin-1 
LPS    Lipopolysaccharide 
TRIF    TIR domain-containing adaptor inducing IFNβ 
MyD88   Myeloid differentiation primary response gene 88 
NF-κB    Nuclear factor kappa B 
TNFα    Tumor necrosis factor alpha 
ISG    IFN-stimulated gene 
RIG-1    Retinoic acid-inducible gene 1 
RLR    RIG like receptor 
CNS    Central nervous system 
JAK    Janus kinase 
 11 
 
TYK    Tyrosine kinase 
STAT    Signal transducer and activator of transcription 
ISRE    IFN stimulated response element 
GAS    Gamma activation site 
SSc    Systemic sclerosis 
SLE    Systemic lupus erythematosus 
HCV    Hepatitis C Virus 
PEG    Polyethylene glycol 
SVR    Sustained virological response 
CML    Chronic myeloid leukaemia 
MS    Multiple sclerosis 
DLCO    Diffusing capacity of the lung for carbon monoxide 
IPAH    Idiopathic pulmonary arterial hypertension 
BMPR2   Bone morphogenetic protein 2 
CTD-PAH   Connective tissue disease associated PAH 
SSc-PAH   Systemic sclerosis associated PAH 
ECE    Endothelin converting enzymes 
ERA    Endothelin receptor antagonist 
PDE    Phosphodiesterase 
GMP    Guanosine monophosphate 
BNP    Brain natriuretic peptide 
HPASMCs   Human pulmonary artery smooth muscle cells 
 12 
 
CXCL4    Platelet factor 4 
DMEM    Dulbecco’s modified Eagle media 
FCS    Foetal calf serum 
Pen    Penicillin 
Strep    Streptomycin 
L-Glut    L-glutamine 
NEAA    Non-essential amino acids 
PBS    Phosphate buffered saline 
BSA    Bovine serum albumin 
HLF    Human lung fibroblast 
HMVEC   Human lung microvascular endothelial cell 
FBS    Foetal bovine serum 
RAGE    Receptor for advanced glycation end products 
NCS    Newborn calf serum 
SEM    Standard error of the mean 
ECMV    Encephalomyocarditis virus 
Poly(I:C)   Polyinosinic-polycytidylic acid 
ELISA    Enzyme linked immunosorbent assays 
HRP    Horseradish peroxidase 
TMB    Tetramethylbenzidine 
RT-PCR   Reverse-transcriptase Polymerase Chain Reaction 
RNA    Ribo-nucleic acid 
 13 
 
Ct    Threshold cycle 
RV    Right ventricle 
BW    Body weight 
IFNAR1-/- mice   Mice lacking a functional type I interferon receptor 
ANOVA   Analysis of variance 
ARDS    Acute respiratory distress syndrome 
DAMP    Danger associated molecular pattern 
PVR    Pulmonary vascular resistance 
mPAP    mean Pulmonary artery pressure 
6MWT    6 minute walk test 
PVOD    Pulmonary venous occlusive disease 
 
 
 
 
 
 
 
 
 
 14 
 
Table of Contents  
Declaration ............................................................................................................................. 1 
Dedication .............................................................................................................................. 2 
Acknowledgements ................................................................................................................ 3 
Abstract .................................................................................................................................. 4 
Publications ............................................................................................................................ 5 
Presentations ......................................................................................................................... 7 
Prizes ...................................................................................................................................... 9 
Abbreviations ....................................................................................................................... 10 
List of Figures ....................................................................................................................... 20 
List of Tables ........................................................................................................................ 24 
Chapter 1: Introduction ........................................................................................................... 26 
Foreword .............................................................................................................................. 27 
1.1 Interferons ................................................................................................................. 28 
1.1.1 Background and Introduction ............................................................................ 28 
1.1.2 Production and action of interferons ................................................................ 31 
1.1.3 Interferon Stimulated Genes (ISGs) ................................................................... 36 
1.1.4 Biological actions of interferons ........................................................................ 37 
1.1.5 Pharmacokinetics and therapeutic utility of interferons .................................. 38 
1.1.6  Side effects of interferon therapy ..................................................................... 43 
 15 
 
1.2 Pulmonary arterial hypertension .............................................................................. 46 
1.2.1  Pathophysiology of pulmonary arterial hypertension ....................................... 46 
1.2.2  Endothelin-1 and its role in pulmonary arterial hypertension .......................... 47 
1.2.3  Link between inflammation and pulmonary arterial hypertension .................. 49 
1.2.4  Link between viruses and pulmonary arterial hypertension ............................. 51 
1.2.5  Link between autoimmunity and pulmonary arterial hypertension ................. 51 
1.2.6  Link between CXCL4 and pulmonary arterial hypertension .............................. 52 
1.2.7 Link between IP10 and pulmonary arterial hypertension ................................. 52 
1.2.8  Link between interferon and endothelin-1 ....................................................... 53 
Chapter 2: General Methods ................................................................................................... 55 
2.1 Cell Culture ................................................................................................................ 56 
2.1.1  Cell cultures from primary sources .................................................................... 56 
2.1.2  Primary Cells ...................................................................................................... 61 
2.1.3  Cell Lines ............................................................................................................ 62 
2.1.4  Cell Counting ...................................................................................................... 65 
2.1.5  Assessment of cell viability using alamarBlue® .................................................. 65 
2.2 Organ Culture ............................................................................................................ 66 
2.2.1  Human pulmonary artery organ culture ............................................................ 66 
2.3 Reagents .................................................................................................................... 67 
2.3.1  Interferons, TNFα, TLR3 agonist and CXCL4 ...................................................... 67 
 16 
 
2.4 Enzyme linked immunosorbent assays (ELISAs) ....................................................... 69 
2.4.1  General principle of Sandwich ELISA ................................................................. 69 
2.4.2 IP10, IL-8, IFNλ and KC ELISAs ............................................................................ 71 
2.4.3  Endothelin-1 ELISA ............................................................................................. 76 
2.4.4  Interferon α ELISA .............................................................................................. 77 
2.4.5  Interferon γ ELISA .............................................................................................. 78 
2.4.6  Veriplex™ Cytokine array ELISA ......................................................................... 80 
2.4.7  MSD array ELISA ................................................................................................. 83 
2.5 Measurement of interferon receptor gene expression ............................................ 83 
2.5.1  Reverse-transcriptase Polymerase Chain Reaction (RT-PCR) ............................ 83 
2.6 Patient Studies .......................................................................................................... 86 
2.6.1  Measurement of IP10 and ET-1 from patients exposed to IFNα therapy ......... 86 
2.6.2 Studies in patients with pulmonary arterial hypertension ................................ 87 
2.6.3  Immunohistochemistry in lungs of patients with PAH ...................................... 87 
2.6.4  Western Blotting of IFNAR1 expression in patients with PAH .......................... 88 
2.7 Animal models of disease ......................................................................................... 88 
2.7.1  Chronic hypoxic mouse model of pulmonary arterial hypertension ................. 88 
2.7.2  Mouse model of acute LPS induced endothelin-1 release ................................ 89 
2.8 Statistics .................................................................................................................... 90 
Chapter 3: Response of human cells to interferons ................................................................ 91 
 17 
 
3.1 Rationale for Chapter 3 ............................................................................................. 92 
3.2 Summary of Methods for Chapter 3 ......................................................................... 94 
3.2.1  Isolation and culture of human cells and whole vessel ..................................... 94 
3.2.2  Cell treatments .................................................................................................. 95 
3.2.3  Gene expression ................................................................................................. 96 
3.2.4  Measurement of IP10, ET-1 and an array of cytokines ..................................... 96 
3.2.5  Measurement of cell viability ............................................................................ 97 
3.2.6  Analysis and Statistics ........................................................................................ 97 
3.3 Results ....................................................................................................................... 97 
3.3.1  Response of human cells to types I, II and III interferons.................................. 97 
3.3.2  Interferon receptor gene expression ................................................................. 98 
3.3.3  Response of human pulmonary artery to types I, II and III interferons ............ 99 
3.3.4  Cytokine release from pulmonary vascular cells and hepatocytes ................... 99 
3.3.5  Effect of the TLR3 agonist, Poly(I:C) on human pulmonary cells ....................... 99 
3.3.6  Effect of CXCL4 on human pulmonary vascular cells ....................................... 100 
3.3.6  Cell viability ...................................................................................................... 102 
3.4 Summary and Limitations ....................................................................................... 102 
3.4.1  Summary .......................................................................................................... 102 
3.4.2  Limitations........................................................................................................ 105 
3.5 Chapter 3: Data ....................................................................................................... 108 
 18 
 
Chapter 4: Interferon and pulmonary arterial hypertension in humans .............................. 146 
4.1 Rationale for Chapter 4 ........................................................................................... 147 
4.2 Summary of Methods for Chapter 4 ....................................................................... 149 
4.2.1 Measurement of endothelin-1 in patients treated with IFNα2a ..................... 149 
4.2.2 Assessment of patients with Systemic Sclerosis with and without PAH ......... 149 
4.2.3  Assessment of interferon receptors and TLR3 in patients with PAH .............. 149 
4.2.4  Analysis and Statistics ...................................................................................... 150 
4.3 Results ..................................................................................................................... 150 
4.3.1  Measurement of serum endothelin-1 in patients treated with IFNα2a .......... 150 
4.3.2  Serum IFN, IP10 and ET-1 levels in patients with SSc-PAH .............................. 151 
4.3.3  Correlations between IP10 and clinical characteristics in SSc-PAH patients .. 151 
4.3.4  Cytokine levels in patients with SSc-PAH, SSc no PAH and healthy controls .. 152 
4.3.5  Demographics of patients with SSc-PAH, SSc no PAH and healthy controls ... 152 
4.3.6  Interferon receptor expression in lungs of patients with PAH ........................ 152 
4.3.7  TLR3 expression in patients with pulmonary arterial hypertension ............... 153 
4.4 Summary and Limitations ....................................................................................... 153 
4.4.1  Summary .......................................................................................................... 154 
4.4.2 Limitations........................................................................................................ 156 
4.5 Chapter 4: Data ....................................................................................................... 158 
Chapter 5: Interferon and pulmonary arterial hypertension in animal models .................... 178 
 19 
 
5.1 Rationale for Chapter 5 ........................................................................................... 179 
5.2 Summary of methods for Chapter 5 ....................................................................... 181 
5.2.1  Mice lacking a functional type I interferon receptor ....................................... 181 
5.2.2  Chronic hypoxia-induced mouse model of pulmonary hypertension ............. 181 
5.2.2  Exogenous interferon treatment of mice ........................................................ 182 
5.2.3  Mouse organ culture model ............................................................................ 182 
5.2.4  Mouse model of acute LPS administration ...................................................... 183 
5.2.5  Analysis and Statistics ...................................................................................... 183 
5.3 Results ..................................................................................................................... 183 
5.3.1  Response of C57Bl/6J and IFNAR1-/- mice to chronic hypoxia......................... 183 
5.3.2  Response of C57Bl/6J mice to exogenous interferon administration ............. 184 
5.3.3 Response of C57Bl/6J and IFNAR1-/- mice to LPS ............................................. 185 
5.4 Summary and Limitations ....................................................................................... 185 
5.4.1  Summary .......................................................................................................... 185 
5.4.2  Limitations........................................................................................................ 186 
5.5 Chapter 5: Data ....................................................................................................... 190 
Chapter 6: General Discussion ............................................................................................... 199 
References: ............................................................................................................................ 215 
 
 
 20 
 
List of Figures 
Chapter 1: Introduction 
Figure 1.1: Types I, II and III interferon signalling pathways      35
     
Chapter 2: Methods 
Figure 2.1: Human pulmonary artery smooth muscle cells under light microscopy  57 
Figure 2.2: Human lung fibroblasts under light microscopy     58 
Figure 2.3: Human lung microvascular endothelial cells under light microscopy  60 
Figure 2.4: Human hepatocytes under electron microscopy     61 
Figure 2.5: A549 cells under light microscopy      62 
Figure 2.6: Human alveolar type I epithelial cells under light microscopy   63 
Figure 2.7: Human bronchial epithelial (Beas2B) cells under light microscopy  64 
Figure 2.8: Chemical equation of reduction of resazurin to resorufin in living cells  65 
Figure 2.9: Schematic of general principles of a sandwich ELISA    70 
Figure 2.10: Representative standard curves for IP10, IL-8, IFNλ and KC ELISAs  75 
Figure 2.11: Representative standard curves for ET-1, IFNα and IFNγ ELISAs  79 
Figure 2.12: Standard curves for 16-plex ELISA      80 
Figure 2.13: Standard curves for IFNα,IFNβ,IFNγ,IFNλ,IL-1α,IL-4,IL-5 and IL-6 ELISAs 81 
Figure 2.14: Standard curves for IL-8,IL-10,IL-12,IL-13,IL-15,IL-17,IL-23 & TNFα ELISAs 82 
 
Chapter 3: Response of human cells to interferons 
Figure 3.1: Response of human pulmonary artery smooth muscle cells to IFNs  108 
Figure 3.2: Response of human lung fibroblasts to IFNs     109 
Figure 3.3: Response of human lung microvascular endothelial cells to IFNs  110 
Figure 3.4: Response of A549 cells to IFNs       111 
 21 
 
Figure 3.5: Response of alveolar Type 1 (TT1) cells to IFNs     112 
Figure 3.6: Response of bronchial epithelial (Beas2B) cells to IFNs    113 
Figure 3.7: Response of human hepatocytes to IFNs      114 
Figure 3.8: Response of human hepatocytes to IFNs with Ribavirin    115 
Figure 3.9: Response of human pulmonary artery smooth muscle cells to type I IFN & 
Ribavirin           116 
Figure 3.10: IFN receptor gene expression in a number of pulmonary cell types normalised 
to expression in hepatocytes         118 
Figure 3.11: Response of freshly harvested human pulmonary artery to IFNs  119 
Figure 3.12: Response of human pulmonary artery smooth muscle cells to Poly(I:C) 124 
Figure 3.13: Response of human lung fibroblasts to Poly(I:C)    126 
Figure 3.14: Response of human lung microvascular cells to Poly(I:C)   128 
Figure 3.15: Response of human lung microvascular endothelial cells to Poly(I:C) – cytokine 
array; MSD (I)           129 
Figure 3.16: Response of human lung microvascular endothelial cells to Poly(I:C) – cytokine 
array; MSD (II)           130 
Figure 3.17: Response of A549 cells to Poly(I:C)      131 
Figure 3.18: Response of human alveolar type I (TT1) cells to Poly(I:C)   132 
Figure 3.19: Response of human bronchial epithelial (Beas2B) cells to Poly(I:C)  133 
Figure 3.20: Response of human pulmonary artery smooth muscle cells to CXCL4 with and 
without IFNα or TNFα – IP10 release        134 
Figure 3.21: Response of human pulmonary artery smooth muscle cells to CXCL4 with IFNα 
and TNFα – IP10 release         135 
Figure 3.22: Response of human pulmonary artery smooth muscle cells treated with CXCL4 
and Poly(I:C) – IP10 release         136 
Figure 3.23: Response of human pulmonary artery smooth muscle cells to CXCL4 with and 
without IFNα or TNFα – ET-1 release        137 
Figure 3.24: Response of human pulmonary artery smooth muscle cells to CXCL4 with IFNα 
and TNFα – ET-1 release         138 
 22 
 
Figure 3.25: Response of human pulmonary artery smooth muscle cells treated with CXCL4 
and Poly(I:C) – ET-1 release         139 
Figure 3.26: Human lung microvascular endothelial cells treated with CXCL4, IFNα, TNFα or 
Poly(I:C) – IP10 release         141 
Figure 3.27: Human lung microvascular endothelial cells treated with CXCL4, IFNα, TNFα or 
Poly(I:C) – ET-1 release         142 
 
Chapter 4: Interferon and pulmonary arterial hypertension in humans 
Figure 4.1: Serum ET-1 levels in HCV patients treated with IFNα2a    158 
Figure 4.2: Serum IP10, ET-1 and IFN levels in patients with SSc-PAH, SSc without PAH and 
healthy controls          160 
Figure 4.3: Serum BNP, IP10 and ET-1 levels measured in cohort of SSc-PAH patients 161 
Figure 4.4: Correlation between IP10 and ET-1 in SSc patients without PAH  162 
Figure 4.5: Correlation of IP10 with clinical and haemodynamic parameters in SSc-PAH 
patients           163 
Figure 4.6: Cytokine serum levels from SSc patients, SSc-PAH patients & controls (I) 164 
Figure 4.7: Cytokine serum levels from SSc patients, SSc-PAH patients & controls (II) 165 
Figure 4.8: IFNAR1 staining in lung tissue from an SSc-PAH patient & a healthy control 171 
Figure 4.9: IFNGR1 staining in lung tissue from an SSc-PAH patient & a healthy control 172 
Figure 4.10: IL28RA staining in lung tissue from an SSc-PAH patient & a healthy control 173 
Figure 4.11: IFNAR1 staining in lung tissue from an IPAH patient & a healthy control 174 
Figure 4.12: IFNAR1 expression in 2 distinct populations of SSc-PAH patient, IPAH patients 
and healthy controls          175 
Figure 4.13: IFNAR1 staining in lung sections from SSc-PAH patients with high & low 
expression            176 
Figure 4.14: TLR3 expression in patients with IPAH and healthy controls   177 
 
Chapter 5: Interferon and pulmonary arterial hypertension in animal models 
Figure 5.1: Effect of abolishing type I IFN signalling on murine responses to hypoxia  190 
 23 
 
Figure 5.2: Histological examples of pulmonary arteries from a C57Bl/6J mouse and an 
IFNAR1-/- mouse after exposure to chronic hypoxia      191 
Figure 5.3: Effect of abolishing type I IFN signalling on murine right ventricular responses to 
chronic hypoxia          192 
Figure 5.4: C57Bl/6J murine serum IP10 and ET-1 levels in response to treatment with 
human pegylated IFNα2b (Viraferon™) at 24 hours      194 
Figure 5.5: C57Bl/6J murine serum IP10 and ET-1 levels in response to treatment with 
human pegylated IFNα2b (Viraferon™) at 72 hours      195 
Figure 5.6: Mouse aorta and lung tissue treated with human and mouse IFNα in organ 
culture experiments          196 
Figure 5.7: Influence of type I IFN signalling on LPS induced ET-1 and IP10 release  197 
Figure 5.8: Influence of type I IFN signalling on LPS induced IFN and KC release  198 
 
Chapter 6: Discussion 
Figure 6.1: Summary of thesis findings providing a link between innate immunity, vascular 
dysfunction and PAH           213 
 
 
 
 
 
 
 
 
 
 24 
 
List of Tables 
Chapter 1: Introduction 
Table 1.1: The human interferons        30 
Table 1.2: The toll like receptors and their ligands      33 
Table 1.3: Summary of published cases of IFN induced pulmonary arterial hypertension 45 
 
Chapter 2: General Methods 
Table 2.1: Donor information for endothelial cells purchased from Lonza   60 
Table 2.2: Donor information for human pulmonary artery segments            66-67 
Table 2.3: Specific activities & relative potency of the types I, II and III IFNs used  68 
 
Chapter 3: Response of human cells to interferons 
Table 3.1: IFN receptor expression in pulmonary cell types and hepatocytes  117 
Table 3.2: Cytokine release from IFN treated pulmonary artery smooth muscle cells 120 
Table 3.3: Cytokine release from IFN treated human lung fibroblasts   121 
Table 3.4: Cytokine release from IFN treated human lung microvascular endothelial cells 122 
Table 3.5: Cytokine release from IFN treated human hepatocytes    123 
Table 3.6: Response of human pulmonary artery smooth muscle cells to Poly(I:C)  125 
Table 3.7: Cytokine release from human lung fibroblasts treated with Poly(I:C)  127 
Table 3.8: Cytokine release from human pulmonary artery smooth muscle cells treated with 
CXCL4            140 
Table 3.9: Cytokine release from human lung microvascular endothelial cells treated with 
CXCL4            143 
Table 3.10: The effect of treatments on cell viability as measured by alamarBlue®     144-145 
 
 
 25 
 
Chapter 4: Interferon and pulmonary arterial hypertension in humans 
Table 4.1: Serum IP10 levels in HCV patients treated with IFNα2a    159 
Table 4.2: Demographic details for SSc-PAH patients (I)     166 
Table 4.3: Demographic details for SSc-PAH patients (II)     167 
Table 4.4: Demographic details for patients with SSc but no evidence of PAH (I)  168 
Table 4.5: Demographic details for patients with SSc but no evidence of PAH (II)  169 
Table 4.6: Demographic details for healthy controls      170 
 
Chapter 5: Interferon and pulmonary arterial hypertension in animal models 
Table 5.1: Baseline cardiovascular physiology comparing wild type and IFNAR1-/- mice 193 
 
 
 
 
 
 
 
 
 
 
 
 26 
 
 
 
 
Chapter 1: Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 27 
 
Foreword 
The main focus of my thesis has been to investigate the action of the interferons 
(IFNs) on the pulmonary vasculature. This has stemmed from the emerging evidence linking 
type I IFN drug therapies with severe and at times irreversible pulmonary arterial 
hypertension (PAH). I have concentrated my research on two potential mediators of 
pulmonary vascular inflammation, endothelin-1 (ET-1) and interferon gamma inducible 
protein 10 (IP10; CXCL10) and have therefore introduced these in detail. Alongside ET-1, 
nitric oxide and prostacyclin play important roles within the vasculature to maintain 
homeostasis and vascular tone but investigation of these two mediators was beyond the 
scope of this body of work and so is not discussed. In this thesis I explore the potential for 
IFNs to induce PAH and investigate the possibility that endogenously produced IFNs in the 
context of chronic viral infection or autoimmune disease could also drive the development 
of PAH. Consequently in this introduction I will discuss the pathobiology of PAH and the 
proposed association between inflammation and PAH. On the whole, type I IFNs (IFNα and 
IFNβ), are generated after toll like receptor (TLR) 3, 7, 8 and 9 signalling. I have focussed on 
TLR3 activation of pulmonary vascular cells but also introduce the other TLRs and their 
signalling pathways.   
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1.1 Interferons 
1.1.1 Background and Introduction 
Type I Interferon 
Interferon (IFN) was first discovered in 1957 by Isaacs and Lindenmann who coined 
the term after discovering an “interference” effect on the growth of influenza virus during 
pioneering experiments on chicken egg chorioallantoic membranes using heat inactivated 
influenza virus (Isaacs and Lindenmann, 1957). However it was not until 20 years later that 
the protein was characterised when in 1978, Pestka and colleagues published the first 
descriptions of the purification of human IFNα and IFNβ. In these studies, leucocytes from 
healthy donors were incubated with Newcastle disease virus or Sendai virus and high 
performance liquid chromatography was performed on the conditioned media (Rubinstein 
et al., 1978; Rubinstein et al., 1979). Not long after this discovery, it became clear that the 
terms “interferon” referred to a family of proteins and numerous isoforms of IFNα were 
identified (Allen and Fantes, 1980). It is now known that 14 human genes comprise the IFNα 
family that encode 12 different IFNα proteins with one pseudogene and two genes coding 
for identical IFNα proteins (Foster and Finter, 1998). Importantly, of all the isoforms of IFNα, 
only IFNα2 is in therapeutic use. In contrast to IFNα, only one IFNβ has been discovered and 
it is encoded by a single gene with no introns and no polymorphisms. Another relevant 
distinction between these IFNs is that while IFNα is produced physiologically by 
conventional and plasmacytoid dendritic cells (PDCs), IFNβ is not produced in health 
requiring the activation of pathogen sensing signalling pathways which will be expanded 
upon later. Since the initial discovery of IFNα and IFNβ (together classed as type I IFNs), a 
further five IFNs have been characterised that are also classified as type I IFNs; IFNε, IFNκ, 
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IFNω, IFNδ and IFNτ. Of these, only IFNε, IFNκ, IFNω are found in humans but to date their 
roles have not yet been fully elucidated (Table 1.1) 
Types II and III IFN 
Two further IFNs subtypes have been found to play biologically relevant roles in 
humans. IFNγ (now classified as type II IFN) was first reported in 1965 as sharing similar 
properties to the IFN of Isaacs and Lindenmann but with a differing chemical identity 
(Wheelock, 1965). IFNγ is now known to contribute to innate immune pathways (along with 
type I IFN) but also has a unique role to play in adaptive immunity (Table 1.1); this will be 
discussed later. IFNλ (type III IFN) is the most recently characterised of the IFNs and was 
initially described by two groups in early 2003 (Kotenko et al., 2003; Sheppard et al., 2003). 
IFNλ1, IFNλ2 and IFNλ3 are known as IL-29, IL28A and IL28B respectively. IFNλ only shares 
20% homology with type I IFN having more in common with the IL-10 family of cytokines but 
owes its classification as an IFN to the shared intracellular pathways common to all three 
IFN subtypes including the Janus-kinase-signal transducers and activators of transcription 
(JAK-STAT) pathway (Fig. 1.1).  
 
 
 
 
 
 
 
 
 
 30 
 
Table 1.1 The human interferons 
IFN Primary Source Function Receptor 
Heterodimers 
Signal transduction 
pathways 
Type I 
 
Antiviral, 
Cytotoxic,  
Anti-tumoural,  
Pro-apoptotic,  
Anti-proliferative 
IFNAR1 
(Ubiquitously 
expressed) 
IFNAR2 
(Ubiquitously 
expressed) 
Jak1, Tyk1, Stat1, Stat2, 
Stat3, Stat4, Stat5, NF-κB, 
MAPK, p53 
IFNα 
Plasmacytoid 
dendritic cells 
(PDCs) 
Macrophages 
   
IFNβ 
All cells (inc.  
Dendritic cells 
Macrophages, 
Fibroblasts, 
Epithelial cells) 
   
IFNε Cells of CNS    
IFNκ Keratinocytes    
IFNω PDCs    
Type II  
Antiviral,  
Antibacterial,  
Anti-tumoural 
IFNGR1 
(Ubiquitously 
expressed) 
IFNGR2 
(Ubiquitously 
expressed) 
Jak1, Jak2, Stat1. Stat3, 
Stat5 
IFNγ 
NK Cells 
T cells 
Macrophages 
   
Type III  
Antiviral, 
Cytotoxic,  
Anti-tumoural,  
Pro-apoptotic,  
Anti-proliferative 
IL-10RB 
(Ubiquitously 
expressed) 
IL-28RA (Epithelial 
cells and 
hepatocytes) 
Jak1, Tyk2, Stat1, Stat2, 
Stat3, Stat5 
IFNλ1/2/3 
PDCs 
Epithelial cells 
Macrophages 
   
Table 1.1 The human interferons. CNS – central nervous system. 
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1.1.2 Production and action of interferons 
Broadly speaking, IFNs are produced in response to pathogen associated molecular 
patterns (PAMPs) binding to pattern recognition receptors (PRRs). These PAMPs are specific 
molecular motifs which are present on the surface of pathogens. The best characterised 
group of PRRs are the toll-like receptors (TLRs). There are 10 TLRs in existence with 
identified ligands for 9, each of which binds to a specific PAMP. Ligation of these receptors 
initiates signalling cascades that result in the expression of inflammatory mediators which 
are an integral part of host defences (Table 2.2). The TLRs are defined by differing amino-
terminal leucocine-rich repeat domains and a carboxy-terminal intracellular tail with a 
conserved region named the Toll/interleukin-1 (TIR) domain (Paul-Clark et al., 2012). Five of 
these ten human TLRs are capable of IFN induction; TLRs 3,7,8 and 9 which are intracellular 
and recognise viral PAMPs and TLR4 which is located on the cell surface membrane and is 
activated by bacterial lipopolysaccharide (LPS) and also various glycoproteins in viral 
envelopes. TLR9 responds to both bacterial and viral PAMPs. The remaining TLRs are on the 
cell surface and do not induce type I or type III IFNs but can induce IFNγ, responding to 
bacterial stimuli to induce pro-inflammatory cytokines such as IL-6.  
Depending on the specific receptor involved, the TLRs recognise either intra- or 
extracellular PAMPs and result in the activation of TIR domain-containing adaptor inducing 
IFNβ (TRIF) and/or myeloid differentiation primary response gene 88 (MyD88). TLR4 is the 
only TLR which can signal via both MyD88 and TRIF adaptor protein pathways. The canonical 
MyD88 pathway is characterised by nuclear factor kappa B (NF-κB) activation and via a 
series of carefully regulated steps with phosphorylation of a number of transcription factors, 
results in the rapid production of cytokines such as IL-6 and tumour necrosis factor alpha 
(TNFα). Via the alternative TRIF pathway, TLR4 ligation results in the induction of IFNβ in a 
 32 
 
MyD88 independent fashion (Sato et al., 2003) and is absolutely reliant on the presence and 
activation of the transcription factor IRF3 (Sakaguchi et al., 2003). Although TLR3 is 
expressed on the cell surface of fibroblasts, it localises to endosomes in conventional 
dendritic cells. The TLR3 signalling pathway is unique in that it is the only TLR that does not 
signal through the MyD88 adaptor protein, exclusively utilising the TRIF adaptor to induce 
the production of IFNβ. TRIF interacts with a number of kinases culminating in 
phosphorylation of IRF3. Phosphorylated IRF3 dimerises and translocates to the nucleus 
where it upregulates the production of IFNβ (Yoneyama et al., 1998). IFNβ acts via autocrine 
and paracrine routes to bind to the type I IFN receptor leading to the activation of a host of 
transcription factors which express IFNα (Fig. 1.1). This initiates a positive feedback loop 
which amplifies the type I IFN response and leads to the upregulation of a number of 
important IFN-stimulated genes (ISGs) including IFNλ (Hertzog et al., 2011).  The explanation 
for the fact that TLR4 activation induces IFNβ while TLR3 activation induces both IFNα and 
IFNβ is thought to be due to the fact that IRF7 is a pre-requisite to IFNα production and TLR4 
is unable to induce IRF7 (Noppert et al., 2007). All other TLRs signal via MyD88 pathways 
and as mentioned earlier, TLRs 7,8 and 9 induce type I IFN (both IFNα and IFNβ) via this 
adaptor protein. These TLRs are expressed by PDCs which when activated produce high 
levels of type I IFN.  Interestingly, unlike TLR3 and TLR4 where MyD88 is not involved in IFN 
production, TLR7, TLR8 and TLR9 require MyD88 to carry out this function.  
Another important type of PRR involved in viral sensing and IFN induction is the 
retinoic acid-inducible gene 1 (RIG-I) like receptor (RLRs) group. These are considered by 
many to play a less important role than the TLRs in IFN production and activation (Takeuchi 
and Akira, 2008) and as they are beyond the scope of this thesis, will not be discussed again. 
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Table 1.2 The toll like receptors and their ligands 
TLR PAMPs Pathogen Location 
TLR1/2 
(heterodimer) 
Pam3/Csk4 
Lipoteichoic acid 
Gram positive 
bacteria 
Cell membrane 
TLR2 Lipoteichoic acid  Mycoplasma Cell membrane 
TLR2/6 
(heterodimer) 
Zymosan,  
Macrophage activating 
lipopetide (MALP-2), 
Hyaluronan 
Mycoplasma 
Yeast 
Cell membrane 
TLR3 Poly(I:C) 
Double stranded 
RNA virus 
Intracellular 
TLR4 Lipopolysaccharide 
Gram negative 
bacteria 
Cell membrane 
TLR5 Flagellin Bacterial flagella Cell membrane 
TLR7 Imidazoquinolones Single stranded 
RNA virus 
Intracellular 
TLR8 
CL-075 
ssRNA40 
Single stranded 
RNA virus 
Intracellular 
TLR9 
Unmethylated CpG sequences in  
DNA (eg ODN2006) 
Bacterial and viral 
DNA 
Intracellular 
TLR10 Pam3CXK4, Zymosan 
Synthetic 
triacylated 
lipoprotein 
Cell membrane 
 
Table 1.2 Toll like receptors, their agonists and their cellular location 
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The IFNs are divided into three types based on their receptor subtypes (Table 1.1). 
Type I IFNs (IFNα and IFNβ) signal through the heterodimeric type I IFN receptor consisting 
of IFNAR1 and IFNAR2. Type II IFNγ signals through the type II IFN receptor which comprises 
IFNGR1 and IFNGR2 and type III IFNλ signals through the type III IFN receptor which is made 
up of IL10RB and IL28RA. While the type I and type II IFN receptors are ubiquitously 
expressed on most human cell types, the type III IFN receptor is more selectively expressed. 
The IL10RB subunit of the type III IFN receptor is widely expressed but the IL28RA subunit is 
found only on hepatocytes and epithelial cell surfaces and is not found on microvascular 
endothelial cells, adipocytes, fibroblasts or cells of the central nervous system (CNS) (Kelly et 
al., 2011). 
Binding of the IFNs to their receptors induces a conformational change to the 
intracellular aspects of the receptor molecules allowing access to and activation of Janus 
kinase (JAK) and tyrosine kinase (TYK). These then recruit, phosphorylate and activate signal 
transducer and activator of transcription (STAT) proteins. Types I and III IFNs have very 
similar signalling pathways activating JAK1 and TYK2 which phosphorylate STAT1 and STAT2 
respectively. Phosphorylated STAT1 and STAT2 then form a heterotrimer with the ISGF3p48 
transcription factor and translocate into the nucleus leading to the activation of ISGs within 
the IFN stimulated response element (ISRE) (Darnell et al., 1994; Fu et al., 1992). However 
type II IFN which is the hallmark of the Th-1 driven cellular immune response has a unique 
signalling mechanism. Binding to the type II IFN receptor activates JAK1 and JAK2 leading to 
phosphorylation of STAT1 homodimers. These phosphorylated STAT1 homodimers then 
upregulate production of a latent cytoplasmic factor which binds to the promoter region of 
the gamma activation site (GAS) (Fig. 1.1).  
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Figure 1.1 Types I, II and III interferon signalling pathways 
 
 Figure 1.1 Interferon signalling pathways.  
Abbreviations: IFNAR1 and 2 –Type I interferon receptor subunits, IL28RA and IL10RB – Type 
III interferon receptor subunits, IFNGR1 and 2 – Type II interferon receptor subunits, TYK – 
Tyrosine kinase, JAK –Janus kinase, ISGF3 – Interferon stimulated gene factor 3, IRF – 
Interferon regulatory factor, STAT – Signal transducer and activator of transcription, ISRE – 
Interferon stimulated response element, GAS – Interferon gamma activated sequence, ISG –
Interferon stimulated genes. Adapted from (George et al., 2012). 
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1.1.3 Interferon Stimulated Genes (ISGs) 
IFN signalling results in the induction of hundreds of ISGs each of which have 
different functions but with the broad aim of effecting antiviral functions (Schoggins et al., 
2011). In this thesis I have focused on two key ISGs, (i) IFNγ inducible protein 10 (IP10; 
CXCL10), which is one of the best characterised of the ISGs and (ii) endothelin (ET)-1, which 
is a mediator and therapeutic target of pulmonary hypertension. IP10 is the cognate ligand 
of CXCR3 which is a seven-transmembrane G protein-coupled receptor. IP10 is an antiviral 
and chemoatttractant that promotes the formation of lymphoid infiltrates commonly seen 
in viral infection and autoimmune disease (Baggiolini et al., 1997) by attracting T 
lymphocytes, monocytes and natural killer cells (Taub et al., 1993; Taub et al., 1995). The 
activation of T lymphocytes causes a sharp increase in IFNγ expression and release which 
initiates and maintains a protective Th1 immune response (Liu et al., 2000). Furthermore, 
IP10 which is secreted by endothelial cells (amongst other cell types such as neutrophils, 
monocytes, keratinocytes and fibroblasts) potentiates the adhesion of T lymphocytes to the 
endothelium (Taub et al., 1993). When chronically produced, IP10 promotes the migration 
of CXCR3+ cells to the lung (Hildebrandt et al., 2004; McAllister et al., 2006), has been 
shown to play a pathogenic role in the development of interstitial lung disease (Agostini et 
al., 2001) and increased levels have been found to correlate with the development of PAH 
(Eloranta et al., 2010). IP10 is considered by some to play a pathogenic role by perpetuating 
autoimmune diseases such as type I diabetes and systemic rheumatological conditions such 
as systemic sclerosis (SSc) and systemic lupus erthyematosus (SLE) (Antonelli et al., 2014). 
ET-1 is a promitogen and is one of the most potent vasoconstrictors known to man. It will be 
discussed in detail later in this introduction. 
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1.1.4 Biological actions of interferons  
Antiviral actions 
 The primary function of type I IFNs is to confer viral resistance to cells. Although the 
precise means by which this is carried out depends on the virus and the cell type involved, 
there are a number of different stages at which IFN regulated genes are able to influence 
viral replication such as viral entry, transcription, assembly and release. For example, IFN 
stimulation of some cells can result in the induction of enzymes that activate a latent 
ribonuclease named RNase L that degrades viral RNA (Zhou et al., 1993). Protein kinase R is 
induced by types I and III IFN to phosphorylate various substrates that block the translation 
of viral RNA (Lu et al., 1999). The IFN-induced Mx proteins form complexes with dynamin to 
disrupt activity of viral polymerases in so doing interfering with viral replication (Stranden et 
al., 1993). IP10 also plays a critical role in host defences to viral infection as discussed above.  
Anti-proliferative and Pro-proliferative actions 
 The IFNs can regulate many molecules involved in cell cycle control, for example by  
rapidly supressing c-Myc (Stranden et al., 1993). They can also inhibit growth factors 
(Iacopino et al., 1996) and play a role in myeloparesis by inhibiting bone marrow derived 
macrophage proliferation in response to colony stimulating factor I (Falk and Vogel, 1990). 
This effect on bone marrow activity has been exploited in the treatment of haematological 
malignancies and this will be discussed later. Of relevance to this thesis, it is worth noting 
that whilst having anti-proliferative actions on some cell types, the IFNs can also be pro-
proliferative. For example, type I IFNs, via IP10, can selectively recruit T cells, monocytes and 
natural killer cells to inflammatory sites thereby propagating inflammation (Farber, 1997).  
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Immunoregulation 
 Type I IFN can regulate many critical cells of both the innate and adaptive immune 
systems. It promotes natural killer cell mediated proliferation and cytotoxicity (Biron et al., 
1999), the survival of memory T cells (Rogge et al., 1998) and the generation of myeloid 
dendritic cells (Blanco et al., 2001). As mentioned above, IFNs via the induction of 
chemokines such as IP10 and CCL12 can also regulate the recruitment of immune cells to 
the site of inflammation. 
1.1.5 Pharmacokinetics and therapeutic utility of interferons 
Pharmacokinetics and effects of pegylation 
The immunomodulatory and antiviral capacity of the IFNs has been explored and 
harnessed for therapeutic use in patients. IFNγ is used as a drug treatment for the rare 
conditions osteopetrosis and chronic granulomatous disease and IFNλ is in phase III clinical 
trials for the treatment of hepatitis C virus (HCV). However the clinical utility of types II and 
III IFNs are dwarfed by that of the type I IFNs - IFNα and IFNβ. IFNα is still the corner stone 
of treatment for chronic HCV and IFNβ is the gold standard treatment for relapsing and 
remitting multiple sclerosis. Type I IFNs are poorly absorbed from the gastrointestinal tract 
and are therefore administered parenterally. The preferred route of administration is via the 
subcutaneous route and leads to a Tmax of approximately 7-10 hours with drug levels 
detectable for at least 30 hours. Given these pharmacokinetics, IFNα for the treatment of 
HCV used to be administered three times a week with variable drug levels and periods when 
concentrations were sub-therapeutic. This has been overcome by conjugation of IFNα with 
polyethylene glycol (PEG) which increases efficacy by increasing solubility and decreasing 
renal clearance and proteolysis. One clinical formulation of pegylated IFNα2a (PEG-IFNα2a; 
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Pegasus®) is mixture of 9 isomers of a 40kDa branched PEG conjugate (Foser et al., 2003). 
Another clinical preparation used to treat HCV is a PEG-IFNα2b (PegIntron®) which is a 
12kDa linear PEG conjugate with 14 different monopegylated positional isomers (Grace et 
al., 2001). Pegylation of INFα drugs has allowed once weekly dosing with more stable 
concentrations. A 20 kDa PEG modification with similar pharmacokinetics has been 
developed for IFNβ and is currently in clinical trials having passed phase I trials (Hu et al., 
2011).  
Therapeutic utility of IFNα 
As mentioned above, by far the commonest use of IFNα is in the treatment of 
chronic HCV (Hoofnagle et al., 1986) which is a blood borne virus that affects approximately 
170 million individuals worldwide (Lavanchy, 2009). It is a small single stranded RNA virus 
and 50-80% of infected individuals become chronically infected. Chronic HCV infection can 
lead to liver fibrosis, hepatocellular carcinoma and eventually death from liver failure (Seeff, 
2002). The current standard of care for chronic HCV is pegylated IFNα in combination with 
ribavirin, a purine nucleotide analogue which enhances IFN signalling (Feld et al., 2010). The 
aims of therapy include prevention of further hepatic fibrosis (and therefore risk of liver 
failure) and eradication of the infectious agent from the population pool. An undetectable 
viral load 6 months after the end of therapy, a sustained virological response (SVR), is 
considered by many as ‘cure’. In the landmark study of 1998, the combination of IFNα2b 
and ribavirin was shown to be efficacious in achieving SVR in about 40% of HCV infected 
individuals which was significantly better than IFNα2b alone (McHutchison et al., 1998). As a 
result, ribavirin is now always co-administered with IFNα preparations for the treatment for 
HCV. Ribavirin is a synthetic purine nucleoside analogue with a broad spectrum of anti-viral 
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activity. In its initial report, it was demonstrated to have activity against 16 DNA and RNA 
viruses in cell culture and in mice including HCV (Sidwell et al., 1972). It acts directly on 
viruses through multiple mechanisms simultaneously including disruption of viral replication 
and incorporation into the viral genome to cause mutation. It can also act as an 
immunomodulatory agent by enhancing host T-cell responses and although it has been 
hypothesised to enhance IFN signalling (Feld et al., 2010), this has never been clearly 
demonstrated. As previously introduced, there are two pegylayed IFNα preparations 
licenced for the treatment of HCV – IFNα2a (Pegasys®) and IFNα2b (Pegintron®). The basis 
for the use of pegylated IFNα preparations in combination with ribavirin are set out in large 
multi-centre studies demonstrating the clinical effectiveness of Pegintron® (Manns et al., 
2001) and Pegasys® (Fried et al., 2002) in achieving SVR. In fact, in the study by Fried and 
colleagues, Pegasys® was shown to be superior to Pegintron® in clearing HCV (Fried et al., 
2002).  
As well as performing antiviral functions, the IFNs also have inhibitory effects on cells 
undergoing malignant change (Table 1.1) (Takaoka et al., 2003). Consequently IFNα is 
considered by some the treatment of choice in the treatment of chronic myeloid leukaemia 
(CML) (Simonsson et al., 2011) and performs favourably when combined with the tyrosine 
kinase inhibitor Imatinib (Preudhomme et al., 2010). IFNα has also been used to treat 
melanoma (Mandelli et al., 1990) and is an established treatment for advanced renal cell 
carcinoma (Escudier et al., 2007).  
Therapeutic utility of IFNβ 
Multiple Sclerosis (MS) is a chronic neurological condition which is characterised by 
neuronal inflammation and demyelination. It manifests itself clinically in profound 
 41 
 
weakness, in-coordination, bladder dysfunction and ocular symptoms. The aetiology of MS 
is still poorly understood but viruses such as human herpes virus-6 have been implicated 
and this theory continues to be tested (Garcia-Montojo et al., 2011). The concept that 
viruses may play a role in the MS provided the initial rationale for the use of IFNβ in this 
debilitating disease but mechanistic studies have led to suggestions that it may work 
therapeutically through immunomodulatory actions on host pathways. For example it is 
hypothesised that IFNβ acts in a neuroprotective fashion by inhibiting the migration of 
activated T cells to into the CNS (Leppert et al., 1996). Randomised control trials of IFNβ in 
the treatment of relapsing remitting MS have shown efficacy by decreasing relapse rates 
(Group, 1995) and a 23% reduction in disease burden on MRI (Paty and Li, 1993). Its long 
term efficacy has recently been demonstrated in a longitudinal study (Ebers et al., 2010). 
More recently, it has been suggested that IFNβ may also have a role to play in the 
treatment of asthma. It has been demonstrated that primary bronchial epithelial cells from 
asthmatics produce less IFNβ than those from healthy controls when experimentally 
infected with rhinovirus (Wark et al., 2005). Furthermore, addition of IFNβ in vitro to 
rhinovirus infected primary bronchial epithelial cells from asthmatic patients results in 
suppression of viral replication (Cakebread et al., 2011). These studies have led to a double-
blind, placebo controlled Phase II clinical trial in which asthmatic patients were treated with 
a nebulised IFNβ 1a preparation (Drug name SNG001, ClinicalTrials.gov Identifier: 
NCT01126177) or placebo. This trial has recently been concluded but the results are yet to 
be published.  
Interestingly, although IFNα and IFNβ have a common receptor and signalling 
pathways, and should theoretically be interchangeable, they are not and IFNα has been 
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shown to be far superior in the treatment of HCV (Pérez et al., 1995) with a response to 
IFNα therapy of 57% compared to that of IFNβ therapy of 5%. This may be due to alternative 
pharmacokinetics or subtle differences in the molecular structure and/or signalling 
mechanics. 
Therapeutic utility of IFNγ 
As previously mentioned the therapeutic remit of IFNγ is very limited and has clinical 
utility in two rare conditions. Chronic granulomatous disease is an extremely uncommon 
hereditary disease that affects 1 individual per 1 million of the population and is 
characterised by chronic immunodeficiency to bacterial and fungal infection which leads to 
recurrent soft tissue and joint infections, abscesses and pneumonias. The only cure is 
through haematopoietic stem cell transplantation but one of the few therapies of proven 
benefit is IFNγ (Marciano et al., 2004) which is now recommended for lifelong infection 
prophylaxis. Osteopetrosis is another uncommon hereditary condition which has an 
incidence of 1 in 250,000 births where a failure of bone resorption leads to abnormal 
skeletal architecture and haematopoietic insufficiency. Through the stimulation of 
superoxide generation within osteoclasts, IFNγ has been shown to normalise osteoclast 
function in these patients (Madyastha et al., 2000) and provide clinically meaningful benefits 
(Key et al., 1995). 
Therapeutic utility of IFNλ 
Given the similarities in signalling between types I and III IFN, it has become 
apparent to investigators that IFNλ might be a potential therapy for the treatment of HCV. 
Preliminary studies have revealed that IFNλ-1 may possess comparable antiviral efficacy to 
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IFNα but with a propensity to a reduction in side effects (Muir et al., 2010) as discussed in 
detail below. The publication of studies comparing its performance in head to head studies 
with currently available therapies is still awaited. 
1.1.6  Side effects of interferon therapy 
General side effects 
IFNα and IFNβ share a similar side effect profile as would be expected given the 
similarities in their intracellular signalling pathways (Dusheiko, 1997; Walther and Hohlfeld, 
1999). A large placebo controlled trial of the use of IFNγ in the treatment of idiopathic 
pulmonary fibrosis demonstrated a similar side effect profile to that of type I IFN (Raghu et 
al., 2004) and so there is likely to be considerable overlap between the side effect profiles of 
types I and II IFN.  
The commonest side effects encountered with IFN therapy are influenza-like 
symptoms such as myalgia, fevers, lassitude and headache and affect up to 59% of exposed 
individuals (Marcellin et al., 2004; Raghu et al., 2004; Walther and Hohlfeld, 1999). Other 
important and well recognised side effects include depression, myelosupression and 
exacerbation of autoimmune disease (Manns et al., 2006), most commonly resulting in 
thyroiditis (Prummel and Laurberg, 2003). 
Pulmonary side effects 
As the therapeutic remit of the IFNs widens, the medical community is becoming 
increasingly aware of the rarer, potentially life threatening side effects. In particular, and of 
direct relevance to my thesis, toxic pulmonary side effects are becoming more apparent. 
Cough is an established complication of IFN therapy and affects up to 26% of patients 
 44 
 
receiving IFNα and ribavirin (Hézode et al., 2009). Pneumonitis has also long been 
associated with IFNα treatment (Kamisako et al., 1993) and has been estimated to have an 
incidence of 0.3% (Ji et al., 2010). In a recent study designed to examine the effect of IFNα 
preparations on lung function, of the 363 patients enrolled, 173 (48%) experienced a decline 
in lung function (diffusing capacity of the lung for carbon monoxide (DLCO)) of at least 15%. 
The majority of these patients were asymptomatic. Importantly, 6 months after 
discontinuation of treatment, this clinically significant decline in DLCO persisted in 57 (18%) 
of patients enrolled to the study (Foster et al., 2013). 
There is also emerging evidence that IFN therapy can have harmful effects on the 
pulmonary vasculature with case reports linking IFNα and IFNβ with PAH. The first of these 
was published in 2001 and reported an isolated case of reversible PAH after IFNα therapy 
for CML (Fruehauf et al., 2001). In subsequent years, more evidence has come to light of IFN 
related PAH and in a proportion of these cases it has been irreversible (Al-Zahrani et al., 
2003; Anderson et al., 2003; Dhillon et al., 2010; Jochmann et al., 2005; Ledinek et al., 2009) 
(Table 1.3). 
Most recently, Montani and colleagues presented data from a retrospectively 
collected series of patients under the care of the French National pulmonary hypertension 
registry in which a group of 12 patients with established PAH were treated with IFNα. 
Within 7 months of initiation of treatment, 10 of these patients experienced an increase in 
pulmonary vascular resistance of at least 20%. In half of these patents, withdrawal of IFNα 
resulted in return to baseline haemodynamics (Savale et al., 2013). 
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Table 1.3 Summary of published cases of IFN induced pulmonary arterial hypertension 
Study IFN 
Disease 
indication 
Length of IFN 
therapy before 
diagnosis 
Reversibility of PAH 
(Fruehauf et 
al., 2001) 
IFNα2b 
(unpegylated) 
CML 6 months Reversible 
(Anderson et 
al., 2003) 
IFNα 
(unpegylated) 
CML 38 months Reversible 
(Jochmann et 
al., 2005) 
IFNα2b 
(unpegylated) 
Melanoma 30 months Irreversible 
(Ledinek et 
al., 2009) 
IFNβ1b Multiple sclerosis 36 months 
Irreversible but 
improvement on 
stopping treatment 
(Dhillon et al., 
2010) 
Patient 1 
IFNα 
(unpegylated) 
HCV 12 months Irreversible 
(Dhillon et al., 
2010) 
Patient 2 
IFNα 
(unpegylated) + 
Ribavirin 
HCV 32 months Irreversible 
(Dhillon et al., 
2010) 
Patient 3 
IFNα 
(unpegylated) + 
Ribavirin 
HCV 10 months Irreversible 
(Dhillon et al., 
2010) 
Patient 4 
PEG-IFNα2b 
(Pegintron®) HCV 8 months Irreversible 
(Savale et al., 
2013) 
10 patients 
Pegylated IFNα 
prepatations HCV 
Average of 7 
months 
Irreversible in 5/10 
patients 
Table 1.3 Published case reports and case series of IFN induced pulmonary arterial 
hypertension 
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1.2 Pulmonary arterial hypertension 
1.2.1  Pathophysiology of pulmonary arterial hypertension 
Pulmonary arterial hypertension (PAH) is a rare but devastating disease which is 
defined as a mean pulmonary artery pressure of greater than or equal to 25mmHg at rest 
with a normal pulmonary capillary wedge pressure of less than or equal to 15mmHg. Its 
pathobiology is defined by aberrant cellular apoptosis and hyperproliferation within the 
three constituent cell types of pulmonary arteries – endothelial cells, smooth muscle cells 
and fibroblasts. Small branching vessels eventually become completely obliterated and the 
pathological hallmark is the finding of plexiform lesions. Additionally, vasoconstriction and 
in situ thrombosis play a key role in contributing to the obstruction of hundreds of 
thousands of distal pulmonary arterioles. Cumulatively, the effect is a rise in the pulmonary 
vascular resistance with consequent strain exerted upon the right ventricle. Death occurs 
from heart failure and untreated, survival is estimated at 2.8 years (D'Alonzo et al., 1991).   
True pre-capillary PAH (as opposed to pulmonary hypertension secondary to left heart 
disease, lung disease or thromboembolic disease) can be idiopathic (I)PAH, heritable with 
mutations in bone morphogentic protein 2 (BMPR2) being the most commonly observed or 
secondary to drugs such as the anorexigens; the cumulative incidence of these three 
aetiologies in 2009 was estimated to be 1.1 cases per million per year (Ling et al., 2012). 
With currently available therapeutic options, data from the French Network on Pulmonary 
Arterial Hypertension registry published in 2010, estimated 3 year survival for incident cases 
of idiopathic, familial and anorexigen-associated PAH at 54.9% (Humbert et al., 2010). HIV is 
strongly associated with PAH and the incidence of PAH in patients with HIV is over 2500 
times that of the general population (Sitbon et al., 2008). Connective tissue disease 
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associated PAH (CTD)-PAH is more common again and the incidence of PAH associated with 
Systemic sclerosis (SSc-PAH) is estimated to be as high as 286 cases per 1 million population 
(Hachulla and Coghlan, 2004). Importantly, data from two different registries found that 
outcomes for SSc-PAH appear to be worse than for PAH associated with other CTDs (Chung 
et al., 2010; Condliffe et al., 2009). The incidence of PAH in patients with SSc is 12 - 15% 
(Mukerjee et al., 2003) and at autopsy, up to two thirds of patients with scleroderma exhibit 
pulmonary vascular pathology (Stupi et al., 1986; Young and Mark, 1978) but as yet the 
mechanisms underlying pulmonary vascular disease related to SSc have not been 
elucidated.  
1.2.2  Endothelin-1 and its role in pulmonary arterial hypertension 
Central to the pathobiology of PAH is the pro-mitogen and potent endogenous 
vasoconstrictor, Endothelin-1 (ET-1) (Shao et al., 2011). The endothelins are a group of 
naturally occurring peptides consisting of ET-1, ET-2 and ET-3. Of the three subtypes, ET-1 is 
the most potent and highly concentrated within the lung. It is primarily produced by the 
vascular endothelium and is amongst the most potent vasoconstrictors known to man 
(Yanagisawa et al., 1988). It is encoded by a gene on chromosome 6 and its production is 
upregulated by a variety of factors including hypoxia (Yamashita et al., 2001), growth factors 
(Rodríguez-Pascual et al., 2003) and cytokines (Woods et al., 1999). Synthesis of the 21 
amino acid ET-1 peptide is a multistep process. Transcription of the EDN1 gene produces a 
further gene that encodes the 212 amino acid preproET-1 peptide (Yanagisawa et al., 1988). 
Proteases then cleave preproET-1 to a 38 amino acid peptide – big ET-1 (Blais et al., 2002). 
The final cleavage step of converting big ET-1 into active ET-1 is mediated by ET converting 
enzymes (ECE) (Emoto and Yanagisawa, 1995). ET-1 exerts its physiological effects by 
binding to two separate ET receptors, ETA and ETB. These seven-transmembrane G protein-
 48 
 
coupled receptors perform distinct roles depending on their location. Activation of ETA 
and/or ETB in vascular smooth muscle mediates vasoconstriction and proliferation whereas 
activation of ETB on vascular endothelial cells stimulates the release of the vasodilators nitric 
oxide and prostaglandin. ETB receptors on vascular endothelial cells also contribute to 
clearing circulating ET-1, 80% of which is cleared through the lungs. The binding of ET-1 to 
its receptor activates heterotrimeric G-proteins. These dissociate to trigger a cascade of 
events culminating in the activation of calcium channels of the sarcoplasmic reticulum to 
increase intracellular calcium and cell contraction. Diacyl glycerol and calcium bind to 
protein kinase C to modulate proliferation. In these ways, ET-1 is responsible for smooth 
muscle contraction and proliferation. 
In health, ET-1 is most abundantly released from the endothelial cell layer 
(Yanagisawa et al., 1988) where it acts to maintain vascular tone by offsetting the 
vasodilatory effects of nitric oxide and prostacyclin (Mitchell et al., 2008). However ET-1 is 
also released by smooth muscle cells. In PAH disruption to the endothelial cell layer allows 
the ingress of serum to the underlying vascular smooth muscle layer which promotes 
smooth muscle proliferation and muscularisation and consequently an increase in ET-1 
release. In a remodelled pulmonary artery, it is considered that the cumulative release of 
ET-1 from the vascular smooth muscle layer far exceeds that which is released from the 
single cell layer of the endothelium (Wort et al., 2001). It has previously been demonstrated 
that ET-1 is released from human pulmonary artery smooth muscle cells (HPASMCs) in 
response to serum factors and acts in an autocrine fashion to promote vascular remodelling 
(Wort et al., 2001). Circulating levels of ET-1 are raised in patients with PAH (Stewart et al., 
1991), gene expression is raised in the lungs of this patient group (Giaid et al., 1993) and 
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levels have been shown to correlate with a number of disease outcomes (Rubens et al., 
2001). Furthermore, ET-1 is a key therapeutic target. Bosentan is an oral dual ETA and ETB 
inhibitor which in large trials was shown to improve disease severity and functional capacity 
in PAH (Channick et al., 2001; Rubin et al., 2002). Despite the fact that blockade of ETB 
should theoretically lead to a reduction in the release of vasodilators such as NO and 
prostacyclin, the efficacy of dual ET receptor antagonists and those of selective ETA 
inhibitors are comparable. Ambrisentan is one such selective ETA inhibitor and has been 
shown to have clinical efficacy in PAH (Galiè et al., 2008). As a result of these and other 
randomised controlled trials, according to the recently updated treatment algorithm for 
PAH, endothelin receptor antagonists (ERAs) are approved as first line drugs for PAH as 
monotherapies or as part of combination strategies which include co-administration of the 
phosphodiesterase (PDE) V inhibitor Sildenafil and prostanoids such as Trepostinil (Galiè et 
al., 2013). PDE V inhibitors prevent the hydrolysis of cyclic GMP thereby prolonging the 
action of NO at the vascular smooth muscle layer and intravenously administered 
vasodilating prostanoids, indicated for patients in WHO functional class IV are the only 
therapy for PAH that have been shown to confer a mortality benefit (Barst et al., 1996). 
1.2.3  Link between inflammation and pulmonary arterial hypertension 
Although the aetiology of PAH is still not clearly established, many investigators 
consider inflammation to be a central protagonist (El Chami and Hassoun, 2012) and it is 
now widely accepted that dysregulated immunity plays a key role through the recruitment 
of inflammatory cells, remodelling of the pulmonary vasculature and promotion of 
autoimmune responses (Hassoun et al., 2009). The term ‘inflammation’ encompasses the 
process by which fluid, plasma proteins and white blood cells accumulate in response to 
local immune responses, injury or infection. This by-product of the innate immune response 
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contributes to the activation of the adaptive immune system where specific antigens are 
recognised and immunological memory is developed. When the adaptive immune system 
attacks the host, autoimmunity ensues and this is often a result of a pathological 
dyregulation in the interplay between the innate and adaptive immune system. The 
consequence of this is sustained cellular activation, chronic inflammation, tissue damage 
and remodelling. Interestingly a recent study has found that there is a high prevalence of 
anti-endothelial cell autoantibodies that recognise cell surface components in patients with 
PAH (Arends et al., 2010). 
 Infiltrating inflammatory cells such as macrophages, dendritic cells and lymphocytes 
have been identified in perivascular spaces as well as being closely associated with 
plexiform lesions in PAH (Savai et al., 2012; Voelkel et al., 1998). Furthermore, cytokines 
such as IL-1 and IL-6 which are known to have relevance to vascular inflammation are 
elevated in patients with PAH (Humbert et al., 1995) and raised levels are associated with a 
poorer prognosis (Soon et al., 2010). At the tissue level, lung histology from patients with 
PAH examined post mortem  demonstrate an increase in macrophages, mast cells, dendritic 
cells and T cells as compared to tissue from control subjects (Savai et al., 2012). As 
previously discussed, dendritic cells are the major source of type I IFN. They are also key 
antigen presenting cells linking the innate and adaptive immune systems and can be 
considered as key modulators of the entire immune process. Dendritic cells have been 
found to accumulate in the remodelled pulmonary vessels of patients with IPAH and in 
animal models of pulmonary hypertension and are therefore a potentially highly relevant 
immune cell type in this disease (Perros et al., 2007). 
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1.2.4  Link between viruses and pulmonary arterial hypertension 
Viruses have long been implicated in the development of PAH (Cool et al., 2011); the 
most widely accepted being HIV where the incidence of PAH is 1 in 200 - over 2500 times 
higher than that of the general population (Pellicelli et al., 2001; Sitbon et al., 2008; Speich 
et al., 1991). However, although viral proteins such as Nef (Marecki et al., 2006), gp120 
(Kanmogne et al., 2005) and Tat (Hofman et al., 1993) have been implicated in HIV 
associated PAH as being endothelial toxins, the virus itself has never been isolated in the 
lungs of affected individuals. There is chronic IFNα production in HIV (Lehmann et al., 2010; 
Zagury et al., 1998), likely a consequence of continued stimulation of plasmacytoid dendritic 
cells (Mandl et al., 2008) and a recent study of 116 HIV infected individuals found a positive 
correlation between IFN levels and pulmonary artery systolic pressure (Morris et al., 2012). 
These data serve to suggest that the relationship between viruses such as HIV and PAH may 
not be a direct one and could in fact be mediated by inflammatory or antiviral host defences 
such as the IFNs.  
1.2.5  Link between autoimmunity and pulmonary arterial hypertension 
 There has been a longstanding proposed link between autoimmunity and PAH but it 
is not yet known how the two are linked. Autoantibodies have been found in patients with 
PAH; 30 – 40% of patients with IPAH are antinuclear antibody positive (Yanai-Landau et al., 
1995) and yet the role of these in disease initiation or progression is not known. There is a 
female preponderance in IPAH which is common to all autoimmune diseases but this merely 
circumstantial evidence of a potential association. In patients with PAH, regulatory T cells 
are thought to be present in sufficient number but with altered function and it is 
hypothesised that due to the dysfunctional state of these cells, immune dysregulation 
occurs leading to the activation of pathogenic autoreactive B-cells and T-cells (Huertas et al., 
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2012). Most recently, tertiary lymphoid organs, which can generate pathogenic antibodies 
have been identified in the plexifom lesions of patients with PAH and these contain many 
characteristic “autoimmune cells” including dendritic cells, the master IFN producer (Perros 
et al., 2012).  
1.2.6  Link between CXCL4 and pulmonary arterial hypertension 
Platelet factor 4 (CXCL4; PF4) is a small CXC chemokine which comprises 2 to 3% of 
the protein content of activated platelets (Rollins, 1997). It is released from alpha-granules 
of activated platelets during platelet aggregation and by neutralising heparin-like molecules 
on endothelial cells, functions as an important pro-coagulant. It has been shown to 
upregulate pro-fibrotic cytokines (Romagnani et al., 2005) and stimulate the proliferation of 
regulatory T cells with defective suppressive function (Liu et al., 2005). It is also chemotactic 
for neutrophils and monocytes thereby having an important role in attracting inflammatory 
cells to sites of vascular damage (Deuel et al., 1981). In a recent proteome wide study, 
CXCL4 was found to be one of the most highly expressed genes in patients with SSc-PAH and 
in patients with SSc and raised serum levels of CXCL4 strongly predicted the future 
development of PAH (van Bon et al., 2014). In the same study, CXCL4 induced the release of 
ET-1 from endothelial cells and augmented TLR stimulated release of type I IFN from 
plasmacytoid dendritic cells.   
1.2.7 Link between IP10 and pulmonary arterial hypertension 
 In the literature, there exists conflicting evidence as to the relationship between IP10 
and the development of PAH although the majority of publications suggest that IP10 plays a 
pathogenic role. I have earlier introduced the in vitro evidence that IP10 is a pro-
inflammatory chemokine with effects at the level of the endothelium. In 2010, Eloranta and 
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colleagues demonstrated that raised serum levels of IP10 correlated with the presence of 
PAH in a cohort of SSc patients (Eloranta et al., 2010) while in the same year, Heresi and 
colleagues found the same to be true in a cohort of IPAH patients (Heresi et al., 2010); 
interestingly in this study, raised levels of IP10 appeared to be predictive of better 
outcomes. In 2012 a study of a heterogenous group of PAH patients (SSc-PAH, congenital 
heart disease associated PAH and IPAH) again demonstrated raised serum IP10 levels in PAH 
patients as compared to controls and lung immunohistochemistry revealed that in all three 
of these patient groups, the main source of CXCR3 was mononuclear cells infiltrating the 
vascular wall (Ross et al., 2012). In a study of patients with chronic thromboembolic 
pulmonary hypertension, IP10 along with CXCL4 were found to be detectable in the 
supernatant of pulmonary endarterectomy tissue and on immunohistochemistry, CXCR3 
(the receptor for both IP10 and CXCL4) was found to be highly expressed in affected areas of 
the lung compared with healthy lung tissue (Zabini et al., 2012). Interestingly, both IP10 and 
CXCL4 affected calcium homeostasis by depleting calcium stores in cultured endothelial cells 
and in vitro treatment with either IP10 or CXCL4 lead to endothelial dysfunction as 
measured by migration assays (Zabini et al., 2012). Most recently, in a cohort of IPAH 
patients, raised serum IP10 levels were shown to be associated with severity markers of 
right ventricular dysfunction including serum brain natriuretic peptide (BNP) as well as WHO 
functional class. 
1.2.8  Link between interferon and endothelin-1 
Over the past 20 years, Professor Mitchell’s group has pioneered the concept that 
ET-1 is an IFN responsive gene. It was first reported that IFNγ could stimulate release of ET-1 
from vascular smooth muscle cells in the late 1990s (Woods et al., 1998; Woods et al., 
1999). Later it was discovered more specifically that this was true of TNFα primed HPASMCs 
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(Wort et al., 2001) and that the mechanism of ET-1 induction was through STAT signalling 
and via NF-κB pathways (Wort et al., 2009). Most recently, work from the group has shown 
that therapeutically relevant pegylated IFNα preparations induce IP10 and ET-1 in human 
lung cells (Badiger et al., 2012). However these studies have focussed almost exclusively on 
in vitro models and the relevance to human disease is yet to be clarified. Furthermore, to 
date there has been no demonstration of ET-1 as an IFN related gene in an in vivo model of 
disease or in man. 
 
The central hypothesis of this thesis was therefore as follows; 
 “Interferon and more specifically, type I interferon drives the development of pulmonary 
arterial hypertension via an action of endothelin-1 or IP10” 
 
The main aims of this thesis were therefore as follow; 
1) To explore the activity of types I, II and III IFN in human pulmonary cells 
2) To explore the role of therapeutic IFNs in driving the production of ET-1 and IP10 in 
patients treated for HCV 
3) To assess the possibility that patients with PAH have raised levels of endogenously 
produced IFNs through a dysregulated immune system and that this has a 
pathological relevance  
4) To explore the role of IFN in an animal model of pulmonary hypertension thereby 
potentially understanding further the mechanisms underpinning the relationship 
between IFN, ET-1 and pulmonary vascular disease 
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2.1 Cell Culture 
2.1.1  Cell cultures from primary sources 
Human pulmonary artery smooth muscle cells (HPASMCs)  
Human pulmonary arteries from healthy segments of lung were obtained from 
patients undergoing pulmonary resection at the Royal Brompton and Harefield NHS 
Foundation Trust (Research Ethics Committee study number 02-081, sub-amendment 3). 
Under sterile conditions, pulmonary arteries were dissected open and the endothelium and 
adventitia denuded. The smooth muscle was cut into 3-4mm2 segments and placed in 25cm2 
(T-25) sterile flasks containing 15-20mls of Dulbecco’s modified Eagle media (DMEM) 
containing 15% heat-inactivated foetal calf serum (FCS), penicillin (Pen) (100U/ml), 
streptomycin (Strep) (100μg/ml), L-glutamine (L-Glut) (2mM) and 1% vol/vol 100xMEM non-
essential amino acids (NEAA) containing L-Alanaine, L-Asparagine, L-Aspartic acid, L-
Glutamic acid, Glycine, L-Proline and L-Serine (GIBCO Life Technologies, UK). Flasks were 
then placed in a humidified incubator at 37oC containing 5% CO2 and cells proliferated in this 
environment so that after 2-3 weeks, a confluent monolayer had grown out. Cells were then 
washed twice with phosphate buffered saline (PBS) followed by the addition of trypsin EDTA 
(0.5% trypsin, 0.2% EDTA) (100μl per cm2 flask area) in PBS. The plate was then returned to 
the incubator for 5 – 7 minutes until cells became free-floating. The trypsin was then 
inactivated by the addition of an equal volume of DMEM with supplementation as above. 
The total cell suspension was transferred to a 50μl Falcon tube and centrifuged for 5 
minutes at 190 x g at room temperature with slow braking. The surplus media was then 
removed, the cell pellet was re-suspended in 1ml of medium and cell density was calculated 
using a haemocytometer. Cells were then reseeded into sterile flasks (either 75cm2 (T-75) or 
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175cm2 (T-175)) in DMEM with 15% FCS and the above supplements in order to expand 
numbers.  
HPASMCs displayed characteristic “hill and valley” morphology when in a confluent 
monolayer (Fig. 2.1) and have been previously shown to be α-smooth muscle actin on 
immunofluorescence by others in the group.  
Figure 2.1 Human pulmonary artery smooth muscle cells under light microscopy. x40  and at 
approximately 60% confluence. Image reproduced with permission from Dr Rekha Badiger. 
 
For experiments described in this thesis, cells between passages 4 and 9 were used. 
Cells were seeded in 96 well plates at 8x103 cells per well (total volume of medium 200μl) 
for cell culture experiments and in 6 well plates at 1x105 cells per well (total volume of 
medium 3mls) for gene expression experiments. For cell culture experiments, 24 hours after 
plating cells in 96 well plates, the medium was changed to serum free DMEM containing 
Pen-Strep, L-Glut, NEAA and 0.1% bovine serum albumin (BSA) in order to ensure 
synchronisation of growth phase for all cells. On the day of treatment, serum free medium 
was replaced with DMEM containing 10% FCS and all other supplements and treatments 
were also made up in DMEM containing 10% FCS. After treatments, cells were re-incubated 
for 24hrs. Supernatants were then removed and stored at -20oC for future assays and cell 
viability experiments were performed and will be discussed later.  
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Human Lung Fibroblasts (HLFs) 
Human lung fibroblasts (HLFs) were cultured by collaborators from healthy segments 
of lung as previously described (Keerthisingam et al., 2001) and kindly given to me as 
growing cultures at passages 3-6 by Dr Andrew Thorley in Department of Lung Cell Biology, 
Imperial College London. HLFs were identified morphologically as demonstrating a branched 
cytoplasm surrounding an elliptical speckled nucleus and when in a confluent monolayer, 
tend to align in parallel clusters (Fig. 2.2). HLFs were also confirmed on 
immunohistochemistry by positive staining for vimentin. 
Figure 2.2 Human Lung Fibroblasts under light microscopy. x40 and at approximately 40% 
confluence. 
 
Cells were grown and passaged in 75cm2 or 175cm2 flasks with DMEM containing 
10% FCS, Pen-Strep, L-Glut and NEAA in an incubator with humidified air at 37oC and 
containing 5% CO2. Cells between passages 4 and 9 were used. Cells were trypsinised and 
plated in 96 well plates as for HPASMCs at a density of 8x103 cells per well (total volume of 
medium 200μl) for cell culture experiments and in 6 well plates at 1x105 cells per well (total 
volume of medium 3mls) for gene expression experiments. Cells were then incubated for 
24hrs in serum free DMEM containing Pen-Strep, L-Glut, NEAA and 0.1% BSA. Media was 
then replaced with DMEM containing 10% FCS, Pen-Strep, L-Glut and NEAA and cells were 
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treated. Again all treatments were made up in the DMEM with 10% FCS as above. Cells were 
incubated for 24hrs before supernatants were removed and stored at -20oC for future 
assays. The effect of treatments on cell viability was then assessed and will be discussed 
later. 
Human lung microvascular endothelial cell (HMVECs) 
Human lung microvascular endothelial cells (HMVECs) were purchased (Lonza, 
Walkersville, MD, USA) and used as per manufacturer instructions. Cells were removed from 
cryogenic storage and defrosted in a water bath.  Cells were then immediately transferred 
into a  T-25 flask containing specific Lonza EBM-2 basal medium supplemented with 25mls 
foetal bovine serum (FBS) (5%), 0.5ml human Endothelial Growth Factor, 2.0ml human 
Fibroblast Growth Factor-B, 0.5ml Vascular Endothelial Growth Factor, 0.5ml ascorbic acid, 
0.2ml hydrocortisone, 0.5ml Long R3-Insulin like Growth Factor-1, 0.5ml heparin and 0.5ml 
gentamycin + amphotericin. Cells were maintained in an incubator with humidified air at 
37oC and containing 5% CO2. Once confluent, cells were washed in HEPES buffered solution 
(200-400μl per cm2 flask area) and trypsin/EDTA (100μL per cm2 flask area) was added to 
the cells for 5 minutes. Once the cells had become free floating, an equal volume of trypsin 
neutralising solution was added. The cell suspension was transferred to a 50μL Falcon tube 
and centrifuged at 200 x g for 5 minutes at room temperature with slow braking. The cell 
pellet was re-suspended in 1ml of supplemented Lonza medium and cell density was 
calculated using a haemocytometer. Cells were then seeded onto sterile flasks at the 
following density as per manufacturer instructions to allow optimal growth conditions; for 
T-25 flask – 6.25x104 to 1.25 x105, for T-75 flask – 1.875x105 to 3.75x105 and for T-175 flask 
4.375x105 to 8.75x105. Cells demonstrated a typical cobblestone morphology (Fig. 2.3) and 
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were validated by the commercial supplier (Lonza) as staining positive for CD31 and von 
Willebrand Factor VIII and negative for α-smooth muscle actin.  
Figure 2.3 Human lung microvascular endothelial cells under light microscopy. x40 and at 
70% confluence. 
 
For all experiments in this thesis, cells between passages 4 and 9 were used. Cells 
were plated in 96 well plates at a seeding density of 7x103 cells per well (total volume of 
medium 200μl) for cell culture experiments and in 6 well plates at 1x105 cells per well (total 
volume of medium 3mls) for gene expression experiments. For cell culture experiments, 
plated cells were incubated for 24 hours and on the day of treatment, media was replaced 
with fresh Lonza media and treatments were made up in the same media. Cells were 
incubated with specific treatments for 24 hours before supernatants were removed and 
stored at -20oC for future assays. The effect of treatments on cell viability was assessed as 
discussed later. Cells from three different donors were used as per Table 2.1. 
Table 2.1 Donor information for endothelial cells purchased from Lonza 
Donor number: Details of donor: 
1. (7F4273) 19 year old male, non-smoker 
2. (6F3836) 41 year old male, non-smoker 
3. (148359) 22 year old male, smoker 
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2.1.2  Primary Cells 
Human Hepatocytes 
Human cryopreserved hepatocytes from deceased donors were purchased from 
Gibco Life technologies, UK and handled as per manufacturer instructions. Cells were 
validated by the commercial supplier through assessment of morphology, metabolic activity 
and genotype testing. Cells were thawed immediately on removal from liquid nitrogen 
storage in a water bath. On thawing, cells were added to a vial of Cryopreserved Hepatocyte 
Recovery Medium (proprietary medium Gibco Life technologies, UK) and centrifuged at 100 
x g for 10 minutes at room temperature. Cells were then re-suspended in 2ml 
Cryopreserved Hepatocyte Plating Medium (proprietary medium Gibco Life technologies, 
UK). Cells were then counted using a haemocytometer and cells were plated on collagen 
pre-coated plates at 5x103 cells per well in 100μl of Williams E maintenance media (Gibco 
Life technologies, UK) which contains 5% FBS, Dexamethasone in DMSO (1μM), Pen-Strep 
(1%), Human Recombinant Insulin (4μg/ml), L-Glut (2mM) and HEPES (15mM). Typical cell 
morphology was demonstrated (Fig. 2.4) 
Figure 2.4 Example of human hepatocytes under electron microscopy at x40 magnification 
taken from www.vitacyte.com 
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Cells were incubated for 2-4 hours to ensure adherence before the media was 
replaced with serum free Williams E maintenance media for 24 hours. At treatment, media 
was replaced by supplemented Williams E maintenance media containing 5% FBS and 
treatments were also made up in this media. Cells were then incubated for 24 hours before 
supernatants were removed and stored at -20oC for future assays. The effect of treatments 
on cell viability was then assessed and will be discussed later. 
2.1.3  Cell Lines 
Human adenocarcinoma alveolar epithelial cell line – A549 cells 
The human adenocarcinoma alveolar epithelial cell line, A549 cells, were purchased 
from ATCC (UK) and validated by the commercial supplier as expressing keratin by 
immunoperoxidase staining. Cells displayed typical morphological features (Fig. 2.5). 
Figure 2.5 Human adenocarcinoma alveolar epithelial cell line, A549 cells under x40 
magnification and at 65% confluence. 
 
Cells were grown in DMEM containing Pen-Strep, L-Glut, NEAA and 10% FCS and 
were also treated in media of the same composition without a need for a serum starvation. 
Cells were plated in 96 well plates at a density of 8x103 cells per well (total volume of 
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medium 200μl) for cell culture experiments and in 6 well plates at 1x105 cells per well (total 
volume of medium 3mls) for gene expression experiments. Cells were incubated for 24hrs 
before supernatants were removed and stored at -20oC for future assays. The effect of 
treatments on cell viability was then assessed and will be discussed later. 
Human alveolar type I epithelial cells 
Human alveolar type I epithelial (TT1) cells were isolated from sections of healthy 
lung from patients undergoing pulmonary resection as previously described (Kemp et al., 
2008) and were a gift from Elizabeth Smith in Professor Tetley’s group (Department of Lung 
Cell Biology, Imperial College London). Cells demonstrated a typical morphology (Fig. 2.6) 
and were validated by members of Professor Tetley’s group as staining positive for receptor 
for advanced glycation end products (RAGE) and Caveolin-1. 
Figure 2.6 Human alveolar type I epithelial cells under light microscopy. x10 and at 60% 
confluence. 
 
TT1 cells were cultured in DCCM media containing 10% newborn calf serum (NCS), 
Pen-Strep and L-Glut and seeded on 96 well plates at 8x103 cells per well. After 24 hours, 
the media was replaced with serum free DCCM containing Pen-Strep and L-Glut. After a 
further 24 hours, the media was replaced with fresh serum free DCCM containing Pen-Strep 
and L-Glut and treatments were made up in the same media. Cells were incubated with 
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treatments for 24 hours before supernatants were removed and stored at -20oC for future 
assays. The effect of treatments on cell viability was then assessed and will be discussed 
later. 
Human bronchial epithelial (Beas2B) cells 
Human bronchial epithelial (Beas2B) cells were purchased from LGC Standards (UK) 
and provided by Dr Elen Jazrawi (Department of Airways Diseases, Imperial College London) 
(Fig. 2.7). Cells were validated by the commercial supplier and shown to express keratins 
and SV40 T antigen. 
Figure 2.7 Human bronchial alveolar epithelial (Beas2B) cells under light microscopy. x40 and 
at 70% confluence. 
 
Cells were cultured in Keratinocyte-SFM supplemented with human recombinant 
Epidermal Growth Factor 1-53 and Bovine Pituitary Extract (Gibco Life technologies, UK) and 
after trypsinisation and cell counting as previously described, cells were seeded onto 96 well 
plates at 8x103 cells per well. After 24 hours, media was replaced with fresh supplemented 
Keratinocyte-SFM media and treatments were added. Cells were incubated with treatments 
for 24 hours before supernatants were removed and stored at -20oC for future assays. The 
effect of treatments on cell viability was then assessed and will be discussed later. 
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2.1.4  Cell Counting 
Cell suspensions were diluted in Trypan blue and were counted by haemocytometer 
to give a total number of cells/ml. Based on the required density for each individual cell 
type, cell suspensions were diluted in the appropriate media and then plated onto either 96 
or 6 well plates. 
2.1.5  Assessment of cell viability using alamarBlue® 
Cell viability was assessed using the alamarBlue® assay (Invitrogen, USA) which works 
on the principle that respiring cells are able to irreversibly convert the active ingredient of 
alamarBlue®, resazurin (blue) to resorufin (pink) (Fig. 2.8). The assay incorporates a 
fluorometric/colorimetric oxidation-reduction (REDOX) indicator. Unless stated in the text, 
no treatment had any effect on cell viability. 
Figure 2.8 Reduction of resazurin to resorufin in living cells 
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2.2 Organ Culture 
2.2.1  Human pulmonary artery organ culture 
Small segments of whole human pulmonary artery were obtained from lung tissue 
that was removed from patients undergoing pulmonary resection at the Royal Brompton 
and Harefield NHS Trust (Royal Brompton and Harefield local ethics committee, number 
09/H0708/72).  Full informed written consent was obtained from each patient. Tissue from 
4 donors was used (Table 2.2). The segments of pulmonary artery were finely dissected 
clean of connective tissue and were washed three times in sterile PBS containing Pen-Strep. 
Segments of pulmonary artery were then carefully cut into 3mmx3mm segments and placed 
into individual wells of a 96 well plate containing 300μl of DMEM with 10% FCS and 
supplemented with Pen-Strep, L-Glut and NEAA. Arterial segments were left to equilibrate 
for 24hrs in a humidified incubator at 37oC in an atmosphere of 5% CO2. Media was then 
replaced with fresh DMEM with 10% FCS and supplements as detailed above and 
treatments were added. Vessel segments were exposed to treatments for 48hrs before 
supernatants were removed and stored at -20oC for future assays.  
Table 2.2 Donor information for human pulmonary artery segments obtained from thoracic 
surgery at the Royal Brompton and Harefield NHS Trust, London, UK 
Donor Age Gender Smoking status Co-morbidity 
1 63 Male Non-smoker 
Lung 
adenocarcinoma 
2 66 Male Non-smoker 
Lung 
adenocarcinoma 
Bronchiectasis 
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3 69 Female Non-smoker 
Metastatic 
myxoid sarcoma 
4 75 Female 
Ex-smoker (40 
pack years) 
Lung 
adenocarcinoma 
 
 
2.3 Reagents 
2.3.1  Interferons, TNFα, TLR3 agonist and CXCL4 
Human Universal Type I Interferon which is an IFNα hybrid consisting of IFNαA and 
IFNαD (Product number 11200-1, PBL Interferon Source, USA) was the standard type I IFN 
used in this thesis and is referred to as IFNα forthwith. However, for the purpose of 
assessing the activity of human IFNα in mouse tissue, and because human Universal Type I 
IFN is known to retain some activity in mice, for one experiment (Fig. 5.6), recombinant 
human IFNα2 was used (Cat. No. 11105-1, PBL Interferon Source, USA) and response 
compared with mouse IFNα (Product number 12100-1, PBL Interferon Source, USA). 
Recombinant human IFNγ was purchased from R&D Systems, Abingdon, UK (Cat. No. 285-IF-
100). Recombinant human IL-29/IFNλ1 was purchased from R&D Systems, Abingdon, UK 
(Product number 1598-IL). An important aspect to consider when assessing the response of 
cells to different IFNs was the potential lack of parity in specific activities of each of the IFNs. 
The specific activity of IFNs is defined using encephalomyocarditis virus (ECMV) killing assays 
(Table 2.3).  Although these are assessed in different cell types making comparisons across 
the IFNs difficult, it provides some indication as to their relative potency. 
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Table 2.3 Specific activities and relative potency of the types I, II and III IFNs used in this 
thesis. Information obtained from the product insert sheets. 
IFN Supplier Assay used Specific activity 
Universal IFNα 
PBL Interferon 
Source 
A549 cells infected 
with ECMV 
3.2x108 units/mg 
IFNγ R&D Systems 
HeLa human cervical 
epithelial carcinoma 
cells infected with 
ECMV. The ED50 for 
this effect is typically 
0.15-0.75 ng/mL 
Not applicable – 
does not kill cells 
 
IFNλ R&D Systems 
HepG2 cells infected 
with ECMV 
2x106 units/mg 
 
In previous in vitro studies performed within the group, particularly those performed 
by Dr Rekha Badiger, IFN concentrations have been based on a mass per ml basis and not on 
specific activity. This is standard practice in the literature and may well reflect the fact that 
assays used to test specific activity are different for each IFN meaning that it is impossible to 
compare specific activities generated across different assays. Previous work from our group 
has demonstrated that to stimulate cells in culture, the optimum concentrations of both 
IFNα (Badiger et al., 2012) and IFNγ (Wort et al., 2000) are 10ng/ml. Based on information 
provided by the manufacturers of the IFNs (Table 2.3), I extrapolated that the specific 
activity of IFNλ is grossly less than that of IFNα by an order of 102. Therefore, in this thesis, 
unless stated otherwise I used a concentration of 10ng/ml for IFNα and IFNγ and 1000ng/ml 
for IFNλ.   
To determine the effect of pegylated human IFNα on mouse tissue, I used pegylated 
human IFNα2b (Viraferon™, Schering Plough, UK) at two concentrations; 80μg/kg and 
800μg/kg. In similar experiments, the effect of mouse IFNα was also assessed and for this 
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experiment, recombinant mouse IFNαA was used (Product number 12100-1, PBL Interferon 
Source, USA). 
For all experiments in which recombinant human TNFα was used, it was utilised at a 
concentration of 10ng/ml (Cat. No. 210-TA-010, R&D Systems, Abingdon, UK). The Toll-like 
receptor 3 (TLR3) agonist Polyinosinic-polycytidylic acid Poly(I:C) was purchased from 
Invivogen (USA). Human mammalian expressed CXCL4 was purchased from R&D Systems 
(UK) (Cat. No. 7989-P4-025). 
In all experimental cell culture conditions described in this thesis, drugs and 
treatments were made up in the same culture medium that cells were plated in. 
 
2.4 Enzyme linked immunosorbent assays (ELISAs) 
2.4.1  General principle of Sandwich ELISA 
ELISAs were used to measure the release of specific cytokines and hormones in 
supernatants from stimulated cells or vessels in culture as well as in serum from mice and 
humans. A general description of the principles of sandwich ELISAs are detailed below and 
in pictorial form (Fig. 2.9) and apply to all specific ELISAs used in this thesis. In the first step, 
a 96 well microplate is coated with a known quantity of capture antibody and left overnight. 
The next day, the plate is washed and any non-specific binding sites on the surface are 
blocked. The plate is then washed again and the sample is added to the plate so that any 
antigen present in the sample binds to the capture antibody. After a period of time, the 
plate is then washed to remove any unbound antigen and an enzyme linked secondary 
(“detection”) antibody is added. The plate is then washed to remove any unbound 
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conjugate and horseradish peroxidase (HRP)-conjugated strepatividin is then added. After 
one final wash step, substrate is then added; typically this is 3,3’,5,5’-tetramethylbenzidine 
(TMB) which is a chromogenic substrate that donates protons for the reduction of hydrogen 
peroxide to water by HRP causing a colour change from colourless to blue. The intensity of 
the colour change is proportional to the activity of HRP. The reaction is then stopped at a 
given time using an acid solution, often H2SO4 and this results in a colour change from blue 
to yellow. The concentration of antigen in the sample is determined by a plate reader which 
assesses the optical density of each well. Based on a standard curve in which there are 
known concentrations of the antigen, it is therefore possible to extrapolate the 
concentration of the protein of interest in the sample assayed. 
 
Figure 2.9 General principle of a sandwich ELISA (from www.epitomics.com) 
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2.4.2 IP10, IL-8, IFNλ and KC ELISAs 
Human IP10 and IL-8 and Mouse IFNλ and KC measurement in Cell culture and Organ culture 
supernatant 
Supernatants were thawed to room temperature prior to analysis. Repeated freeze-
thaw cycles were avoided. Human IP10 and IL-8 and mouse IFNλ and KC were measured in 
cell organ culture supernatants as well as mouse serum using very similar protocols and 
commercially available duoset ELISA kits in accordance with the manufacturer’s instructions 
(IP10 Cat No. DY266; IL-8 Cat No. DY208, IFNλ Cat No. DY1789B, KC Cat No. DY453; all R&D 
Systems, UK). In brief, the protocol for the IP-10, IFNλ and KC ELISAs are as follows. A 96 well 
microplate (R&D systems) was coated with mouse anti-human IP-10 antibody, rat anti-
mouse IL-28A/B or rat anti-mouse KC antibody and incubated overnight. The following day, 
the plate was washed 3 times with wash buffer consisting of PBS/Tween (Sigma), and then 
blocked using reagent diluent consisting of 1% BSA (Sigma) in PBS. Reagent diluent was 
corrected to pH 7.2 – 7.4 and passed through a 0.2μm filter prior to use and 150μl was 
added per well to block the ELISA plate for a minimum of one hour. A seven point standard 
curve was prepared using recombinant human IP-10, recombinant mouse IL-28B or 
recombinant mouse KC diluted in reagent diluent, using 2-fold serial dilutions and a highest 
standard of 2000pg/ml for IP10 and IFNλ and 1000pg/ml for KC. After one hour, the ELISA 
plate was washed again and 50μl of thawed cell culture supernatant or serum (diluted in 
reagent diluent if necessary) and standards, were added to the plate and left at room 
temperature for two hours. After another wash step, the plate was incubated for a further 
two hours with 50μl per well of biotinylated goat anti-human IP-10 antibody, biotinylated 
rat anti-mouse IL-28A/B or biotinylated goat anti-mouse KC; the detection antibody, again 
diluted to working concentration in reagent diluent. Following another wash step, 50μl of 
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streptavidin conjugated to horseradish peroxidise (Strep-HRP), diluted to the working 
concentration in reagent diluent, was added to each well and the plate incubated for 20 
minutes away from direct light. After a last wash step, 50μl of substrate solution (a 1:1 mix 
of H2O2 and tetramethylbenzidine (BD Biosciences, UK) was added to each well, and again 
the plate was incubated away from direct light for 20 minutes. In wells containing IP10, IFNλ 
or KC, there was a colour change in substrate from colourless to blue. Finally, the colour 
reaction was stopped after 20 minutes using 25μl of stop solution (2N sulphuric acid) per 
well, with a colour change in substrate from blue to yellow. The optical density of each well 
was then determined using a microplate reader (Dynex, Magellan Biosciences) set to 450nm 
with wavelength correction set to 570nm. The concentrations of IP10 or KC in each well 
were then calculated by interpolating the unknown values from the known values generated 
by the optical densities generated by the standard curve, using computer software that 
generated a four parameter logistic (4-PL) curve-fit (Graphpad Prism version 5.0). The limit 
of detection for the IP10 and IFNλ ELISAs was 31.25ng/ml and for the KC ELISA was 
15.6ng/ml. The following modifications were made for IL-8: the reagent diluent consists of 
0.1% BSA and 0.05% Tween 20 in Tris Buffered saline. Representative IP10 (Fig. 2.10 A), IL-8 
(Fig. 2.10 B), IFNλ (Fig. 2.10 C) and KC (Fig. 2.10 D) standard curves are shown below. 
IP10 measurements in human serum 
Serum was thawed to room temperature prior to analysis. For the measurement of 
IP10 in human serum, specific IP10 Quantikine ELISA kits which are validated for serum were 
used (Cat No DIP100; R&D Systems, UK). 75μl of assay diluent (RD1-56) was added to each 
well of a 96 well polystyrene microplate pre-coated with a mouse monoclonal antibody to 
IP10. Human IP10 Standard was reconstituted in 1ml of deionized water and allowed to sit 
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for a minimum of 15 minutes.  An eight point standard curve was prepared using the 
reconstituted human IP10 Standard diluted in Calibrator Diluent (RD6Q), using 2-fold serial 
dilutions and a top standard of 1000pg/ml. 75μl of serum (undiluted) or standard were 
added to the each well and incubated at room temperature for two hours. The plate was 
then washed four times with wash buffer (provided with kit). 200μl of IP10 Conjugate was 
then added to each well and the plate was then incubated at room temperature for a 
further two hours before the plate was again washed four times. Colour reagents A and B 
were then mixed together in equal volumes to make up the Substrate Solution and 200μl of 
this was then added to each well.  The plate was incubated for a further 30 minutes at room 
temperature away from direct light and in wells containing IP10, there was a colour change 
in substrate from colourless to blue. 50μl of Stop Solution was added to each well and the 
colour in wells changed from blue to yellow. The optical density of each well was assessed 
using a microplate reader (Dynex, Magellan Biosciences) set to 450nm with wavelength 
correction set to 570nm. The concentration of IP10 in each well was then calculated by 
interpolating the unknown values from the known values generated by the optical densities 
generated by the standard curve, using computer software that generated a four parameter 
logistic (4-PL) curve-fit (Graphpad Prism version 5.0). The limit of detection for the ELISA was 
7.8ng/ml. A representative human IP10 Standard curve is shown below (Figure 2.10 E). 
IP10 measurements in mouse serum 
Serum was thawed to room temperature prior to analysis. For the measurement of 
IP10 in mouse serum, a specific IP10 Quantikine ELISA kits which is validated for serum was 
used (Cat No. MCX100; R&D Systems, UK). 50μl of assay diluent (RD1N) was added to each 
well of a 96 well polystyrene microplate pre-coated with a mouse monoclonal antibody to 
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IP10. Mouse IP10 Standard was reconstituted in 2ml of Calibrator Diluent (RD5-17) and 
allowed to sit for a minimum of 5 minutes with gentle mixing.  A nine point standard curve 
was prepared using the reconstituted human IP10 Standard diluted in Calibrator Diluent 
(RD5-17), using 2-fold serial dilutions and a top standard of 2000 pg/ml. 50μl of serum 
(undiluted) or standard were added to the each well and incubated at room temperature for 
two hours. The plate was then washed four times with wash buffer (provided with kit). 
100μl of IP10 Conjugate was then added to each well and the plate was then incubated at 
room temperature for a further two hours before the plate was again washed four times. 
Colour reagents A and B were then mixed together in equal volumes to make up the 
Substrate Solution and 100μl of this was then added to each well.  The plate was incubated 
for a further 30 minutes at room temperature away from direct light and in wells containing 
IP10, there was a colour change in substrate from colourless to blue. 100μl of Stop Solution 
was added to each well and the colour in wells changed from blue to yellow. The optical 
density of each well was assessed using a microplate reader (Dynex, Magellan Biosciences) 
set to 450nm with wavelength correction set to 570nm. The concentration of IP10 in each 
well was then calculated by interpolating the unknown values from the known values 
generated by the optical densities generated by the standard curve, using computer 
software that generated a four parameter logistic (4-PL) curve-fit (Graphpad Prism version 
5.0). The limit of detection for the ELISA was 7.8ng/ml. A representative human IP10 
Standard curve is shown below (Figure 2.10 F). 
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Figure 2.10 Representative standard curves for IP10 (A, E, F), IL-8 (B), IFNλ (C) and KC (D) 
ELISAs 
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2.4.3  Endothelin-1 ELISA 
ET-1 measurements in cell culture supernatant, organ culture supernatant, human serum 
and mouse serum 
ET-1 in cell culture supernatant and serum (both mouse and human) were measured 
using a validated Quantikine ELISA kit (Cat No. SET100; R&D Systems, UK). Samples were 
thawed and repeated freeze thaw cycles were avoided. 150μl of assay diluent (RD1-105) 
was added to each well of a 96 well polystyrene microplate pre-coated with a rat 
monoclonal antibody to ET-1. ET-1 Standard was reconstituted in 1ml of deionized water 
and allowed to sit for a minimum of 15 minutes with gentle agitation. Calibrator diluent 
(RD5-48) was prepared by diluting 5ml into 20ml of deionized water to prepare a 25ml final 
volume.  An eight point standard curve was prepared using the reconstituted human ET-1 
Standard diluted in Calibrator Diluent (RD5-48), using 2-fold serial dilutions and a top 
standard of 50pg/ml. 75μl of sample (serum undiluted and cell culture supernatants at times 
diluted in Calibrator Diluent (RD5-48) as appropriate) or standard were added to the each 
well and incubated at room temperature for one hour. The plate was then washed four 
times with wash buffer (provided with kit). 200μl of ET-1 Conjugate was then added to each 
well and the plate was then incubated at room temperature for a further three hours before 
the plate was again washed four times. Colour reagents A and B were then mixed together 
in equal volumes to make up the Substrate Solution and 200μl of this was then added to 
each well.  The plate was incubated for a further 30 minutes at room temperature away 
from direct light and in wells containing ET-1 there was a colour change in substrate from 
colourless to blue. 50μl of Stop Solution was added to each well and the colour in wells 
changed from blue to yellow. The optical density of each well was assessed using a 
microplate reader (Dynex, Magellan Biosciences) set to 450nm with wavelength correction 
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set to 570nm. The concentration of ET-1 in each well was then calculated by interpolating 
the unknown values from the known values generated by the optical densities generated by 
the standard curve, using computer software that generated a four parameter logistic (4-PL) 
curve-fit (Graphpad Prism version 5.0). The limit of detection of the ELISA was 0.39ng/ml. A 
representative ET-1 Standard curve is shown below (Figure 2.11 A).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
2.4.4  Interferon α ELISA 
Mouse IFNα was measured in serum using a validated ELISA kit as per manufacturer 
instructions (Cat No.  42120-1; pbl assay science, USA). Samples were thawed and repeated 
freeze thaw cycles were avoided. A 7 point Standard curve was prepared using the 
reconstituted mouse IFNα Standard diluted in Sample Buffer, using 2-fold serial dilutions 
and a top standard of 400pg/ml. Antibody concentrate was diluted in the recommended 
volume of Concentrate Diluent. To each well 100μl of serum (all neat) or Standard and 50μl 
of diluted Antibody Solution was added to each well. The plate was incubated at room 
temperature for 1 hour and then transferred to the fridge to be incubated at 4oC for 20 – 24 
hours. The next day, the plate was washed four times with diluted Wash Solution and 100μl 
of diluted HRP Solution (diluted in a recommended volume of assay diluent) was added to 
each well and incubated at room temperature for 2 hours. The plate was then washed 4 
times and 100μl of TMB Substrate Solution was added to each well and incubated for 15 
minutes at room temperature and protected from direct light. After 15 minutes, 100μl of 
Stop Solution was added to each well. The optical density of each well was assessed using a 
microplate reader (Dynex, Magellan Biosciences) set to 450nm. The concentration of IFNα in 
each well was then calculated by interpolating the unknown values from the known values 
generated by the optical densities generated by the standard curve, using computer 
software that generated a four parameter logistic (4-PL) curve-fit (Graphpad Prism version 
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5.0). The limit of detection of the ELISA was 6.25ng/ml. A representative IFNα Standard 
curve is shown below (Figure 2.11 B). 
2.4.5  Interferon γ ELISA 
IFNγ in mouse serum was measured using a validated ELISA kit as per manufacturer 
instructions (Cat No. MIF100 R&D Systems, UK). Samples were thawed and repeated freeze 
thaw cycles were avoided. 50μl of assay diluent (RD1-21) was added to each well of a 96 
well polystyrene microplate pre-coated with a mouse monoclonal antibody to IFNγ. IFNγ 
Standard was reconstituted in 2ml of Calibrator Diluent (RD6-12) and allows to sit for a 
minimum of 5 minutes with gentle agitation. An eight point standard curve was prepared 
using the reconstituted mouse IFNγ Standard diluted in Calibrator Diluent (RD6-12), using 2-
fold serial dilutions and a top standard of 300pg/ml. 50μl of sample (undiluted) or standard 
were added to the each well and incubated at room temperature for two hours. The plate 
was then washed four times with wash buffer (provided with kit). 100μl of IFNγ Conjugate 
was then added to each well and the plate was then incubated at room temperature for a 
further two hours before the plate was again washed four times. Colour reagents A and B 
were then mixed together in equal volumes to make up the Substrate Solution and 100μl of 
this was then added to each well.  The plate was incubated for a further 30 minutes at room 
temperature away from direct light and in wells containing IFNγ there was a colour change 
in substrate from colourless to blue. 100μl of Stop Solution was added to each well and the 
colour in wells changed from blue to yellow. The optical density of each well was assessed 
using a microplate reader (Dynex, Magellan Biosciences) set to 450nm with wavelength 
correction set to 570nm. The concentration of IFNγ in each well was then calculated by 
interpolating the unknown values from the known values generated by the optical densities 
generated by the standard curve, using computer software that generated a four parameter 
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logistic (4-PL) curve-fit (Graphpad Prism version 5.0). The limit of the detection for the ELISA 
was 2.34ng/ml. A representative IFNγ Standard curve is shown below (Figure 2.11 C).  
Figure 2.11 Representative standard curves for ET-1 (A), IFNα (B) and IFNγ (C) ELISAs 
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2.4.6  Veriplex™ Cytokine array ELISA 
Veriplex Cytokine array  
The following cytokines were measured in cell culture supernatants and human serum by 
Multiplex ELISA array using the Veriplex™ Human Cytokine 16-plex ELISA; IFNα, IFNβ, IFNγ, 
IFNλ, IL-1α, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-15, IL-17, IL-23 and TNFα (Cat No. 
51510-1; pbl interferon source) by tebu-bio sciences, France. Reference Standard curve 
from the company performing the assay are provided below (Fig. 2.12). 
Figure 2.12 Standard curves for 16-plex ELISA provided by company (pbl interferon source, 
USA) 
 
Raw data was re-analysed by myself and representative standard curves are shown below 
(Figs. 2.13 – 2.14). 
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Figure 2.13 Representative standard curves for IFNα (A), IFNβ (B), IFNγ (C), IFNλ (D), IL-1α 
(E), IL-4 (F), IL-5 (G) and IL-6 (H) Veriplex ELISAs. 
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Figure 2.14 Representative standard curves for IL-8 (A), IL-10 (B), IL-12 (C), IL-13 (D), IL-15 
(E), IL-17 (F), IL-23 (G) and TNFα (H) Veriplex ELISAs. 
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2.4.7  MSD array ELISA 
MSD Cytokine Array 
Release of IFN-γ, IL-2, TNF-α, IL-1β, granulocyte-macrophage colony-stimulating 
factor (GM-CSF), IP-10, IL-12p70, IL-6 and IL-8 was measured in supernatants from cultured 
HMVECs using the Meso Scale Discovery® human proinflammatory 9-plex base kit (Meso 
Scale Discovery, Gaithersburg, MD, USA) by my colleague Mr Daniel Reed.   
 
2.5 Measurement of interferon receptor gene expression 
2.5.1  Reverse-transcriptase Polymerase Chain Reaction (RT-PCR) 
For measurement of IFN receptor gene expression, unstimulated cells under basal 
conditions were cultured on 6 well plates at seeding densities previously specified in this 
chapter. Ribo-nucleic acid (RNA) was extracted from cells using a commercial RNA extraction 
kit (Qiagen, USA) according to manufacturer instructions as detailed below. Cells were 
plated and incubated in a humidified incubator at 37oC with 5% CO2. After 24 hours, media 
was removed from the cells which were then washed three times with sterile PBS. 350µl of 
buffer RLT (containing guanidine salt and supplemented with a 1:100 dilution of β-
mercaptoethanol) was used to lyse the cells and inactivate RNases. Cell lysis was 
encouraged by agitation with a sterile cell scraper. The lysate was collected by pipette and 
transferred into a 1.5ml DNase / RNase free eppendorf where the sample was homogenised 
by passing through an 18-gauge needle and syringe 5 times.  
RNA was then extracted from homogenised cell lysates as detailed below. To the cell 
lysates, an equal volume of 70% ethanol was added and mixed in well. The combined 700µl 
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of sample was then transferred to an RNeasy® spin column (containing a silica matrix that 
the RNA adheres to) and centrifuged for 15 seconds at 10,000 x g in a microcentrifuge 
(BOECO, Germany). To eliminate contamination of the RNA sample with genomic DNA, a 
DNase treatment step was performed and following two further wash and centrifuge steps, 
RNA was eluted from the RNeasy® column using RNA-free H20. The concentration and purity 
of RNA in each sample was assessed by UV spectrophotometry (Nanodrop ND 1000, 
Thermo). A ratio of absorbance readings at 260nm and 280nm (A260:A280) was assessed and 
a ratio of between 1.9 and 2.1 was regarded as pure RNA. Eluted RNA was stored at -80oC 
prior to further analysis. 
Measurement of IFN receptors in a range of human cell types 
RNA was obtained from cultured cells as described above and converted to 
complimentary DNA (cDNA) using SuperScript II reverse transcriptase (Life Technologies, UK) 
and oligo(dT) primers (Life Technologies, UK). Briefly, the volume of sample required to give 
250ng of RNA was transferred into an RNase free eppendorf and added to it was 1µl of Oligo 
dT (a short sequence of deoxy-thymine nucleotides), 1µl of 10mM deoxynucleotide 
triphosphates (dNTP). The sample was made up to 20µl with RNase free H20 and transferred 
to a Thermocycler to be heated to 65oC for 5 minutes. The sample was then transferred to 
ice for 1 minute and to it, 1µl of Reverse Transcriptase and 4µl of Reverse Transcriptase 
Buffer was added. The 25µl sample was then transferred back to the Thermocycler and run 
to the following protocol; 25oC for 5 minutes, 50oC for 45 minutes and then 70oC for 15 
minutes. Following the reverse transcription step, the cDNA sample was kept on ice or 
frozen at -20oC if not proceeding directly with PCR.  
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IFN receptor gene expression levels in HPASMCs, HLFs, HMVECs, A549 cell and 
human hepatocyte samples were measured using TaqMan hydrolysis probes labelled with 6-
carboxyfluorescein. The following probes were used: IFNAR1 (probe ID: Hs01066116_m1), 
IFNAR2 (probe ID: Hs00174198_m1), IFNGR1 (probe ID: Hs00988304_m1), IFNGR2 (probe 
ID: Hs00194264_m1), IL10RB (probe ID: Hs00175123_m1), IL28RA (probe ID: 
Hs00417120_m1) and 18S (probe ID: Mm03928990_g1). All probes were purchased from 
Applied Biosystems, UK. Relative quantitative PCR of IFN receptors was performed using an 
RotorGeneQ instrument (Corbett Robotics, UK) and ABsolute qPCR ROX master mix (Thermo 
Scientific, UK) with IFN receptor gene expression in each cell type examined and compared 
to 18S expression. For each sample (run in duplicate), the following was pipetted into 
nuclease-free 0.1ml PCR tubes; 2µl of cDNA, 0.5µl of the relevant TaqMan probe, 5µl of 
TaqMan® Universal Master Mix II and 2.5µl of RNase free water. Tubes were capped then 
loaded into the instrument with the following programme: 15 minutes at 95oC for Taq 
activation followed by 40 cycles (95oC for 15 seconds and 60oC for 1 minute) for 
amplification. Threshold cycle (Ct) values were obtained for each gene of interest and are 
defined as the number of cycles required for the fluorescent signal to cross the threshold 
(exceed background level). The Ct value increases with a decreasing amount of template and 
so provides a relative measure of concentration of the target in the PCR reaction. Fold 
changes in gene expression were calculated using the ΔΔCt method. In brief, the Ct of the 
housekeeping gene (18S) was subtracted from the Ct of gene of interest to give a ΔCt of the 
gene of interest. As human hepatocytes are known to expresses the receptors for all three 
subtypes of IFN receptor (George et al., 2012), expression of IFN receptors in the pulmonary 
cell types was normalised to expression in hepatocytes. To this end, the ΔΔCt was calculated 
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by subtracting the ΔCt of the gene of interest in the cell type of interest from the ΔCt of the 
gene of interest in hepatocytes.  
 
2.6 Patient Studies 
2.6.1  Measurement of IP10 and ET-1 from patients exposed to IFNα therapy 
In collaboration with Professor Graham Foster’s group at Queen Mary, University of 
London, I identified 16 patients infected with HCV in whom serum had been stored (for 
other research studies) prior to commencement of pegylated IFNα2a therapy and then at 
designated time point over the course of treatment. I chose to measure serum levels of IP10 
and ET-1 (R&D Systems, UK) at the following time points; pre-treatment, day 1 post 
treatment, day 8, week 4, week 8 and week 24. In this way the effect of IFNα therapy on 
IP10 and ET-1 induction over a 6 month period could be assessed. I handled serum in a 
designated Category 3 laboratory in the Blizzard Institute, Queen Mary University of 
London. Hepatitis C viral load had been measured by the hospital laboratory at these time 
points and so the potential effect of viraemia could be explored. Written and verbal consent 
was obtained by the recruiting team at the time of enrolment to the study and with local 
research ethics committee approval. The inclusion criteria were as follows; 
 Previously untreated genotype I HCV 
 Age between 18 and 65 
 Absence of other viral infection 
 No evidence of cirrhosis on a recent biopsy 
 6 months of unbroken IFNα therapy with no interruptions of treatment 
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2.6.2 Studies in patients with pulmonary arterial hypertension 
Twenty-eight patients with systemic sclerosis (SSc) and 35 patients with systemic 
sclerosis associated PAH (SSc-PAH) proven on right heart catheterisation were recruited 
from two specialist centres – the Royal Free Hospital, London (REC ref 6398) and Papworth 
Hospital Research Tissue Bank (REC ref 08/H0304/56). Healthy controls were recruited from 
the Royal Free Hospital, London and the Royal Brompton Hospital, London. Serum was 
analysed for ET-1, IP10 (R&D Systems, UK) and serum IFNs and related cytokines (tebu-bio 
sciences, France). Clinical data from each patient were collected and correlations were 
sought for relationships between serum mediators and clinical parameters. Patients with 
pulmonary hypertension secondary to lung disease or left heart disease were excluded. 
Patients with SSc but no evidence of PAH were identified on the basis of echocardiographic 
studies which were non suggestive of PAH. 
2.6.3  Immunohistochemistry in lungs of patients with PAH 
Lung tissue immunohistochemistry was performed by Dr Peter Dorfmuller (INSERM 
U999, France). IFNAR1, IFNGR1 and IL28RA expression was studied in the lungs of patients 
with SSc-PAH, IPAH and healthycontrols. Briefly, immunohistochemistry was performed on 
3μm-thick sections of paraffin embedded tissue. After routine preparation and pressure 
cooker unmasking at pH8 (Electron miscroscopy science, Hatfield, USA) and blocking with 
horse serum, slides were processed with rabbit anti-IFNAR1, anti-IFNGR1, anti-IL28RA or 
anti-TLR3 antibodies (Sigma-Aldrich, Lyon, France). According to manufacturer instructions, 
biotinylated horse anti-rabbit, streptavidin-alkaline phosphatase conjugate and Vector Red 
Substrate (Vector laboratories, USA) were used for primary antibody detection. Controls 
used for this antibody included omission of the primary antibody and substitution of the 
primary antibody by rabbit IgG. 
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2.6.4  Western Blotting of IFNAR1 expression in patients with PAH 
Western blotting experiments were performed by Dr Peter Dorfmuller (INSERM 
U999, France). Briefly, human lung samples from healthy controls, and patients with IPAH or 
SSc-PAH were prepared in lysis buffer. Total protein lysates (40μg) were separated on SDS-
PAGE and transferred to a nitrocellulose membrane. After blocking, membranes were 
incubated with primary antibodies; rabbit anti-IFNAR1 polyclonal antibody (LifeSpan 
BioSciences) and mouse monoclonal antibody against βActin (Sigma, France). Blots were 
incubated with HRP-conjugated goat anti-mouse (Cell Signalling, USA) or with HRP-
conjugated goat anti-rabbit (Cell Signalling, USA). Antibodies were revealed using ECL 
reagents (PerkinElmer, USA) and ImageJ software was used to quantify the level of protein 
expression. 
 
2.7 Animal models of disease 
All animal studies were conducted in accordance with UK Home Office Animals 
(Scientific Procedures) Act 1986 and institutional guidelines. Personal licence number PIL 
70/25012. 
2.7.1  Chronic hypoxic mouse model of pulmonary arterial hypertension 
Male C57Bl/6J mice (Charles River, Margate, UK) and male mice lacking a functional 
type I IFN receptor (IFNAR1-/- on a C57Bl/6J background), aged 8-10 weeks old and weighing 
≈20 grams were placed in a normobaric hypoxic chamber (FiO2 10%) for 14 days (n=8 per 
group) to induce pulmonary hypertension. IFNAR1-/- mice were a kind gift by Dr Nathan 
Bartlett (Imperial College, London) and have an established genotype and phenotype as 
recently published (Bartlett et al., 2012). It is well accepted that there can be subtle genomic 
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and phenotypic differences between strains of wild type mice (eg C57Bl/6J). With this in 
mind littermate control mice would have been the optimal control to use. Unfortunately 
littermate control mice were not available and beyond the scope of my fellowship funds to 
generate in house and so control mice were purchased. Control animals were housed in 
room air for the same period. At day 14, animals were weighed and anaesthetised 
(fentanyl/fluanisone 0.25ml/kg; midazolam 25mg/kg IP) and right ventricular systolic 
pressure (RVSP) was measured via direct cardiac puncture using a closed-chest technique in 
the spontaneously breathing, anaesthetised animal. Blood was taken and serum obtained 
for measurement of IP10, ET-1 and IFN levels as described above. Right ventricular 
hypertrophy was assessed as the ratio of the weight of the right ventricle (RV) to body 
weight (BW) and also by Fulton’s Index which is a ratio of the weight of the RV to the left 
ventricle plus septum. Lungs were fixed by inflation with 10% formalin, embedded in 
paraffin and sectioned for histology. Transverse lung sections were stained with elastic Van 
Gieson and alpha smooth muscle-actin antibody (Sigma, UK). Vascular muscularisation was 
defined as the proportion of α-smooth muscle actin vessels (<50μm diameter) of the total 
number of vessels stained with elastin. Vessels were counted by myself as well as two 
separate experienced investigators (Dr Lan Zhao and Dr Eduardo Oliver) who were blinded 
to genotype from two separate sections from each animal.  
2.7.2  Mouse model of acute LPS induced endothelin-1 release 
Male C57Bl/6J mice (Charles River, Margate, UK) and male mice lacking a functional 
type I IFN receptor (IFNAR1-/- on a C57Bl/6J background), aged 8-10 weeks old and weighing 
≈20 were intraperitoneally injected with 8μl per gram of either vehicle control (0.9% NaCl) 
or LPS from Escherichia Coli 055:B5 (1.25mg/ml, L6529; Sigma, UK). At 4 hours, mice were 
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humanely sacrificed. Blood was taken, serum obtained and IP10, ET-1, IFNs and KC levels 
were measured by ELISA (as detailed above). 
2.8 Statistics 
For cell culture experiments, data are presented as mean ± standard error of the 
mean (SEM) and unless otherwise stated, data from at least n=3 experiments were obtained 
from protocols that were repeated on at least 3 separate experimental days with separately 
prepared cells and drugs. For organ culture experiments, data are presented as mean ± SEM 
from individual donors or separate animals. For patient studies, data are presented as 
means with individual data points referring to each patient and the mean of all patients in 
the cohort represented by a horizontal line. In some cases means ± SEM are also displayed 
to show differences between cohorts. For animal experiments, data are presented as mean 
± SEM from animals grouped together by genotype or experimental condition. For all data, 
the Kolmogorov-Smirnov test of normality was applied. All normally distributed data were 
analysed by one-way analysis of variance (ANOVA) followed by Bonferroni post-test 
adjustment for multiple comparisons and for correlations with clinical parameters, the 
Pearson correlation test was applied. Nonparametric data were analyzed by the Kruskal–
Wallis test followed by Dunn multiple comparison test and, for correlations, the Spearman 
rank test was used. One way ANOVA and Kruskal-Wallis tests were used to analyse 
differences between group means. These tests take into account variation within the data 
set. Post-test adjustments take into account potential error introduced as a consequence of 
multiple comparisons. Pearson and Spearman tests give a measure of the linear correlation 
between two variables and also take into account variability within a data set. Graphpad 
Prism was used for all statistical analysis. Values of p<0.05 were considered significant. 
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3.1 Rationale for Chapter 3 
The scope for therapeutic application of the IFNs is growing. Type I IFNs are by far 
the most widely utilised in human disease – IFNα remains the cornerstone for the treatment 
of chronic hepatitis C virus (HCV) and IFNβ is the gold standard treatment for relapsing and 
remitting multiple sclerosis (George et al., 2012). In a recent pilot study, IFNβ also 
demonstrated efficacy in the treatment of acute respiratory distress syndrome (ARDS) 
(Bellingan et al., 2014). Type II IFN, IFNγ, is less commonly used but is an effective treatment 
for the rare conditions chronic granulomatous disease and osteopetrosis and there is 
emerging evidence that type III IFN, IFNλ, has equivalent anti-viral activity as IFNα when 
used to treat HCV but with an improved side effect profile (George et al., 2012). 
Although they can represent effective treatments, the IFNs carry with them a range 
of unappealing side effects. Fever, lassitude and myalgia are common but subside with time 
and are reversible. More serious however is the association between type I IFN and 
pulmonary disease. It had initially been estimated that the incidence of pneumonitis 
associated with IFNα therapy was between 0.3% and 0.45% (Ji et al., 2010). In a more recent 
study which was specifically designed to examine the effect of IFNα therapy on the 
respiratory system, 48% of patients treated with IFNα therapy developed a decrease in lung 
function (diffusing capacity of lung for carbon monoxide (DLCO)) of at least 15%. In a third of 
these affected patients, the deficit in DLCO persisted 6 months after cessation of therapy 
(Foster et al., 2013). There is now a growing appreciation for a link between type I IFN and 
severe and irreversible pulmonary PAH. The first case of PAH linked to IFN treatment was 
published in 2001 (Fruehauf et al., 2001) and as the circumstantial evidence base has grown, 
in the most recent World Symposium on Pulmonary Hypertension (Nice, 2013), type I IFN 
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was added to the list of drugs that may be associated with PAH (Simonneau et al., 2013). 
The mechanisms behind IFN induced pneumonitis and/or PAH are not yet known but our 
group has previously identified IP10 (Badiger et al., 2012) and the promitogen ET-1 as 
candidate mediators (Wort et al., 2009). 
TLR3 responds to double stranded RNA from viruses or single stranded RNA viruses 
such as respiratory scyncytial virus and via TRIF pathways induces the production of IFNs 
from a number of cell types including fibroblasts and conventional dendritic cells which are 
an important source of type I IFN (Diebold et al., 2003). There is evidence that TLR3 
activation can play a role in respiratory disease (Satkunanathan et al., 2014), vascular 
disease (Farina et al., 2011) and cardiac dysfunction (Gao et al., 2012). There is also recent 
evidence that plasmacytoid dendritic cells play a further important role in systemic sclerosis 
associated PAH through the production of platelet factor 4 (CXCL4). Clinically, it has been 
found that CXCL4 correlates with lung fibrosis and PAH and in vitro, CXCL4 induces ET-1 
from endothelial cells and augments the production of IFNα by plasmacytoid dendritic cells 
stimulated with TLR agonists (van Bon et al., 2014). 
The research questions and aims, which are addressed in this chapter, were therefore as 
follows: 
1) To establish the response of a variety of human pulmonary cells and whole human 
blood vessels to types I, II and III IFNs by measuring the release of IP10, ET-1 and a 
range of cytokines. 
2) To assess the expression of the IFN receptors in a variety of human pulmonary cell 
types.  
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3) To assess the effect of the viral toll like receptor (TLR)3 agonist Poly(I:C) on 
pulmonary vascular cell types and to establish whether any effects seen can be 
ascribed to downstream IFN induction. 
4) To explore the relationship between CXCL4, IFN and Poly(I:C)  
 
3.2 Summary of Methods for Chapter 3 
A detailed methodological description is given in Chapter 2 and is summarised 
below. 
3.2.1  Isolation and culture of human cells and whole vessel 
As previously described, human pulmonary artery smooth muscle cells (HPASMCs) 
(Wort et al., 2000) and human lung fibroblasts (HLFs) (Maher et al., 2010) were isolated and 
cultured from macroscopically normal peripheral human lung. Lung tissue was obtained 
from patients undergoing lobectomy or pneumonectomy for lung cancer with confirmed 
consent from donors and under Royal Brompton Hospital ethics (ethics number 
09/H0708/72). Cells were grown in supplemented DMEM with 15% FCS and were passaged 
every 3-4 days. Experiments in HPASMCs and HLFs were performed in cells from passages 3 
to 10. TT1 cells (a recently created immortalised type I pneumocyte cell line) were isolated 
and cultured as previously described (Kemp et al., 2008). Human lung microvascular 
endothelial cells (HMVECs) were purchased from Lonza as cryopreserved cells. Cells were 
grown and maintained in Lonza-EGM2 media and grown on 1% gelatinised 75cm2 flasks. 
HMVECs were used between passages 3 and 10. Human cryopreserved hepatocytes were 
purchased from Life Technologies and plated immediately as per manufacturer instructions 
in CHPM media on pre-coated collagen plates. A549 cells (an adenocarcinoma cell line with 
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type II pneumocyte characteristics) were purchased from ATCC (UK) and Beas2B cells (a 
bronchial epithelial cell line) were purchased from LGC Standards (UK). Both cell types were 
cultured and passaged as per manufacturer instructions. For organ culture experiments, 
human pulmonary artery was dissected from freshly excised human lung obtained from lung 
cancer resection operations with ethics and consent as described above. Briefly, branch 
pulmonary arteries were dissected away and small segments each approximately 2mm x 
2mm were placed in individual wells of a  96 well plate in 300μl of DMEM with 10% FCS, 
Penicillin (100U/ml), L-Glutamine (2 mM), streptomycin (100 μg/ml), amphotericin B (2.5 
μg/ml) and 1% vol/vol 100 x MEM non-essential amino acids as previously described 
(Gatheral et al., 2012). Vessel segments were left to equilibrate for 24hrs and then treated 
for 48 hours.  
3.2.2  Cell treatments 
Cells were plated on 96-well plates and seeded at a density of 8x103 cells/well. 
HPASMCs, HLFs and A549 cells were plated, incubated and treated in DMEM with 10% FCS. 
HMVECs were treated in Lonza-EGM2 media with 10% FBS. Hepatocytes were plated, 
incubated and treated in Williams E maintenance media with 5% FBS. TT1 cells were plated, 
incubated and treated in DCCM with 10% NCS and Beas2B cells were plated, incubated and 
treated in keratinocyte media (Invitrogen, Paisley, UK) containing human recombinant 
epithelial growth factor and bovine pituitary extracts. Cells were treated with recombinant 
human IFNα A/D, recombinant human IFNγ, recombinant human IFNλ1, recombinant 
human TNFα (R&D systems, Abingdon, UK), the TLR3 agonist Poly(I:C) (Invitrogen, UK) or 
mammalian expressed CXCL4 (R&D systems, Abingdon, UK) for 24 hours. Supernatants were 
then collected and stored at -200C for future analysis. 
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3.2.3  Gene expression 
For gene expression experiments, cells were plated in 6 well plates in their 
respective media as described above at a seeding density of 150 x 103 cells/well. At 6 hours, 
cells were lysed, RNA extracted and converted to cDNA. cDNA was amplified and 
quantitated by qPCR using Taqman gene expression assays (Life Technologies, UK) for 
IFNAR1, IFNAR2, IFNGR1, IFNGR2, IL10RB and IL28RA. Data were analysed using the 
comparative Ct method with GAPDH utilised as the housekeeping gene against which gene 
expression was compared. Unstimulated cells under basal conditions were assessed for IFN 
receptor expression and expression of GAPDH which is stable under these conditions based 
on work performed by others in the group. The expression of the gene of interest was 
normalised to the expression of the housekeeping gene GAPDH (to generate delta Ct values) 
to give an indication of relative expression. IFN receptor gene expression in the pulmonary 
cell types examined was normalised to expression in hepatocytes as they were found to 
express all 6 receptor subunits. This approach allowed me to gather semi-quantitative data 
on the relative expression of IFN receptors between different cell types versus hepatocytes.  
3.2.4  Measurement of IP10, ET-1 and an array of cytokines 
IL-8, IP10 and ET-1 were measured in supernatants by specific ELISA according to 
manufacturer instructions as described in detail in Chapter 2. Optical density was measured 
using a microplate reader (Dyne Magellan Biosciences) with absorbance readings at 450-
570nm. A host of cytokines were measured using array technology (Tebu Biosciences, 
France or MSD). 
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3.2.5  Measurement of cell viability 
Cell viability following incubations was determined using the commercially available 
alamarBlue® assay. 
3.2.6  Analysis and Statistics 
Data are presented as mean ± standard error of the mean (SEM) and were analysed 
using Graph Pad Prism 5 using statistical tests referred to in the figure legends. In all cases 
an individual “n” refers to a single experimental run either in singlicate or the average of 
two duplicates. Multiple “ns” refer to separate experimental runs with treatments made up 
separately for each experiment. A p value of <0.05 was taken as significant and denoted by 
either * or # and p>0.05 was considered non-significant and denoted by NS.  
 
3.3 Results 
3.3.1  Response of human cells to types I, II and III interferons 
HPASMCs and HLFs responded to types I and II IFNs to release IP10 (Figs 3.1 – 3.2).  
HPASMCs, but not HLFs, also released ET-1. Neither cell type responded to type III IFN (Figs. 
3.1 – 3.2). Whilst TNFα had little or no direct effect on release of IP10 or ET-1, it greatly 
accentuated the effects of IFNs on the release of these mediators by HPASMCs and HLFs 
(Figs 3.1 – 3.2). Similarly, HMVECs also responded to types I and II but not III IFN to release 
IP10 but no increase in the release of ET-1 was observed (Fig. 3.3). Much like the pulmonary 
vascular cells, none of the three pulmonary epithelial cell lines tested responded to IFNλ. 
A549 cells released IP10 and ET-1 after stimulation with types I and II IFN but for these 
effects, the presence of TNFα was essential (Fig. 3.4). TT1 cells were relatively insensitive to 
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stimulation with IFNα but responded to IFNγ to release IP10, an effect which was 
augmented by co-stimulation with TNFα (Fig. 3.5). ET-1 was not induced in this cell type by 
any of the treatments used. Beas2B cells were also significantly more sensitive to the effects 
of IFNγ than IFNα in terms of IP10 release, which was again increased by the presence of 
TNFα. Once again, in this cell type, ET-1 release was not induced by any of the treatments 
tested (Fig. 3.6). As hepatocytes are known to respond to types I, II and III IFNs, I wished to 
establish that the doses and subtypes of IFNs used to stimulate pulmonary cell types were 
appropriate. Like pulmonary cells, human hepatocytes responded to IFNs –α and –γ. 
However, unlike pulmonary cells hepatocytes also responded to IFNλ. This was seen as a 
concentration dependent increase in IP10 release (Fig. 3.7). This effect was not accentuated 
by TNFα. None of the IFNs tested stimulated ET-1 release from human hepatocytes (Fig. 
3.7). To establish whether Ribavirin augments IFN activity and potentially its toxic effects 
when administered therapeutically, I conducted experiments where cells were exposed to 
both agents. Co-administration of Ribavirin with types I, II or III IFN did not augment IP10 
release from hepatocytes (Fig. 3.8) or IP10 and ET-1 release from pulmonary artery smooth 
muscle cells (Fig. 3.9). 
3.3.2  Interferon receptor gene expression 
The type I IFN receptor subunits (IFNAR1 and IFNAR2) and the type II IFN receptor 
subunits (IFNGR1 and IFNGR2) were ubiquitously expressed throughout all cell types tested 
to varying degrees (Table 3.1). The type III IFN receptor subunits were however differentially 
expressed. While the IL10RB subunit was widely expressed throughout, the IL28RA subunit 
was only highly expressed in hepatocytes and to a lesser extent in A549 cells but was not 
present in the other pulmonary cell types examined (Table 3.1). The data is also 
demonstrated as gene expression normalised to expression in hepatocytes (Fig. 3.10). 
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3.3.3  Response of human pulmonary artery to types I, II and III interferons 
The results presented so far in this thesis show that whilst human hepatocytes 
respond avidly to type III IFNλ, lung cells do not. Hepatocytes are terminally differentiated 
and so must be used as primary isolations.  In order to be sure that the apparent differences 
I found were not due to the use of cell lines (where receptors can be lost) versus primary 
cells, I performed separate experiments using fresh human pulmonary artery in organ 
culture. In a similar pattern to lung cells in culture, whole human pulmonary artery 
responded to IFNα and IFNγ to release IP10 but was not sensitive to IFNλ (Fig. 3.11). None of 
the IFNs induced the release of IL-8 or ET-1 (Fig. 3.11).  
3.3.4  Cytokine release from pulmonary vascular cells and hepatocytes 
As PAH is characterised by inflammation and raised levels of inflammatory mediators 
are associated with poorer outcomes, I assessed the potential for lung cells and hepatocytes 
to release cytokines after exposure to IFNs. In response to IFNα and TNFα co-treatment, 
HPASMCs released significantly raised levels of IFNβ, IL-1α and IL-13. IFNλ and TNFα co-
treatment induced the release of IFNγ and IL-13 and TNFα induced the release of IL-6 and IL-
8 (Table 3.2). In HLFs, TNFα induced the release of IFNλ, IL-5, IL-8 and IL-15 and IFNλ and 
TNFα co-treatment induced release of IL-12 and IL-23 (Table 3.3). In HMVECs, IFNα and 
TNFα co-treatment induced release IFNβ and IL-6, IFNλ induced the release of IFNγ and 
treatment with TNFα induced the release of IL-1α and IL-8 (Table 3.4). In hepatocytes, only 
IL-13 was induced after exposure to IFNs –α or –λ in the presence of TNFα (Table 3.5). 
3.3.5  Effect of the TLR3 agonist, Poly(I:C) on human pulmonary cells 
As discussed earlier, there is published evidence that viral TLRs, and in particular 
TLR3 may have a role to play in cardiac dysfunction and cardiac disease. I consequently 
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wished to investigate its potential role in the pathogenesis of PAH. I found that HPASMCs 
responded to Poly(I:C) to release IL-8, IP10, ET-1 and IL-5, and, with the exception of IL-8 
release, this effect was accentuated by the co-administration of TNFα (Fig 3.12 and Table 
3.6). Poly(I:C) did not induce any of the IFNs in this cell type – in the presence of TNFα there 
was trend to an increase in IFNλ levels but this did not meet statistical significance. HLFs 
released IP10 and IL-8 but not ET-1 in response to Poly(I:C) (Fig. 3.13) and Poly(I:C) also 
raised levels of IFNλ, IL-5, IL-6 and IL-10 (Table 3.7). HMVECs released IP10 but not ET-1 in 
response to Poly(I:C) (Fig. 3.14). After treatment with Poly(I:C), HMVECs released statistically 
significant levels of GM-CSF, IFNγ, IL-1β, IL-2, IL-6, IL-8 and IL-12p70 and non-significant 
amounts of IL-10 and TNFα (Figs. 3.15 & 3.16). In terms of the response of pulmonary 
epithelial cells to Poly(I:C), A549 cells did not respond to Poly(I:C) (Fig 3.17) but TT1 cells 
released both IP10 and ET-1 when exposed to Poly(I:C) and TNFα (Fig 3.18) and Beas2B cells 
responded to Poly(I:C) to release IP10 and ET-1 in the presence or absence of TNFα (Fig 
3.19). 
3.3.6  Effect of CXCL4 on human pulmonary vascular cells 
CXCL4 has recently been implicated in the development of SSc associated PAH and 
lung fibrosis through the augmentation of TLR responses and the release of ET-1 from 
endothelial cells (van Bon et al., 2014). I wished to develop this theory further by examining 
its role in two relevant pulmonary cell types.  
HPASMCs 
CXCL4 did not induce IP10 from HPASMCs in the absence or presence of either IFNα 
or TNFα (Fig. 3.20). As seen in previous experiments, IFNα alone stimulated IP10 release in a 
concentration dependent manner (Fig. 3.20A and Fig 3.20B). In order to test the idea that 
 101 
 
CXCL4 would stimulate cells with a mixture of cytokine stimuli, cells were co-treated with 
INFα plus TNFα alone or in the presence of increasing concentrations of CXCL4. As seen 
before, the co-addition of INFα and TNFα synergised to release IP10 (Fig. 3.21, see Fig. 3.20 
for effects of TNFα and IFNα alone). However, with IFNα and in the presence of TNFα 
(10ng/ml for each), the highest concentration of CXCL4 augmented the release of IP10 from 
HPASMCs (Fig. 3.21). Whilst CXCL4 did not release IP10 when given alone, it proved additive 
when given with Poly(I:C) to HPASMCs (Fig. 3.22). By contrast to release of IP10, CXCL4 
induced the release of ET-1 in a concentration dependent fashion and also augmented the 
release of ET-1 in an additive fashion in response to IFNα stimulation (Fig. 3.23). By contrast, 
TNFα did not increase the ability of CXCL4 to release ET-1 from HPASMCs (Fig. 3.23). 
However, when cells were co-stimulated with IFNα (1 or 10ng/ml) and TNFα (10ng/ml) ET-1 
release by CXCL4 was again increased. Of all the conditions tested the highest levels of ET-1 
release by HPASMCs was seen from cells treated with TNFα, IFNα (10ng/ml) and CXCL4 
(30μg/ml) (Fig. 3.24B). In separate experiments, CXCL4 again induced ET-1 release from 
HPASMCs, an effect that was additive in cells co-treated with Poly(I:C) (Fig. 3.25). CXCL4 did 
not induce any other of 9 cytokines from HPASMCs (Table 3.8).  
HMVECs 
CXCL4 had no effect on IP10 release by HMVECs. However, in the presence of either 
1 or 10ng/ml IFNα or Poly(I:C) (10μg/ml), CXCL4 did increase IP10 release from these cells 
(Fig. 3.26A, B & D). By contrast, co-stimulation of cells with TNFα did not reveal any effect of 
CXCL4 on IP10 release by HMVECs (Fig. 3.26C). CXCL4 significantly increased ET-1 release 
from HMVECs but this was not further increased by either IFNα, TNFα or by Poly(I:C) (Fig. 
 102 
 
3.27). As was the case with HPASMCs, CXCL4 did not induce release of any other of 9 
cytokines from HMVECs (Table 3.9).  
3.3.6  Cell viability 
No in vitro condition resulted in any detrimental effect on cell viability as assessed 
using alamarBlue® assay. Cell viability data can be found in full in Table 3.10.  
 
3.4 Summary and Limitations 
Below is a brief summary of the data presented in this chapter. This work is 
discussed in detail and in the context of the entire thesis in Chapter 6. 
3.4.1  Summary 
In this chapter I have demonstrated that pulmonary vascular cells, lung epithelial 
cells and whole human pulmonary artery sense types I and II IFN but not type III IFN 
whereas human hepatocytes can respond to all three IFN subtypes. While both subunits for 
the type I and II IFNs were expressed in all cell types tested, the IL28RA subunit of the type 
III IFN receptor was only expressed in hepatocytes (and to a significantly lesser degree in 
A549 cells). Since both subunits are required for IFN signalling via JAK-STAT pathways the 
relative insensitivity of pulmonary cells to type III IFNλ as compared to hepatocytes can 
therefore be explained by receptor expression in these cell types.  
Broadly speaking, I have demonstrated that types I and II IFN induced the release of 
the vasoconstrictor and promitogen ET-1 and/or the neutrophil chemoattractant IP10 from 
human pulmonary vascular cells and some lung epithelial cell types.  I have shown that 
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other important pro-inflammatory mediators such as IL-1α, IL-6 and IL-8 can also be induced 
but in many cases, there is a requirement for TNFα co-treatment.  
It is clear that the predominant response of human pulmonary cells and whole 
human pulmonary artery to IFN stimulation is the induction of IP10. The finding that type I 
and II IFN can stimulate the release of IP10 as well as ET-1 from human pulmonary cells is 
important as it may help explain why therapeutic IFN administration can cause pulmonary 
side effects such as pneumonitis or PAH in some patients. Indeed, it may shed light on why 
patients with autoimmune conditions such as systemic sclerosis where endogenous IFN 
levels are chronically raised have a propensity to pulmonary vascular disease and interstitial 
lung disease. This idea is addressed later in the thesis in Chapter 4. Furthermore, as the 
immunomodulatory and antiviral properties of the IFNs continue to be explored, the finding 
that human pulmonary cells and whole vessel are insensitive to the effects of type III IFNλ is 
potentially exciting as IFNλ is currently in Phase III trials for the treatment of chronic 
Hepatitis C virus and has been shown to possess good antiviral activity with a tendency to a 
reduction in side effects.  
Although ribavirin is always co-administered with IFNα for the treatment of HCV as a 
result of improved efficacy in clinical trials, its mechanism of action is poorly understood. 
One group has found that in vivo, patients receiving both IFNα and ribavirin mount a higher 
circulating IP10 response than those receiving IFNα alone (Feld et al., 2010). However there 
is a paucity of convincing in vitro data in this field. My finding that ribavirin does not 
increase IP10 release from IFNα treated hepatocytes is novel and suggests that the 
mechanism for increased circulating IP10 levels may be through alternative means. 
Furthermore, the finding that ribavirin did not increase IP10 or ET-1 release from human 
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pulmonary artery smooth muscle cells suggests that pulmonary vascular toxicity associated 
with IFN use is independent of ribavirin. This reflects the clinical phenomenon where people 
who are treated with type I IFN in the absence of ribavirin for conditions such as multiple 
sclerosis have developed PAH.  
With the exception of A549 cells, all cells tested sensed the TLR3 agonist Poly(I:C) to 
release IP10 and a variety of cytokines. Some cell types also released ET-1 in response to 
Poly(I:C). Other than stimulating the release of IFNλ from HLFs, on the whole, Poly(I:C) did 
not induce IFN release from the pulmonary cell types assessed and so it is reasonable to 
surmise that the release of ET-1 in this context is IFN independent. When relating these 
findings to human pathology, it is worth noting that as well as double stranded and single 
stranded RNA viruses, endogenously produced activated cells or necrotic cells, so called 
danger associated molecular patterns (DAMPs), have been implicated in autoimmune 
diseases such as systemic sclerosis where TLR3 activity is thought to play a pathological role 
(Piccinini and Midwood, 2010).  This and other aspects of this work are discussed in detail in 
Chapter 6. 
My findings that CXCL4 acts on the vascular smooth muscle and endothelium to 
release ET-1 and that it augments IFN and Poly(I:C) responses in pulmonary artery smooth 
muscle cells is potentially very interesting and identifies the dendritic cell as a key cell type 
in the pathogenesis of PAH. It builds upon the recent study by van Bon and colleagues 
where CXCL4 was found to be an important marker of PAH in the context of systemic 
sclerosis (van Bon et al., 2014). Notwithstanding this, given the vascular smooth muscle is 
considered by many to be the important cell type in the development of PAH, the finding 
that it responds to CXCL4 to exaggerate IFN and Poly(I:C) sensing is of significance. It is 
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worth noting that levels of CXCL4 required to activate cells were between 5 and 10 μg/ml 
whereas serum levels (although not representative of tissue levels) in SSc-PAH patients are 
around 0.025 μg/ml  (van Bon et al., 2014). 
3.4.2  Limitations 
There are a number of ways in which this chapter could have been expanded upon 
further had time allowed. The vast majority of the data I have generated has relied on 
protein release as measured by ELISA. This would have benefitted from validation with gene 
expression – particularly for HMVECs where basal release of ET-1 into supernatant is so high 
as to make induction of protein very difficult to assess with ELISA. Furthermore, it was 
surprising that cells treated with Poly(I:C) did not release IFNs and I have tentatively 
speculated that this suggests that Poly(I:C) mediated release of cytokines and ET-1 may be 
IFN independent. It is however possible that Poly(I:C) induces IFNs which act intracellularly 
and are not released by the cell. This could again have been investigated using gene 
expression experiments or by using Western blotting. In addition, measurement of TLR3 
expression at the gene and protein level would have informed as to the likelihood of 
response to Poly(I:C). 
The data would have been enhanced with validation of IFN receptor function. I was 
unable to establish the specificity of IFN receptors and so it would have been interesting to 
knock down the two subunits of the types I, II and III IFN receptors as well as TLR3 
sequentially using small interfering RNA (siRNA). This would have allowed me to identify 
whether either of the subunits for the individual receptors play separate roles and could 
allow the identification of specific IFN receptor subunits as drug targets. One recently 
published example of this has demonstrated that the IFNAR1 can form an IFNAR1-IFNβ 
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complex independent of IFNAR2 to transduce inflammatory and potentially pathological 
signals (de Weerd et al., 2013). Although I have not established this through my work, it is 
important to note that it is known that the IFN receptors are primarily regulated at the level 
of transcription (Ivashkiv and Donlin, 2014). Whilst I was able to compare IFN receptor 
expression in pulmonary cell types versus hepatocytes, which are well-known to express IFN 
receptors and associated signalling pathways, I did not fully quantify expression and this is a 
limitation of these experiments. To address this, fully quantitative PCR could have been 
achieved by constructing standard curves relating Ct to known quantities of each gene of 
interest and this would provide data to further support my conclusions. It would have been 
interesting to assess the potential for IFNs to induce proliferation particularly in HPASMCs. It 
is well established that ET-1 is a potent vasoconstrictor (Yanagisawa et al., 1988) which also 
promotes cellular proliferation in vascular smooth muscle (Wort et al., 2001). The effect of 
IFN on HPASMC proliferation is unknown and I could have investigated this by designing 
protocols in which proliferation of HPASMCs was measured after treatments with IFNs in 
the presence and absence of ET-1 receptor blockers. In this way I could have determined 
whether IFNs (particularly types I and II IFN) induce cellular proliferation and whether or not 
this is mediated by ET-1. Through the use of myography experiments, I could have assessed 
the effect of IFNs on cellular contraction and again used increasing concentrations of ET-1 
inhibitors. 
It has previously been shown that IFNγ induced ET-1 release from HPASMCs is due to 
synergy with TNFα and is due to cooperative p65 binding and histone acetylation at sites 
within the preproET-1 promoter (Wort et al., 2009). While it is possible that type I IFN 
induces ET-1 through the same mechanism, the signalling pathways for types I and II IFN are 
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different and so a more developed examination of this, although beyond the scope of this 
thesis, would have been interesting.  The mechanism underpinning TLR3 activation and ET-1 
release are even less well developed and through the use of anti-IFN antibodies and signal 
transducer and activator of transcription (STAT) inhibitors, I would have been able to 
explore whether Poly(I:C) mediated ET-1 is indeed IFN independent.  
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3.5 Chapter 3: Data 
Figure 3.1 Response of human pulmonary artery smooth muscle cells to types I, II and III IFN 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Human pulmonary artery smooth muscle cells (HPASMCs) treated with IFNα (A & 
B), IFNγ (C & D) and IFNλ (E & F) with and without TNFα and assayed for IP10 (A,C,E) and ET-
1 (B,D,F). Data are expressed as mean ± standard error of the mean (SEM) from n=4 
experiments performed in singlicate. Statistical significance (*p<0.05) compared to control 
was determined by one-way ANOVA with Dunnett’s multiple comparison post-test 
adjustment. Statistical significance (# p<0.05) for effect of TNFα was determined by two-way 
ANOVA. Non-significance denoted as NS. Control referred to as ‘C’. 
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Figure 3.2 Response of human lung fibroblasts to types I, II and III IFN 
 
 
Figure 3.2 Human lung fibroblasts (HLFs) treated with IFNα (A & B), IFNγ (C & D) and IFNλ (E 
& F) with and without TNFα (10ng/ml) and assayed for IP10 (A,C,E) and ET-1 (B,D,F). Data 
are expressed as mean ± standard error of the mean (SEM) from n=3 experiments performed 
in singlicate. Statistical significance (*p<0.05) compared to control was determined by one-
way ANOVA with Dunnett’s multiple comparison post-test adjustment. Statistical 
significance (# p<0.05) for effect of TNFα was determined by two-way ANOVA. Non-
significance denoted as NS. Control referred to as ‘C’. 
0.
1 1 10 10
0
0
5000
10000
15000
20000
C
+ TNF
*
control
#
**
IFN(ng/ml)
IP
1
0
 (
p
g
/m
l)
0.
1 1 10 10
0
0
2
4
6
8
10
C
+ TNF
control
NS
IFN(ng/ml)
E
T
-1
 (
p
g
/m
L
)
0.
1 1 10 10
0
0
10000
20000
30000 + TNF
C
control
NS
*
**
**
IFN(ng/ml)
IP
1
0
 (
p
g
/m
l)
0.
1 1 10 10
0
0
2
4
6
8
10 + TNF
C
control
NS
IFN(ng/ml)
E
T
-1
 (
p
g
/m
L
)
1 10 10
0
10
00
0
500
1000
1500
2000 + TNF
C
control
NS
IFN(ng/ml)
IP
1
0
 (
p
g
/m
l)
1 10 10
0
10
00
0
2
4
6
8
10 + TNF
C
control
NS
IFN(ng/ml)
E
T
-1
 (
p
g
/m
L
)
A 
F E 
D C 
B 
 110 
 
Figure 3.3 Response of human lung microvascular endothelial cells to types I, II and III IFN 
 
Figure 3.3 Human lung microvascular endothelial cells (HMVECs) treated with IFNα 
(10ng/ml) (A & B), IFNγ (10ng/ml) (C & D) and IFNλ (1000ng/ml) (E & F) with and without 
TNFα (10ng/ml) and assayed for IP10 (A,C,E) and ET-1 (B,D,F). Data are expressed as mean ± 
standard error of the mean (SEM) from n=4 experiments for IP10 and n=3 experiments for 
ET-1 performed in singlicate. Statistical significance (*p<0.05) compared to control was 
determined by one-way ANOVA with Dunnett’s multiple comparison post-test adjustment. 
Statistical significance (# p<0.05) for effect of TNFα was determined by two-way ANOVA. 
Non-significance denoted as NS. Control referred to as ‘C’. 
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Figure 3.4 Response of A549 cells to types I, II and III IFN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Human A549 cells treated with IFNα (10ng/ml) (A), IFNγ (10ng/ml) (C) and IFNλ 
(1000ng/ml) (E) with and without TNFα (10ng/ml) and assayed for IP10 (A,C,E) and ET-1 (B & 
D). Data are expressed as mean ± standard error of the mean (SEM) from n=3 experiments 
performed in singlicate. Statistical significance (*p<0.05) compared to control was 
determined by one-way ANOVA with Dunnett’s multiple comparison post-test adjustment. 
Statistical significance (# p<0.05) for effect of TNFα was determined by two-way ANOVA. 
Non-significance denoted as NS. Control referred to as ‘C’. 
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Figure 3.5 Response of alveolar Type 1 (TT1) cells to types I, II and III IFN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Human alveolar type I cells (TT1) treated with IFNα (10ng/ml), IFNγ (10ng/ml) or 
IFNλ (1000ng/ml) in the absence (A & B) and presence of TNFα (10ng/ml) (C & D) and 
assayed for IP10 (A & C) and ET-1 (B & D). Data are expressed as mean ± standard error of 
the mean (SEM) from n=3 experiments performed in singlicate. Statistical significance 
(*p<0.05) compared to control was determined by one-way ANOVA with Dunnett’s multiple 
comparison post-test adjustment. 
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Figure 3.6 Response of bronchial epithelial (Beas2B) cells to types I, II and III IFN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Human bronchial epithelial cells (Beas2B) treated with IFNα (10ng/ml), IFNγ 
(10ng/ml) or IFNλ (1000ng/ml) in the absence (A & B) and presence of TNFα (10ng/ml) (C & 
D) and assayed for IP10 (A & C) and ET-1 (B & D). Data are expressed as mean ± standard 
error of the mean (SEM) from n=3 experiments performed in singlicate. Statistical 
significance (*p<0.05) compared to control was determined by one-way ANOVA with 
Dunnett’s multiple comparison post-test adjustment. 
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Figure 3.7 Response of human hepatocytes to types I, II and III IFN 
 
Figure 3.7 Human hepatocytes treated with increasing concentrations of IFNα (A), IFNγ (C) 
and IFNλ (E) or fixed concentrations of IFNα (10ng/ml), IFNγ (10ng/ml) or IFNλ (1000ng/ml) 
(B & D) with and without TNFα and assayed for IP10 (A,C,E) and ET-1 (B & D). Data are 
expressed as mean ± standard error of the mean (SEM) from n=3 experiments performed in 
singlicate. Statistical significance (*p<0.05) compared to control was determined by one-way 
ANOVA with Dunnett’s multiple comparison post-test adjustment. Statistical significance (# 
p<0.05) for effect of TNFα was determined by two-way ANOVA. Non-significance denoted as 
NS. Control referred to as ‘C’. 
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Figure 3.8 Response of human hepatocytes to types I, II and III IFNs with Ribavirin 
 
 
Figure 3.8. Human hepatocytes treated with IFNα (A), IFNγ (B) and IFNλ (C) with and without 
Ribavirin and assayed for IP10. Data are expressed as mean ± standard error of the mean 
(SEM) from n=3 experiments performed in singlicate. Statistical significance (*p<0.05) 
compared to control was determined by one-way ANOVA with Bonferroni’s multiple 
comparison post-test adjustment. Statistical significance (# p<0.05) for effect of Ribavirin 
was determined by one-way ANOVA followed by Bonferroni’s multiple comparison post-test 
adjustment – all non significant. 
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Figure 3.9 Response of human pulmonary artery smooth muscle cells to IFNα and Ribavirin 
 
 
Figure 3.9 Human pulmonary artery smooth muscle cells treated with IFNα and Ribavirin and 
assayed for IP10 (A) and ET-1 (B).  Pilot data from n=1 experiment. 
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Table 3.1 IFN receptor expression in pulmonary cell types and hepatocytes 
 
ΔCt Hepatocytes HPASMCs HMVECs HLFs A549 
IFNAR1 11.20 ± 0.91 12.00 ± 0.58 10.20 ± 0.37 12.22 ± 0.56 11.76 ± 0.30 
IFNAR2 8.32 ± 0.52 11.30 ± 0.57 9.04 ± 0.32 10.75 ± 0.80 10.19 ± 0.12 
IFNGR1 10.16 ± 0.25 10.49 ± 0.68 9.85 ± 0.43 11.60 ± 0.48 11.30 ± 0.51 
IFNGR2 10.77 ± 2.10 9.93 ± 0.63 9.04 ± 0.31 10.21 ± 1.15 10.00 ± 0.54 
IL-10RB 11.95 ± 0.44 11.61 ± 0.58 10.94 ± 0.50 12.09 ± 0.24 11.38 ± 0.14 
IL-28RA 14.74 ± 
0.49* 
21.40 ± 1.34 21.68 ± 0.59 23.77 ± 0.63 16.07 ± 
0.35# 
 
Table 3.1 IFN receptor gene expression in a variety of pulmonary cell types and in 
hepatocytes expressed as fold change (ΔCt) relative to expression of the housekeeping gene 
GAPDH. Data expressed as mean ± SEM from n=3 separate experiments. Statistical 
significance (*<0.05 for gene expression in hepatocytes versus HPASMCs, HMVECs and HLFs 
and #<0.05 for gene expression in A549 cells versus HPASMCs, HMVECs and HLFs) was 
determined by one-way ANOVA with Bonferroni’s multiple comparison post-test adjustment. 
Statistically significant results in bold. 
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Figure 3.10 IFN receptor gene expression in a number of pulmonary cell types normalised to 
expression in hepatocytes 
 
Figure 3.10 Type I IFN receptor expression (IFNAR1 and IFNAR2) (A & B) in hepatocytes, 
A549 cells, human pulmonary artery smooth muscle cells (HPASMCs), human lung 
microvascular endothelial cells (HMVECs) and human lung fibroblasts (HLFs), type II IFN 
receptor expression (IFNGR1 and IFNGR2) (C & D) and type III IFN receptor expression 
(IL28RA and IL10RB) (E & F)  in the same cell types. Data are presented as mean ± SEM from 
n=3 separate experiments and are plotted as fold difference vs hepatocytes (=1). Statistical 
significance for normalised data compared to hepatocytes (*p<0.05) was determined one-
sample t-test. Statistical significance for comparison between A549 cells and other cell types 
(*p<0.05) was determined by one-way ANOVA with Dunnett’s multiple post-test adjustment. 
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Figure 3.11 Response of freshly harvested human pulmonary artery to types I, II and III IFNs 
 
 
 
 
Figure 3.11 Segments of freshly harvested human pulmonary artery treated with IFNα 
(10ng/ml), IFNγ (10ng/ml) or IFNλ (1000ng/ml) and assayed for IP10 (A), IL-8 (B) and ET-1 
(C). Data  are expressed as mean ± standard error of the mean (SEM). Statistical significance 
(*p<0.05) compared to control was determined by one-way ANOVA with Dunnett’s multiple 
comparison post-test adjustment. 
Control IFN IFN IFN
0
2000
4000
6000
*
*
IP
1
0
 (
p
g
/m
l)
Control IFN IFN IFN
0
100000
200000
300000
400000
IL
-8
 (
p
g
/m
l)
Control IFN IFN IFN
0
5
10
15
E
T
-1
 (
p
g
/m
l)
A 
C 
B 
 120 
 
Table 3.2 Cytokine release from IFN treated human pulmonary artery smooth muscle cells 
 
pg/ml Control IFNα IFNλ TNFα IFNα + 
TNFα 
IFNλ + 
TNFα 
IFNα ND N/A ND 21.11  
± 21.11 
N/A ND 
IFNβ ND ND ND ND 32.84 
± 15.78 * # 
ND 
IFNγ ND ND 19.24  
± 19.24 
ND ND 75.75± 
14.38 * # + 
IFNλ ND ND N/A ND ND N/A 
IL-1α ND 37.83  
± 19.00 
ND 8.45  
± 8.45 
51.10  
± 3.00 * # 
27.21  
± 14.12 
IL-4 ND ND ND ND ND ND 
IL-5 ND ND 3.47  
± 3.47 
36.23  
± 14.85 
ND 25.70  
± 16.43 
IL-6 2292.66 
± 305.00 
3254.84 
± 602.21 
1764.56 
± 528.75 
4855.36  
± 176.80 * 
4185.82  
± 81.94 * 
4435.35  
± 53.17 * 
IL-8 277.09  
± 132.28 
585.26   
± 288.94 
197.87  
± 91.44 
2712.97  
± 106.91 * 
2473.63  
± 25.89 * 
2596.19  
± 37.93 * 
IL-10 ND ND ND ND ND 2.37 ± 2.37 
Il-12 ND ND ND 2.79  
± 1.66 
1.30 ± 1.30 4.44 ± 2.44 
IL-13 ND ND ND 7.67  
± 7.67 
45.87  
± 0.28 * # 
41.84  
± 11.77 * # 
IL-15 ND ND ND ND ND ND 
Il-17 ND ND ND ND ND ND 
IL-23 ND ND ND ND ND ND 
TNFα ND ND ND N/A N/A N/A 
Table 3.2 Human pulmonary artery smooth muscle cells treated with IFNα (10ng/ml) or IFNλ 
(1000ng/ml) in the presence of absence of TNFα (10ng/ml) and assayed for a variety of 
cytokines. Data are expressed in pg/ml as mean ± standard error of the mean (SEM) from 
n=3 – 4 experiments performed in singlicate. Statistical significance (*<0.05 for effect versus 
control, #<0.05 for effect versus TNFα and +<0.05 for effect versus IFN) was determined by 
one-way ANOVA with Bonferroni’s multiple comparison post-test adjustment. ND = not 
detected. N/A = not applicable. Statistically significant results in bold. 
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Table 3.3 Cytokine release from IFN treated human lung fibroblasts 
pg/ml Control IFNα IFNλ TNFα IFNα + 
TNFα 
IFNλ + 
TNFα 
IFNα ND N/A ND 8.74±8.74 N/A 6.90±6.90 
IFNβ 16.21  
± 13.49 
27.24  
± 7.39 
15.79  
± 9.52 
9.75 
± 9.75 
38.50  
± 9.70 
20.24  
± 17.75 
IFNγ ND 2.00 
±2.00 
19.76 
±19.76 
ND ND 30.00 
± 17.56 
IFNλ ND ND N/A 348.19  
± 42.53 * 
238.82  
±56.00 * # 
N/A 
IL-1α ND 35.75  
± 35.75 
ND ND 52.00  
± 52.00 
10.84  
± 10.84 
IL-4 ND ND ND ND ND ND 
IL-5 7.20  
± 3.90 
19.13  
± 9.58 
54.00  
± 40.00 
119.84  
± 7.90 * 
80.00  
± 24.90 
166.30  
± 22.23 * 
IL-6 1895.42  
± 601.28 
2537.74  
± 438.87 
1997.07  
± 950.80 
5690.80  
± 236.14 
7229.29  
± 1807.09 
9505.78  
± 2678 * 
IL-8 1231.60 
 ± 172.56 
651.09  
± 223.89 
1352.15  
± 542.24 
3303.36  
± 83.01 * 
3509.56  
± 503.68 * 
3988.13  
± 476.25 * 
IL-10 ND 10.26±7.43 1.32±1.32 13.09±7.17 14.78±7.96 5.93±5.93 
Il-12 ND 0.44  
± 0.44 
0.58  
± 0.58 
3.01  
± 1.52 
1.69  
± 0.84 
5.86  
± 1.28 * 
IL-13 13.08  
± 6.82 
ND 8.53  
± 8.53 
23.01  
± 3.56 
21.76  
± 11.11 
30.24  
± 2.87 
IL-15 ND 2.76  
± 1.51 
ND 23.01  
± 3.56 * 
4.00  
± 2.37 # 
4.82  
± 3.85 # 
Il-17 ND ND 0.35±0.35 ND ND ND 
IL-23 ND ND 26.29  
± 26.29 
190.15  
± 61.35 
215.56  
± 85.52 
290.24  
± 45.32 * 
TNFα ND ND ND N/A N/A N/A 
Table 3.3 Human lung fibroblasts treated with IFNα (10ng/ml) or IFNλ (1000ng/ml) in the 
presence or absence of TNFα (10ng/ml) and assayed for a variety of cytokines. Data are 
expressed in pg/ml as mean ± standard error of the mean (SEM) from n=3 experiments 
performed in singlicate. Statistical significance (*<0.05 for effect versus control and #<0.05 
for effect versus TNFα) was determined by one-way ANOVA with Bonferroni’s multiple 
comparison post-test adjustment. ND = not detected. N/A = not applicable. Statistically 
significant results in bold. 
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Table 3.4 Cytokine release from IFN treated human lung microvascular endothelial cells 
 
pg/ml Control IFNα IFNλ TNFα IFNα + 
TNFα 
IFNλ + 
TNFα 
IFNα ND N/A ND ND N/A ND 
IFNβ ND ND ND ND 32.84 ± 
15.78 * # 
ND 
IFNγ ND ND 76.70 ± 
11.30 * 
ND ND 56.07 ± 
12.00 * # 
IFNλ ND ND N/A ND ND N/A 
IL-1α ND 14.63 ± 
14.63 
ND 41.40 ± 
7.14 * 
49.64 ± 
3.21 * 
ND # 
IL-4 ND ND ND ND ND ND 
IL-5 ND ND ND ND ND ND 
IL-6 ND ND ND ND 90.89 ± 
11.78 * # 
8.02 ± 
8.02 
IL-8 1104.51 ± 
225.27 
651.83 ± 
167.60 
851.97 ± 
215.98 
2818.89 ± 
100.26 * 
2588.28 ± 
72.92 * 
2609.95 ± 
94.72 * 
IL-10 ND ND ND ND ND ND 
Il-12 ND ND ND 1.68 ± 
1.68 
ND 3.65 ± 
2.18 
IL-13 7.48 ± 
7.48 
ND ND ND ND ND 
IL-15 ND ND ND ND ND ND 
Il-17 ND ND ND ND ND ND 
IL-23 ND ND ND ND ND ND 
TNFα ND ND ND N/A N/A N/A 
 
Table 3.4 Human lung microvascular endothelial cells treated with IFNα (10ng/ml) or IFNλ 
(1000ng/ml) in the presence of absence of TNFα (10ng/ml) and assayed for a variety of 
cytokines. Data are expressed in pg/ml as mean ± standard error of the mean (SEM) from 
n=3 experiments performed in singlicate. Statistical significance (*<0.05 for effect versus 
control and #<0.05 for effect versus TNFα) was determined by one-way ANOVA with 
Bonferroni’s multiple comparison post-test adjustment. ND = not detected. N/A = not 
applicable. Statistically significant results in bold. 
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Table 3.5 Cytokine release from IFN treated human hepatocytes 
 
pg/ml Control IFNα IFNλ TNFα IFNα + 
TNFα 
IFNλ + 
TNFα 
IFNα ND N/A ND ND N/A ND 
IFNβ ND 37.83 ± 
37.83 
ND ND 59.42 ± 
39.28 
ND 
IFNγ 15.50 ± 
15.50 
ND ND ND ND 23.54 ± 
23.54 
IFNλ ND ND N/A ND ND N/A 
IL-1α ND ND ND ND 21.54 ± 
21.54 
ND 
IL-4 ND ND ND ND ND ND 
IL-5 ND ND ND ND ND ND 
IL-6 ND ND 8.42 ± 
8.42 
26.53 ± 
26.53 
ND 18.17 ± 
18.17 
IL-8 497.44 ± 
99.65 
249.54 ± 
52.79 
453.83 ± 
221.80 
1355.37 ± 
504.49 
563.50 ± 
164.36 
1392.49 ± 
436.01 
IL-10 ND ND ND ND ND 3.63 ± 
3.63 
Il-12 ND ND ND ND ND ND 
IL-13 ND ND ND 8.48 ± 
8.48 
25.77 ± 
0.76 * # 
31.54 ± 
1.46 * # 
IL-15 ND 3.63 ± 
3.63 
ND ND ND ND 
Il-17 ND ND ND ND ND ND 
IL-23 ND ND ND ND ND ND 
TNFα ND ND ND N/A N/A N/A 
 
Table 3.5 Human hepatocytes treated with IFNα (10ng/ml) or IFNλ (1000ng/ml) in the 
presence of absence of TNFα (10ng/ml) and assayed for a variety of cytokines. Data are 
expressed in pg/ml as mean ± standard error of the mean (SEM). Statistical significance 
(*<0.05 for effect versus control and #<0.05 for effect versus TNFα) was determined by one-
way ANOVA with Bonferroni’s multiple comparison post-test adjustment. ND = not detected. 
N/A = not applicable. Statistically significant results in bold.  
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Figure 3.12 Response of human pulmonary artery smooth muscle cells to the TLR3 agonist 
Poly(I:C) 
 
Figure 3.12 Human pulmonary artery smooth muscle cells (HPASMCs) treated with the TLR3 
agonist Poly(I:C) with and without TNFα (10ng/ml) and assayed for IL-8 (A), IP10 (B) and ET-
1 (C). Data are expressed as mean ± standard error of the mean (SEM) from n=4 experiments 
performed in singlicate. Statistical significance (*p<0.05) compared to control was 
determined by one-way ANOVA with Dunnett’s multiple comparison post-test adjustment. 
Statistical significance (# p<0.05) for effect of TNFα was determined by two-way ANOVA. 
Control referred to as ‘C’. 
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Table 3.6 Response of human pulmonary artery smooth muscle cells to the TLR3 agonist 
Poly(I:C) 
 
 
Table 3.6 Human pulmonary artery smooth muscle cells treated with the TLR3 agonist 
Poly(I:C) (10μg/ml) in the presence or absence of TNFα (10ng/ml) and assayed for a variety 
of cytokines. Data are expressed in pg/ml as mean ± standard error of the mean (SEM) from 
n=3-4 experiments performed in singlicate. Statistical significance (*<0.05 for effect versus 
control and #<0.05 for effect versus TNFα) was determined by one-way ANOVA with 
Bonferroni’s multiple comparison post-test adjustment. ND = not detected. N/A = not 
applicable. Statistically significant results in bold. 
 
 
 
 
 
pg/m
l 
Control TNFα Poly(I:C) Poly(I:C) + TNFα 
IFNα ND ND ND ND 
IFNβ 11.59 ± 11.59 ND ND ND 
IFNγ ND ND ND ND 
IFNλ ND ND 23.05 ± 23.05 176.23 ± 95.79 
IL-1α ND 8.45 ± 8.45 28.56 ± 16.59 16.70 ± 16.70 
IL-4 ND ND ND ND 
IL-5 ND 36.29 ± 14.85 40.50 ± 14.11 59.18 ± 13.79* 
IL-6 2292.66 ± 
305.00 
4855.36 ± 176.80 6222.61 ± 1697.01* 5926.08 ± 996.72 
IL-8 277.08 ± 132.28 2712.97 ± 106.91* 3124.39 ± 536.64* 3042.63 ± 
252.75* 
IL-10 ND ND ND ND 
Il-12 ND 2.79 ± 1.66 2.31 ± 2.31 1.70 ± 1.70 
IL-13 ND 7.67 ± 7.67 ND ND 
IL-15 ND ND ND ND 
Il-17 ND ND ND ND 
IL-23 ND 58.23 ± 58.23 ND 227.95 ± 123.53 
TNFα ND N/A ND N/A 
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Figure 3.13 Response of human lung fibroblasts to the TLR3 agonist Poly(I:C) 
 
 
Figure 3.13 Human lung fibroblasts treated with the TLR3 agonist Poly(I:C) (10μg/ml) with 
and without TNFα (10ng/ml) and assayed for IL-8 (A), IP10 (B) and ET-1 (C). Data are 
expressed as mean ± standard error of the mean (SEM) from n=5-12 experiments performed 
in singlicate. Statistical significance (*<0.05 for effect versus control and #<0.05 for effect 
versus TNFα) was determined by one-way ANOVA with Bonferroni’s multiple comparison 
post-test adjustment. 
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Table 3.7 Cytokine release from human lung fibroblasts treated with the TLR3 agonist 
Poly(I:C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.7 Human lung fibroblasts treated with the TLR3 agonist Poly(I:C) (10μg/ml) and 
assayed for a variety of cytokines. Data are expressed in pg/ml as mean ± standard error of 
the mean (SEM) from n=3 experiments performed in singlicate. Statistical significance 
(*<0.05) was determined by unpaired t test. ND = not detected. Statistically significant 
results in bold. 
 
 
pg/ml Control Poly(I:C) 
IFNα ND ND 
IFNβ 16.21 ± 
13.49 
4.83 ± 4.83 
IFNγ ND ND 
IFNλ ND 275.51 ± 
41.59 * 
IL-1α ND ND 
IL-4 ND 12.32 ± 
12.32 
IL-5 7.20 ± 3.90 146.94 ± 
11.80 * 
IL-6 1895.42 ± 
601.28 
10082.12 ± 
843.07 * 
IL-8 1231.60 ± 
172.56 
4252.05 ± 
353.03 * 
IL-10 ND 28.10 ± 
1.26 * 
Il-12 ND 0.42 ± 0.42 
IL-13 13.08 ± 
6.82 
30.70 ± 
2.67 
IL-15 ND ND 
Il-17 ND ND 
IL-23 ND ND 
TNFα ND ND 
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Figure 3.14 Response of human lung microvascular endothelial cells to the TLR3 agonist 
Poly(I:C) 
 
Figure 3.14 Human lung microvascular endothelial cells  treated with the TLR3 agonist 
Poly(I:C) (10μg/ml) or TNFα (10ng/ml) and assayed for IP10 (A) and ET-1 (B). Data are 
expressed as mean ± standard error of the mean (SEM) from n=3-4 experiments performed 
in singlicate. Statistical significance (*p<0.05) compared to control was determined by one-
way ANOVA with Dunnett’s multiple comparison post-test adjustment. 
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Figure 3.15 Response of human lung microvascular endothelial cells to the TLR3 agonist 
Poly(I:C) – MSD (I) 
 
 
 
 
 
Figure 3.15 Human lung microvascular endothelial cells treated with the TLR3 agonist 
Poly(I:C) (10μg/ml) and assayed for GM-CSF (A), IFNγ (B), IL-1β (C) and IL-2 (D). Data are 
expressed as mean ± standard error of the mean (SEM) from n=3 experiments performed in 
singlicate. Statistical significance (*p<0.05) compared to control was determined by paired t-
test. 
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Figure 3.16 Response of human lung microvascular endothelial cells to the TLR3 agonist 
Poly(I:C) – MSD (II) 
 
Figure 3.16 Human lung microvascular endothelial cells  treated with the TLR3 agonist 
Poly(I:C) (10μg/ml) and assayed for IL-6 (A), IL-8 (B), IL-10 (C) and IL-12p70 (D) and TNFα (E). 
Data are expressed as mean ± standard error of the mean (SEM) from n=3 experiments 
performed in singlicate. Statistical significance (*p<0.05) compared to control was 
determined by one-sample paired t-test. 
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Figure 3.17 Response of A549 cells to the TLR3 agonist Poly(I:C) 
 
 
Figure 3.17 Human A549 cells treated with the TLR3 agonist Poly(I:C) with and without TNFα 
(10ng/ml) and assayed for IP10 (A) and ET-1 (10μg/ml of Poly(I:C) used) (B). Data are 
expressed as mean ± standard error of the mean (SEM) from n=3 experiments performed in 
singlicate. Statistical significance (*p<0.05) compared to control was determined by one-way 
ANOVA with Dunnett’s multiple comparison post-test adjustment. Statistical significance 
(p<0.05) for effect of TNFα was determined by two-way ANOVA. Non-significance denoted as 
NS. Control referred to as ‘C’. 
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Figure 3.18 Response of human alveolar type I (TT1) cells to the TLR3 agonist Poly(I:C) 
 
Figure 3.18 Human alveolar type I cells treated with the TLR3 agonist Poly(I:C) (10μg/ml) in 
the presence or absence of TNFα (10ng/ml) and assayed for IP10 (A) and ET-1 (B). Data are 
expressed as mean ± standard error of the mean (SEM) from n=3 experiments performed in 
singlicate. Statistical significance (*<0.05 for effect versus control and #<0.05 for effect 
versus TNFα) was determined by one-way ANOVA with Bonferroni’s multiple comparison 
post-test adjustment. 
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Figure 3.19 Response of human bronchial epithelial (Beas2B) cells to the TLR3 agonist 
Poly(I:C) 
 
Figure 3.19 Human bronchial epithelial cells (Beas2B) treated with the TLR3 agonist Poly(I:C) 
(10μg/ml) in the presence or absence of TNFα (10ng/ml) and assayed for IP10 (A) and ET-1 
(B). Data are expressed as mean ± standard error of the mean (SEM) from n=3 experiments 
performed in singlicate. Statistical significance (*<0.05 for effect versus control and #<0.05 
for effect versus TNFα) was determined by one-way ANOVA with Bonferroni’s multiple 
comparison post-test adjustment. 
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Figure 3.20 Response of human pulmonary artery smooth muscle cells to CXCL4 with and 
without IFNα or TNFα – IP10 release 
 
Figure 3.20 Human pulmonary artery smooth muscle cells treated with CXCL4 and IFNα 
1ng/ml (A) and 10ng/ml (B) or TNFα (C) and assayed for IP10. Data are expressed as mean ± 
standard error of the mean (SEM) from n=3 experiments performed in singlicate. Statistical 
significance (*p<0.05) compared to control was determined by one-way ANOVA with 
Dunnett’s multiple comparison post-test adjustment. Statistical significance (p<0.05) for 
effect of IFNα or TNFα was determined by two-way ANOVA. Non-significance denoted as NS. 
Control referred to as ‘C’. 
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Figure 3.21 Response of human pulmonary artery smooth muscle cells to CXCL4 with IFNα 
and TNFα – IP10 release 
 
Figure 3.21 Human pulmonary artery smooth muscle cells treated with CXCL4 and IFNα 
1ng/ml (A) or 10ng/ml (B) in the presence or absence of TNFα (10ng/ml) and assayed for 
IP10. Data are expressed as mean ± standard error of the mean (SEM) from n=3 experiments 
performed in singlicate. Statistical significance (*p<0.05) compared to control was 
determined by one-way ANOVA with Dunnett’s multiple comparison post-test adjustment. 
Statistical significance (# p<0.05) for effect of IFNα and TNFα was determined by two-way 
ANOVA. Non-significance denoted as NS. Control referred to as ‘C’. 
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Figure 3.22 Response of human pulmonary artery smooth muscle cells treated with CXCL4 
and Poly(I:C) – IP10 release 
 
 
Figure 3.22 Human pulmonary artery smooth muscle cells treated with CXCL4 (5μg/ml) 
and/or the TLR3 agonist Poly(I:C) (10μg/ml) and assayed for IP10. Data are expressed as 
mean ± standard error of the mean (SEM) from n=3 experiments performed in singlicate. 
Statistical significance (*<0.05 for effect versus control) was determined by one-way ANOVA 
with Bonferroni’s multiple comparison post-test adjustment. 
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Figure 3.23 Response of human pulmonary artery smooth muscle cells to CXCL4 with and 
without IFNα or TNFα – ET-1 release 
 
Figure 3.23 Human pulmonary artery smooth muscle cells treated with CXCL4 and IFNα 
1ng/ml (A) and 10ng/ml (B) or TNFα (10ng/ml) (C) and assayed for ET-1. Data are expressed 
as mean ± standard error of the mean (SEM) from n=3 experiments performed in singlicate. 
Statistical significance (*p<0.05) compared to control was determined by one-way ANOVA 
with Dunnett’s multiple comparison post-test adjustment. Statistical significance (# p<0.05) 
for effect of IFNα or TNFα was determined by two-way ANOVA. Non-significance denoted as 
NS. Control referred to as ‘C’. 
0.01 0.1 1 10
0
5
10
15 + IFN  1ng/ml
Control
*
*
#
C
* *
*
[CXCL4](g/ml)
E
T
-1
 (
p
g
/m
L
)
0.01 0.1 1 10
0
5
10
15
20 + IFN  10ng/ml
Control
*
*
C
*
#
[CXCL4](g/ml)
E
T
-1
 (
p
g
/m
L
)
0.01 0.1 1 10
0
2
4
6
8 + TNF
Control
NS
C
[CXCL4](g/ml)
E
T
-1
 (
p
g
/m
L
)
A 
B 
C 
 138 
 
Figure 3.24 Response of human pulmonary artery smooth muscle cells to CXCL4 with IFNα 
and TNFα – ET-1 release 
 
Figure 3.24 Human pulmonary artery smooth muscle cells treated with CXCL4 and IFNα 
1ng/ml (A) or 10ng/ml (B) in the presence or absence of TNFα (10ng/ml) and assayed for ET-
1. Data are expressed as mean ± standard error of the mean (SEM) from n=3 experiments 
performed in singlicate. Statistical significance (*p<0.05) compared to control was 
determined by one-way ANOVA with Dunnett’s multiple comparison post-test adjustment. 
Statistical significance (# p<0.05) for effect of IFNα and TNFα was determined by two-way 
ANOVA. Non-significance denoted as NS. Control referred to as ‘C’. 
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Figure 3.25 Response of human pulmonary artery smooth muscle cells treated with CXCL4 
and Poly(I:C) – ET-1 release 
 
Figure 3.25 Human pulmonary artery smooth muscle cells treated with CXCL4 (5μg/ml) 
and/or the TLR3 agonist Poly(I:C) (10μg/ml) and assayed for ET-1. Data are expressed as 
mean ± standard error of the mean (SEM) from n=3 experiments performed in singlicate. 
Statistical significance (*<0.05 for effect versus control and #<0.05 for effect versus Poly(I:C)) 
was determined by one-way ANOVA with Bonferroni’s multiple comparison post-test 
adjustment. 
 
 
C
on
tr
ol
P
ol
y(
I:C
)
C
X
C
L4
C
X
C
L4
 +
 P
ol
y(
I:C
)
0
2
4
6
8
10
*
* #
E
T
-1
 (
p
g
/m
L
)
 140 
 
Table 3.8 Cytokine release from human pulmonary artery smooth muscle cells treated with 
CXCL4 
pg/ml Control CXCL4 
GM-CSF 8.20 ± 3.28 8.44 ± 3.49 
IFNγ 3.96 ± 0.82 6.14 ± 2.11 
IL-1β 5.70 ± 0.92 2.18 ± 0.67 * 
IL-2 3.01 ± 0.86 1.67 ± 0.76 
IL-6 1656 ± 373.5 2399 ± 812.5 
IL-8 457.9 ± 61.06 336.6 ± 160.1 
IL-10 4.29 ± 1.36 5.45 ± 1.08 
IL-12p70 2.02 ± 0.25 1.83 ± 0.51 
TNFα 10.15 ± 8.03 11.51 ± 8.16 
 
Table 3.8 Human pulmonary artery smooth muscle cells treated with CXCL4 (5μg/ml) and 
assayed for a variety of cytokines. Data are expressed in pg/ml as mean ± standard error of 
the mean (SEM) from n=3 experiments performed in singlicate. Statistical significance 
(*<0.05) was determined by paired t test. Statistically significant results in bold. 
 
 
 141 
 
Figure 3.26 Human lung microvascular endothelial cells treated with CXCL4, IFNα, TNFα or 
Poly(I:C) – IP10 release 
 
Figure 3.26 Human lung microvascular endothelial cells treated with CXCL4 and IFNα 1ng/ml 
(A), IFNα 10ng/ml (B), TNFα (10ng/ml) (C) or Poly(I:C) (10μg/ml) (D) and assayed for IP10. 
Data are expressed as mean ± standard error of the mean (SEM) from n=3 experiments 
performed in singlicate. Statistical significance (*p<0.05) compared to control was 
determined by one-way ANOVA with Dunnett’s multiple comparison post-test adjustment. 
Statistical significance (# p<0.05) for effect of IFNα, TNFα or Poly(I:C) was determined by 
two-way ANOVA. Non-significance denoted as NS. Control referred to as ‘C’. 
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Figure 3.27 Human lung microvascular endothelial cells treated with CXCL4, IFNα, TNFα or 
Poly(I:C) – ET-1 release 
 
Figure 3.27 Human lung microvascular endothelial cells treated with CXCL4 and IFNα 1ng/ml 
(A), IFNα 10ng/ml (B), TNFα (10ng/ml) (C) or Poly(I:C) (10μg/ml) (D) and assayed for IP10. 
Data are expressed as mean ± standard error of the mean (SEM) from n=3 experiments 
performed in singlicate. Statistical significance (*p<0.05) compared to control was 
determined by one-way ANOVA with Dunnett’s multiple comparison post-test adjustment. 
Statistical significance (p<0.05) for effect of IFNα, TNFα or Poly(I:C) was determined by two-
way ANOVA. Non-significance denoted as NS. Control referred to as ‘C’.  
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Table 3.9 Cytokine release from human lung microvascular endothelial cells treated with 
CXCL4 
pg/ml Control CXCL4 
GM-CSF 1.61 ± 0.41 1.20 ± 0.69 
IFNγ 0.75 ± 0.26 0.70 ± 0.28 
IL-1β 0.44 ± 0.17 1.11 ± 0.82 
IL-2 0.33 ± 0.06 4.57 ± 4.38 
IL-6 1.72 ± 1.36 1.87 ± 1.70 
IL-8 181.5 ± 37.1 240.2 ± 57.4 
IL-10 0.40 ± 0.16 0.13 ± 0.13* 
IL-12p70 0.69 ± 0.22 0.77 ± 0.31 
TNFα 0.23 ± 0.05 0.17 ± 0.08 
 
Table 3.9 Human lung microvascular endothelial cells treated with CXCL4 (5μg/ml) and 
assayed for a variety of cytokines. Data are expressed in pg/ml as mean ± standard error of 
the mean (SEM) from n=3 experiments performed in singlicate. Statistical significance 
(*<0.05) was determined by one-sample paired t test. Statistically significant results in bold. 
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Table 3.10 The effect of treatments on cell viability as measured by the alamarBlue® test 
 
Treatment HPASMC HMVEC HLFs HEPS A549 TT1 Beas2B 
Basal 0.84±0.2 0.31±0.1 0.18 ± 0.0 0.11 ± 0.0 0.54 ± 0.0 0.17 ± 0.0 0.40 ± 0.0 
IFNα 0.86 ± 0.2 
+2.4% 
0.31 ± 0.1 
0% 
0.17 ± 0.0 
-5.5% 
0.08 ± 0.0 
-27.3%  
0.58 ± 0.0 
+7.4% 
0.18 ± 0.0 
+ 5.9% 
0.40 ± 0.0 
0% 
IFNγ 0.82 ± 0.3 
-2.4% 
0.33 ± 0.0 
+ 6.5% 
0.18 ± 0.0 
+5.9% 
0.10 ± 0.0 
-9.1% 
0.50 ± 0.1 
-7.4% 
0.18 ± 0.0 
+5.9% 
0.40 ± 0.0 
0% 
IFNλ 0.96 ± 0.2 
+14.3% 
0.38 ± 0.1 
+22.6% 
DM 0.10 ± 0.0 
-9.1% 
0.55 ± 0.0 
+1.9% 
0.16 ± 0.0 
-5.9% 
0.40 ± 0.0 
0% 
Poly(I:C) 0.92 ± 0.2 
+9.5% 
0.30 ± 0.0 
-3.2% 
0.17 ± 0.0 
-5.6% 
N/A 0.57 ± 0.0 
+5.6% 
0.19 ± 0.0 
+11.7% 
0.41 ± 0.0 
+2.5% 
TNFα 0.86 ± 0.3 
+2.4% 
0.31 ± 0.0 
0% 
0.17 ± 0.0 
0% 
0.12 ± 0.0 
+9.1% 
0.56 ± 0.0 
+3.7% 
0.18 ± 0.0 
+5.9% 
0.36 ± -0.0 
-10% 
IFNα/TNFα 0.85 ± 0.3 
+1.2% 
0.42 ± 0.1 
+35.5% 
0.17 ± 0.0 
0% 
0.09 ± 0.0 
-18.2% 
0.59 ± 0.0 
+9.3% 
0.19 ± 0.0 
+11.7% 
0.40 ± 0.0 
0% 
IFNγ/TNFα 0.84 ± 0.3 
0% 
0.36 ± 0.0 
+16.1% 
0.18 ± 0.0 
+5.9% 
0.11 ± 0.0 
0% 
0.58 ± 0.0 
+7.4% 
0.22 ± 0.0 
+29.4% 
0.40 ± 0.0 
0% 
IFNλ/TNFα 0.85 ± 0.3 
+1.2% 
0.35 ± 0.0 
+12.9% 
DM 0.10 ± 0.0 
-9.1% 
0.58 ± 0.0 
+7.4% 
0.19 ± 0.0 
+11.7% 
0.39 ± 0.02 
-2.5% 
Ribavirin N/A N/A N/A 0.12 ± 0.0 
+9.1% 
N/A N/A N/A 
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Ribavirin/ IFNα 
Ribavirin / IFNγ 
Ribavirin / IFNλ 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
.09(-18%) 
.08(-27%) 
.12(+9%) 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
 Poly(I:C)/TNFα 0.88 ± 0.2 
+4.7% 
N/A 0.17 ± 0.0 
-5.6% 
N/A 0.54 ± 0.0 
0% 
0.18 ± 0.0 
+5.9% 
0.39 ± 0.01 
-2.5% 
CXCL4 0.84 ± 0.1 
0% 
0.31±0.0 
0% 
N/A N/A N/A N/A N/A 
CXCL4 & TNFα 0.88 ± 0.0 
0% 
0.28±0.1 
-9.7% 
N/A N/A N/A N/A N/A 
CXCL4/IFNα/TNFα 0.88±0.0 
+ 4.8% 
N/A N/A N/A N/A N/A N/A 
+ CXCL4/Poly(I:C) 0.72±0.0 
-14.3% 
0.26 ±0.0 
-16.1% 
N/A N/A N/A N/A N/A 
 
Table 3.10 The effects of treatments on cell viability as measured by the alamarBlue® test. 
Results are shown for the highest concentrations of each treatment tested. Results are 
expressed as optical densities and are presented as mean ± standard error of the mean 
(SEM) from n=3-4 experiments. Data also presented as percentage change as compared to 
basal conditions for unstimulated cells. Statistical significance (*<0.05) was determined by 
one-way ANOVA compared to basal levels. DM denotes data missing. N/A denotes not 
applicable – treatment condition not studied. 
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Chapter 4: Interferon and pulmonary arterial 
hypertension in humans 
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4.1 Rationale for Chapter 4 
In Chapter 3 I have demonstrated that a range of human pulmonary vascular cells 
and human pulmonary epithelial cells can sense type I and type II IFNs to release a range of 
pro-inflammatory cytokines as well as the lymphocyte chemoattractant IP10 and the 
promitogen and vasoconstrictor ET-1. However, it is well recognised that in vitro conditions 
do not always accurately represent the dynamic multi-system state that encompasses 
human health and disease. Notwithstanding this, my findings in Chapter 3 led me to 
hypothesise that endogenously produced IFNs could potentially activate human cells in vivo 
to induce pulmonary vascular dysfunction. This may have particular relevance in conditions 
where IFNs are chronically over-produced as is the case in certain autoimmune conditions.  
Systemic sclerosis (SSc) is one such condition where there exists a strong IFN (and 
specifically type I IFN) signature and type I IFN activation has been found to associate with 
pulmonary vascular disease manifestations (Christmann et al., 2011; Eloranta et al., 2010). 
Indeed SSc is a major risk factor for PAH with a prevalence of 12% (Mukerjee et al., 2003). In 
addition to the established link between autoimmune conditions such as SSc and PAH, there 
is now a growing body of evidence to implicate the role of inflammation in the initiation and 
promotion of PAH even in idiopathic forms of the condition (Tuder et al., 2013). 
Although the association between SSc and PAH is well established, the pathobiology 
remains largely unexplained. As mentioned above, a relationship between type I IFN and 
pulmonary vascular disease in SSc has been suggested but no mechanism has been 
elucidated. ET-1 is a critical therapeutic target in PAH and so my findings from Chapter 3 
that type I and II IFNs strongly activate pulmonary vascular cells to release it are potentially 
important.  
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These findings led me to hypothesise that; 
“Chronic endogenous generation of type I interferons can induce ET-1 in humans and 
therefore result in pulmonary vascular dysfunction and pulmonary arterial hypertension.” 
The aims of this chapter were therefore as follows: 
1) To assess whether exogenous IFN administration results in ET-1 induction in 
humans. 
2) To measure the levels of ET-1, IP10, IFNs and related cytokines in the serum of 
patients with SSc associated PAH (SSc-PAH) and to make comparisons with 
patients with SSc and no evidence of PAH and healthy controls. 
3) To establish whether the production of ET-1 in SSc-PAH patients is dependent 
on IFN pathways.  
4) To look for correlations between IFN pathways and clinical characteristics in 
patients with SSc-PAH. 
5) To assess for the presence of IFN receptors and TLR3 in the pulmonary 
vasculature of PAH patients. 
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4.2 Summary of Methods for Chapter 4 
A detailed methodological description is given in Chapter 2 and is summarised below 
4.2.1 Measurement of endothelin-1 in patients treated with IFNα2a 
Serum levels of ET-1 were measured by ELISA (R&D Systems, Abingdon, UK) in 16 
patients with HCV in whom a decision had been made to commence IFNα2a therapy with 
Pegasys® at 180μg subcutaneously once a week. ET-1 levels were measured in serum taken 
prior to commencement of therapy and in serum taken at designated time points over a six 
month period of treatment. HCV viral load was also measured at the same intervals. In all 
patients sampled, cirrhosis (and therefore any chance of portopulmonary hypertension) was 
excluded by biopsy. As these were archival samples, respiratory symptoms were not 
monitored. 
4.2.2 Assessment of patients with Systemic Sclerosis with and without PAH 
63 patients with SSc (28 patients with SSc-PAH and 35 SSc patients without PAH) 
were recruited from two centres; Royal Free Hospital, London and Papworth Hospital 
Research Tissue Bank. Healthy controls were recruited from Royal Free Hospital and Royal 
Brompton Hospital. Serum IFN, IP10, ET-1 and cytokine levels were measured by specific 
ELISA as described in detail in Chapter 2. Clinical data were collected for each patient where 
available. Patients with PAH secondary to lung disease or left heart disease were excluded 
and only those SSc patients with PAH confirmed on right heart catheterisation were 
included. Patients with SSc and no PAH were defined as such on echocardiographic criteria. 
4.2.3  Assessment of interferon receptors and TLR3 in patients with PAH 
IFNAR1, IFNGR1, IL28RA and TLR3 expression was studied using 
immunohistochemistry performed on lung tissue from patients with SSc-PAH, idiopathic 
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(I)PAH and healthy controls. IFNAR1 expression in the same group of patients was measured 
by Western blotting and ImageJ software was used to quantify protein expression. A more 
detailed description of the methods used is given in Chapter 2.  
4.2.4  Analysis and Statistics 
Data is presented as mean ± standard error of the mean (SEM) and data points 
represent individual patient readouts. Data was analysed with Graph Pad Prism 5 using 
statistical tests referred to in the figure legends. For all data, the Kolmogorov-Smirnov test 
of normality was applied. All normally distributed data were analysed by one-way ANOVA 
followed by Bonferroni post-test adjustment for multiple comparisons and for correlations 
with clinical parameters, the Pearson correlation coefficient was applied. Nonparametric 
data were analysed by the Kruskal-Wallis test followed by Dunn multiple comparison test 
and for correlations, the Spearman rank test was used. A p value of <0.05 was taken as 
significant and denoted by * and p>0.05 was considered non-significant.  
 
4.3 Results 
4.3.1  Measurement of serum endothelin-1 in patients treated with IFNα2a 
Of 16 patients with HCV treated with subcutaneous IFNα2a over a six month period, 
two individuals responded with an increase in circulating ET-1 (Fig. 4.1 A – B) despite a drop 
in hepatitis C viral load to undetectable levels. In the other 14 patients there was no 
increase in ET-1 after IFNα2a treatment regardless of whether patients responded to the 
treatment to clear virus (Fig. 4.1 C) or not (Fig. 4.1 D). 24 hours after treatment with IFNα2a 
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there was a clear and significant increase in serum IP10 levels. This was transient since IP10 
was not elevated at later treatment time points of IFNα2a therapy (Table 4.1). 
4.3.2  Serum IFN, IP10 and ET-1 levels in patients with SSc-PAH 
Five (18%) SSc-PAH patients had detectable IFNα levels whilst only 2 (5.7%) patients 
in the SSc but no PAH had detectable levels. In all control subjects, serum IFNα was below 
the level of detection (Fig 4.2 A). There was a similar pattern for serum IFNγ levels where 6 
(21%) patients with SSc-PAH had detectable levels but IFNγ could only be measured in 2 
(5.7%) SSc without PAH patients and was not detectable in any of the controls (Fig. 4.2 C). 
IFNβ levels were similar in all three groups (Fig. 4.2 B). There was a clear but non-significant 
trend to increased levels of serum IFNλ in patients with SSc-PAH as compared to SSc without 
PAH and healthy controls. Serum levels of IP10 and ET-1 were significantly raised in SSc-PAH 
patients as compared to SSc without PAH and healthy controls (Fig. 4.2 E – F). SSc-PAH 
patients in whom at least one of the IFNs was detectable had more severe right ventricular 
dysfunction as measured by serum BNP levels (Fig. 4.3 A). In SSc-PAH patients, serum levels 
of IP10 and ET-1 correlated well together suggesting that the production of ET-1 may be 
linked to IFN pathways as reflected by IP10 (Fig. 4.3 B). Importantly, in patients with SSc but 
no evidence of PAH, there was no relationship between serum IP10 and ET-1 levels (Fig. 4.4) 
4.3.3  Correlations between IP10 and clinical characteristics in SSc-PAH patients 
In patients with SSc-PAH, serum levels of IP10 correlated well with a number of 
clinical and haemodynamic parameters. A positive correlation was found between IP10 and 
pulmonary vascular resistance (PVR) (Fig. 4.5 A), IP10 and mean pulmonary artery pressure 
(mPAP) (Fig. 4.5 B) and IP10 and serum BNP (Fig. 4.5 C) and a negative correlation was found 
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between IP10 and cardiac index (Fig. 4.5 D) and IP10 and 6 minute walk test (6MWT) (Fig. 
4.5 E).  
4.3.4  Cytokine levels in patients with SSc-PAH, SSc no PAH and healthy controls 
In patients with SSc (with and without PAH), there were trends to raised levels of IL-
1α (Fig. 4.6 A) and IL-8 (Fig. 4.7 A) and in SSc-PAH patients there were statistically significant 
increases in levels of IL-6 (Fig. 4.6 D), IL-12p70 (Fig. 4.7 C) and TNFα (Fig. 4.7 F). 
4.3.5  Demographics of patients with SSc-PAH, SSc no PAH and healthy controls  
The majority of SSc-PAH patients had limited cutaneous forms of the disease and the 
mean age was 63.04 years of age (Tables 4.2 & 4.3) while the mean age of the SSc but no 
PAH group was 69.14 (Tables 4.4 and & 4.5) and the mean age of the healthy controls was 
51.78 (Table 4.6). Statistical significance was found for age at sampling between healthy 
controls and SSc-PAH as well as healthy control and SSc but no PAH as assessed by one-way 
ANOVA followed by Bonferroni’s multiple comparison post-test. No difference between age 
at sampling for patients with SSc-PAH and those with SSc but no PAH. No other significant 
difference between the groups was found. 
4.3.6  Interferon receptor expression in lungs of patients with PAH 
There was a greatly increased level of IFNAR1 expression in lung sections from 
patients with SSc-PAH as compared to controls and this was most abundantly concentrated 
within the smooth muscle layer, endothelium and vascular interstitium as well as within 
inflammatory intravascular cells (Fig. 4.8). There was also an increase in IFNGR1 expression 
which was far less profound although following similar morphological patterns to IFNAR1 
(Fig. 4.9). An increase in IL28RA expression in SSc-PAH was also observed although the 
pattern of receptor expression differed to that of the types I and II IFNs with staining 
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predominantly seen within the epithelial cell layer (Fig. 4.10). In addition to these findings in 
SSc-PAH patients, there was also a striking increase in IFNAR1 expression in lung sections 
from patients with idiopathic (I)PAH (Fig 4.11). Using Western blot quantification of IFNAR1 
from total lung homogenate, there were significantly raised protein levels in lung tissue of 
all IPAH patients tested (Fig. 4.12). This was not the case for all SSc-PAH patients where 
IFNAR1 expression was raised in some but not all patients tested raising the possibility of 
two distinct populations (Fig. 4.12). To some extent, on histological assessment, all six SSc-
PAH patients examined displayed important venous involvement. However, the three SSc-
PAH patients with a predominance of arterial involvement with profound arterial 
inflammation and concentric laminar fibrosis of the intima - histopathology that more 
closely resembled IPAH, had far higher IFNAR1 gross lung levels (Fig. 4.12 A lines 10-12) & 
(Fig. 4.13 A & B). In contrast, the three SSc-PAH patients with a predominance of venous 
involvement with fibrotic occlusive remodelling and relatively less arteriopathy had far 
lower total IFNAR1 levels which were similar to levels observed in healthy controls (Fig. 4.12 
A lines 7-9) & (Fig. 4.13 C).     
4.3.7  TLR3 expression in patients with pulmonary arterial hypertension 
IPAH patients displayed an abundance of TLR3 within plexiform lesions, vascular 
smooth muscle layers, the vascular interstitium and intravascular inflammatory cells as 
compared to controls (Fig 4.14).  
 
4.4 Summary and Limitations 
Below is a brief summary of the data presented in this chapter. This work is 
discussed in detail and in the context of the entire thesis in Chapter 6. 
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4.4.1  Summary 
In this chapter I have demonstrated that exogenous IFNα administration can induce 
ET-1 in a small proportion of exposed individuals. I have also shown that in patients with 
SSc-PAH, endogenous IFN pathways are chronically activated and that the archetypal IFN 
stimulated gene IP10, correlates strongly with ET-1 and a number of clinical and 
haemodynamic parameters. IP10 is a potent chemoattractant that promotes the formation 
of lymphoid infiltrates by attracting T lymphocytes to the endothelium (Taub et al., 1993) as 
well as mediating endothelial dysfunction by disrupting calcium homeostasis (Zabini et al., 
2012). The finding that serum IP10 levels are raised in patients with SSc-PAH and correlate 
well with ET-1 lends credence to the hypothesis that endogenous IFNs can induce the 
release of ET-1 in humans and result in a pulmonary vascular disease phenotype.   
I have discovered that there exists heterogeneity in the abundance of IFNAR1 
expression in patients with SSc-PAH depending on the level of arterial involvement. While 
those patients with an arteriopathy that histomorphologically more closely resembled true 
pulmonary arterial hypertension had very high IFNAR1 expression, SSc-PAH patients with 
relatively less arterial disease and more venous involvement which more closely resembled 
pulmonary venous occlusive disease (PVOD) had very low IFNAR1 expression. This is of 
possible clinical relevance since it is known that patients with pulmonary venous disease in 
the context pulmonary hypertension associated with SSc do not respond well to PAH 
targeted therapy and that pulmonary vasodilators are contraindicated in PVOD given the 
high risk of pulmonary oedema and even death. These findings suggest that there exists a 
spectrum of relative arterial and venous involvement in SSc-PAH and that this is mirrored by 
IFNAR1 expression. It would be now be interesting to explore whether a serum marker of 
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IFN activation such as IP10 could identify individuals with a predominance of arterial disease 
and hence those patients who would benefit most from specific PAH therapies. 
It was an unexpected finding that there was an abundance of IFNAR1 expression in 
the lung section of all IPAH patients examined. While the importance of inflammation and 
potentially undiagnosed autoimmunity in PAH has long been debated (Nicolls et al., 2005), 
the importance of IFN signalling in IPAH patients has not previously been explored. The 
finding that type I IFN receptor expression is relevant in the lungs of patients with IPAH 
provides a new and exciting perspective suggesting that modulation of IFN signalling 
pathways may be of benefit in patients with IPAH as well as SSc-PAH. 
The increase in TLR3 expression within lung sections of patients with PAH presents 
an intriguing window into the potential effect of inappropriate TLR activation within the 
lungs of patients with PAH. There is a long standing link between viruses and PAH (Cool et 
al., 2011) and this finding may corroborate this line of thought or conceivably suggest that 
TLR3 ligation by DAMPs or autoantibodies may result in the initiation or propagation of 
pulmonary vascular dysfunction in affected individuals.  An alternative explanation is that 
TLR3 expression could be induced by IFN. It has previously been demonstrated that TLR3 is 
an ISG (Sykes et al., 2012) and it is conceivable that continued IFN activity within the lungs 
could lead to upregulation of TLR3. Whether the observation that TLR3 expression is raised 
in the lungs of patients with PAH is cause or effect now requires further study. 
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4.4.2 Limitations 
 Measurement of ET-1 and IP10 in IFNα2a treated HCV patients 
The main limitation was that the serum samples assayed were archival ones and not 
prospectively collected. While demographic data were available, there was no way of 
assessing individual patients for respiratory symptoms or potential manifestations of IFN 
induced pulmonary vascular disease. Although the clinical notes were examined for overt 
symptoms (none were reported), this is clearly inferior to direct questioning of patients and 
measurement of clinical parameters through the use of echocardiography, lung function 
testing, chest imaging and blood tests such as BNP levels. Furthermore, as these were 
banked samples with no possibility for patient recall, it was not possible to look for 
phenotypic characteristics that could help identify which patients are more likely to respond 
to exogenous IFNα by mounting an ET-1 response. An additional limitation was that with the 
exception of the day 1 sample, it proved impossible to accurately determine exactly how 
many days post IFNα2a therapy the serum sample had been taken. This was due to the fact 
that patients self-administer the drug at home on a once weekly basis and sampling time 
points were determined based on duration of time since commencing therapy and not time 
since last dose. For this reason, it is difficult to establish whether the spike in serum IP10 
levels at day 1 was simply because blood was taken exactly one day after a dose or whether 
there tolerance effect over time was being exhibited. These two limitations would need to 
be answered by performing a larger study in prospectively recruited patients where blood 
was taken at predefined time points and clinical parameters of respiratory and cardiac 
function were collected.  
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 Relationship of IFNs with PAH in SSc patients 
Although IFN levels were raised in the serum of patients with SSc-PAH, it is worth noting 
that serum levels may not accurately reflect activity at the tissue level (Prinz et al., 2008). 
The half-life of IFNα is between 10 and 20 minutes and generally, circulating levels are low 
due to dilution in body fluids, diffusion from plasma to extracellular fluid compartments, 
binding to cell surface receptors and rapid breakdown by the kidneys, liver, muscle and 
lungs (Bocci, 1981). Consequently while serum IFN levels provide a representative readout 
of net total body concentration they can only inform as to the dynamic homeostatic balance 
between production and excretion in humans.  
The majority of patients with SSc-PAH had the limited cutaneous form of the disease and 
while there is no reason to suggest that patients with diffuse cutaneous systemic sclerosis 
should differ in terms of type I IFN pathways or cytokine profiles, this would be worth 
testing in a further discrete cohort of patients. 
There was no significant difference in the ages of the SSc-PAH and SSc but no PAH 
cohort. However, the control group were significantly younger than both the SSc cohorts. 
While it is possible that this explained the differences in IFN activation, it is known that IFN 
responses dampen down with age (Qian et al., 2011) suggesting that if anything, the 
differences found may have been underestimated. 
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4.5 Chapter 4: Data 
Figure 4.1 Serum ET-1 levels in HCV patients treated with IFNα2a  
 
Figure 4.1 Serum levels of Endothelin-1 (ET-1) and Hepatitis C Viral (HCV) Load in 16 patients 
receiving IFNα2a (180μg subcutaneously once weekly) and weight-based oral Ribavirin 
(1000-1200mg daily) over a 6 month period.  n=16, M:F10:6, Age range (mean): 24 years 5 
months – 61 years 1 month (45 years, 2 months). (A) Patient 1 – Hepatitis C viral suppression 
from week 8 of IFN therapy that was maintained through treatment and level of ET-1 that 
became elevated peaking at week 4 of treatment. (B) Patient 2 – Hepatitis C viral 
suppression from week 4 of IFN therapy that was maintained through treatment and level of 
ET-1 that showed a considerable rise at week 8 and was even further elevated at 24 weeks. 
(C) Patients 3 – 13 – Patients who responded well to IFN therapy with viral suppression by 24 
weeks but in whom ET-1 levels did not become elevated. (D) Patients 14 – 16 – Patients who 
did not respond to IFN therapy and in whom ET-1 levels were not elevated. Two patients had 
treatment up to week 12 and one patient continued to receive treatment up until week 24. 
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Table 4.1 Serum IP10 levels in HCV patients treated with IFNα2a 
pg/ml Pre-
Treatment Day 1 Day 8 Week 4 Week 8 Week 24 
Patient 
1 75.26 7.77 246.44 304.32 158.37 134.70 
Patient 
2 290.57 1476.64 287.76 350.19 244.67 306.57 
Patient 
3 290.63 1106.58 583.58 203.15 IS 198.21 
Patient 
4 1790.91 4772.62 2160.98 2118.04 1185.56 1064.54 
Patient 
5 1033.36 1364.78 1672.34 IS 486.63 1171.17 
Patient 
6 72.65 486.97 182.32 146.14 96.24 125.24 
Patient 
7 183.80 1073.71 225.91 287.93 283.17 IS 
Patient 
8 205.00 567.53 IS 177.50 152.40 167.45 
Patient 
9 428.05 672.81 220.79 152.70 104.64 111.50 
Patient 
10 514.74 405.17 394.53 241.27 180.05 IS 
Patient 
11 586.84 533.91 530.01 186.38 145.08 IS 
Patient 
12 244.32 618.60 260.71 IS 138.54 129.35 
Patient 
13 300.00 710.99 377.03 IS 310.02 346.33 
Patient 
14 484.04 412.06 310.31 136.65 178.36 200.87 
Patient 
15 365.84 1348.09 IS 271.76 309.18 173.39 
Patient 
16 135.49 529.38 503.74 223.73 101.99  IS 
Mean 
±SEM 
437.59 ± 
107.93 
1005.48 ± 
271.10 * 
568.32 ±
158.26 
369.21 ± 
146.87 
271.66 ± 
70.73 
344.11 ±
106.55 
 
Table 4.1 Serum levels of IP10 in 16 patients receiving IFNα2a (180μg subcutaneously once 
weekly) and weight-based oral Ribavirin (1000-1200mg daily) over a 6 month period.  n=16, 
M:F10:6, Age range (mean): 24 years 5 months – 61 years 1 month (45 years, 2 months). 
Data expressed as individual patient samples in pg/ml and also as mean ±standard error of 
the mean (SEM). Statistical significance (*p<0.05 for effect of treatment versus Pre-
treatment levels) was determined by one-way ANOVA with Dunnett’s post-test adjustment. 
IS = Insufficient sample available for assay. Statistically significant results in bold. 
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Figure 4.2 Serum IP10, ET-1 and IFN levels in patients with SSc-PAH, SSc without PAH and 
healthy controls
 
Figure 4.2 Serum levels of IFNα (A), IFNβ (B), IFNγ (C), IFNλ (D), IP10 (E) and ET-1 (F) from 
controls, n=9, Systemic sclerosis (SSc) patients without PAH, n=35 and SSc-PAH patients, 
n=28. Individual data points refer to each patient and means of all patients in the cohort are 
represented by horizontal lines. Statistical significance (*p<0.05) for all three groups 
compared to each other was determined by Kruskal-Wallis test followed by Dunn’s multiple 
comparison post-test for non-parametric data (A-D) and by one-way ANOVA followed by 
Bonferroni’s multiple comparison post-test for normally distributed data (E & F). 
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Figure 4.3 Serum BNP, IP10 and ET-1 levels measured in cohort of SSc-PAH patients 
 
Figure 4.3 Serum brain natriuretic peptide (BNP) levels in “IFN positive” and “IFN negative” 
SSc-PAH patients (A). Data expressed as mean ± SEM. Statistical significance (*p<0.05) 
determined using a t-test. Serum IP10 and ET-1 levels measured in SSc-PAH patients, n=28 
(B). Data points represent individual patient readouts. Correlation was determined using 
Pearson’s correlation coefficient and r and p values are shown. 
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Figure 4.4 Correlation between IP10 and ET-1 in SSc patients without PAH 
 
Figure 4.4 Correlation between IP10 and ET-1 in SSc patients without PAH, n=35. Data points 
represent individual patient readouts. Correlation was determined using Pearson’s 
correlation coefficient and r and p values are shown. 
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Figure 4.5 Correlation of IP10 with clinical and haemodynamic parameters in SSc-PAH 
patients 
Figure 4.5 Correlation of IP10 with clinical and haemodynamic parameters in SSc-PAH 
patients. Pearson’s correlation coefficient was determined between IP10 and pulmonary 
vascular resistance (PVR) (dynes), n=27 (A), mean pulmonary artery pressure (mPAP) 
(mmHg), n=27 (B), cardiac index, n=27 (D), 6-minute walk test (6MWT) (metres), n=27 (E) 
and Spearman’s rank correlation coefficient was determined between IP10 and serum brain 
natriuretic peptide (BNP) levels (pg/ml), n=18 (C). Data points represent individual patient 
readouts and r and p values are shown. 
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Figure 4.6 Cytokine serum levels from SSc patients with and without PAH and controls (I)
 
Figure 4.6 Serum IL-1α (A), IL-4 (B), IL-5 (C) and IL-6 (D) from controls, n=9, SSc patients 
without PAH, n=35 and SSc-PAH patients, n=28. Data are presented as means and statistical 
significance (*p<0.05) was determined by Kruskal-Wallis test followed by Dunn’s multiple 
comparison post-test adjustment. 
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Figure 4.7 Cytokine serum levels from SSc patients with and without PAH and controls (II) 
 
Figure 4.7 Serum IL-8 (A), IL-10 (B), IL-12p70 (C), IL-13 (D), IL-15 (E) and TNFα (F) were 
measured in controls, n=9, SSc patients without PAH, n=35 and SSc-PAH patients, n=28. Data 
are presented as means and statistical significance (*p<0.05) was determined by Kruskal-
Wallis test followed by Dunn’s multiple comparison post-test adjustment. 
 
 
 
Control SSc without PAH SSc-PAH
0
2
4
6
8
10
1000
2000
3000
4000
IL
-8
 (
p
g
/m
l)
Control SSc without PAH SSc-PAH
0
10
20
30
IL
-1
0
 (
p
g
/m
l)
Control SSc without PAH SSc-PAH
0
2
4
6
8
*
IL
-1
2
p
7
0
 (
p
g
/m
l)
Control SSc without PAH SSc-PAH
0
20
40
60
80
IL
-1
3
 (
p
g
/m
l)
Control SSc without PAH SSc-PAH
0
5
10
15
20
25
IL
-1
5
 (
p
g
/m
l)
Control SSc without PAH SSc-PAH
0
50
100
150
200
400
800 *
T
N
F

 (
p
g
/m
l)
A 
F E 
D C 
B 
 166 
 
Table 4.2 Demographic details for SSc-PAH patients (I) 
Patient 
No: 
Gender Age at 
Sampling 
Diagnosis Lung 
Function 
Antibody 
status 
Comorbidities 
1 F 61 LcSSc- PAH Unknown ACA None 
2 F 72 LcSSc- PAH DLCO 33% ACA None 
3 F 57 LcSSc- PAH 
FEV1 81%, 
FVC 101%, 
DLCO 71% 
U3RNP Atrial Fibrillation 
4 F 58 LcSSc- PAH 
FEV1 107% 
DLCO 38%  
ACA None 
5 F 62 LcSSc- PAH 
FVC 61% 
DLCO49% 
Negative None 
6 F 68 LcSSc- PAH 
FVC 110% 
 DLCO 62% 
ACA None 
7 F 62 LcSSc- PAH 
FVC 74%,  
FEV 74%,  
DLCO 49% 
ACA None 
8 F 68 LcSSc- PAH 
FVC 129% 
 FEV 97%  
DLCO 39% 
ACA None 
9 M 48 LcSSc- PAH DLCO 38% ACA None 
10 F 65 LcSSc- PAH 
FVC 105%, 
 FEV1 86%, 
DLCO 29.8% 
ACA None 
11 F 52 LcSSc- PAH Unknown ACA None 
12 F 74 LcSSc- PAH Unknown ACA None 
13 F 72 LcSSc- PAH 
FVC 111%,  
FEV1 105%, 
DLCO 52% 
ACA None 
14 F 62 LcSSc- PAH DLCO 60% Unknown None 
Table 4.2 Demographic details for patients with Systemic Sclerosis associated pulmonary 
arterial hypertension. LcSSc-PAH = limited cutaneous systemic sclerosis associated 
pulmonary arterial hypertension. FEV1 = forced expiratory volume in 1 second, FVC = forced 
vital capacity, DLCO = transfer factor of lung for carbon monoxide. ACA = anti-centromere 
antibody. Patients 1 – 14 
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Table 4.3 Demographic details for SSc-PAH patients (II) 
Patient 
No: 
Gender Age at 
Sampling 
Diagnosis Lung Function Antibody 
status 
Comorbidities 
15 F 54 LcSSc-PAH 
FEV1 78.5%,  
DLCO 48.1% 
ACA None 
16 F 73 LcSSc-PAH Normal ACA None 
17 F 71 LcSSc-PAH Normal ACA Hypothyroidism 
18 F 60 LcSSc-PAH 
FVC 105%, 
TLC 95%, DLCO 55% 
ACA None 
19 F 68 LcSSc-PAH DLCO 40%, FVC 88% ACA None 
20 F 70 LcSSc-PAH 
FEV1 73%, 
FVC 96%, DLCO 41% 
ACA None 
21 F 39 
DcSSc-
PAH 
FVC 79%,  
FEV1 82%,DLCO 67% 
ACA None 
22 F 58 
LcSSc- 
PAH 
FCV 122%, FEV1 
120%, DLCO 28% 
ANA None 
23 F 66 
LcSSc- 
PAH 
DLCO 53% ACA None 
24 F 55 SSc-PAH Unknown Unknown None 
25 M 70 SSc-PAH Unknown Unknown None 
26 M 82 SSc-PAH Unknown Unknown None 
27 M 36 SSc-PAH Unknown Unknown None 
28 F 82 SSc-PAH Unknown Unknown None 
Mean ± 
SEM  
63.04 ± 
 2.07     
Table 4.3 Demographic details for patients with Systemic Sclerosis associated pulmonary 
arterial hypertension. LcSSc-PAH = limited cutaneous systemic sclerosis associated pulmonary 
arterial hypertension, DcSSc-PAH = diffuse cutaneous systemic sclerosis associated 
pulmonary arterial hypertension. SSc-PAH = Systemic sclerosis associated PAH (unknown 
whether limited or diffuse subtype), FEV1 = forced expiratory volume in 1 second, FVC = 
forced vital capacity, DLCO = transfer factor of lung for carbon monoxide, TLC = total lung 
capacity. ACA = anti-centromere antibody, ANA = anti-neutrophil antibody. Mean age of all 
28 SSc-PAH patients with standard error of the mean (SEM) calculated. 
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Table 4.4 Demographic details for patients with SSc but no evidence of PAH (I) 
Patient 
No: 
Gender Age at 
sampling 
Antibody 
Status 
Disease 
subtype 
1 M 79 ACA LcSSc 
2 M 59 Unknown LcSSc 
3 F 79 ARA LcSSc 
4 F 80 ANA LcSSc 
5 F 84 ATA LcSSc 
6 F 81 ARA LcSSc 
7 M 62 Pm-Scl LcSSc 
8 M 71 ACA LcSSc 
9 F 74 ACA LcSSc 
10 F 64 ANA LcSSc 
11 F 61 nRNP LcSSc 
12 F 61 ANA LcSSc 
13 M 61 ACA LcSSc 
14 M 75 PM-Scl LcSSc 
15 F 77 ACA LcSSc 
16 F 66 ACA LcSSc 
17 F 79 ACA LcSSc 
18 F 66 ACA LcSSc 
 
Table 4.4 Demographic details for patients with systemic sclerosis but no evidence of 
pulmonary arterial hypertension. LcSSc = limited cutaneous systemic Sclerosis. ACA = anti-
centromere antibody, ANA = anti-neutrophil antibody, ATA = anti-topoisomerase antibody, 
ARA = anti-RNA polymerase III antibody, nRNP = ribonucleotide antibody, PM-Scl = 
autoantibodies to the polymyositis/scleroderma complex. 
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Table 4.5 Demographic details for patients with SSc but no evidence of PAH (II) 
Patient 
No: Gender 
Age at 
sampling 
Antibody 
Status 
Disease 
subtype 
19 F 71 ARA DcSSc 
20 F 75 ARA DcSSc 
21 F 66 AFA DcSSc 
22 F 75 ARA DcSSc 
23 F 56 ARA DcSSc 
24 F 70 ARA DcSSc 
25 F 59 ARA DcSSc 
26 F 47 ARA DcSSc 
27 F 54 ARA DcSSc 
28 F 68 ANA DcSSc 
29 F 62 ATA DcSSc 
30 F 61 ATA DcSSc 
31 M 91 ARA DcSSc 
32 F 68 ARA DcSSc 
33 F 79 ATA DcSSc 
34 F 71 ATA DcSSc 
35 F 68 ANA DcSSc 
Mean ± 
 SEM  
69.14 ± 
 1.61   
Table 4.5 Demographic details for patients with systemic sclerosis but no evidence of 
pulmonary arterial hypertension. DcSSc - diffuse cutaneous systemic Sclerosis. ACA – anti-
centromere antibody, ANA – anti-neutrophil antibody, ATA - anti-topoisomerase antibody, 
ARA – anti-RNA polymerase III antibody. Mean age of all 35 patients with standard error of 
the mean (SEM) calculated. 
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Table 4.6 Demographic details for healthy controls. 
Control No: Gender Age at Sampling 
1 F 63 
2 F 45 
3 F 51 
4 M 73 
5 F 74 
6 F 68 
7 F 29 
8 M 40 
9 M 23 
Mean ± SEM  51.78 ± 6.31 
 
Table 4.6 Demographic details for healthy controls. Mean age with standard error of the 
mean (SEM) calculated. 
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Figure 4.8 IFNAR1 staining in lung tissue from a SSc-PAH patient and a healthy control 
 
  
 
Figure 4.8 IFNAR1 immunohistochemistry in lung sections from a patient SSc-PAH (A & B) 
and a non-PAH control (C). Figures shown are representative images from n=3 patients. 
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Figure 4.9 IFNGR1 staining in lung tissue from a SSc-PAH patient and a healthy control 
 
 
 
Figure 4.9 IFNGR1 immunohistochemistry in lung sections from a patient with SSc-PAH (A & 
B) and a healthy control (C). Figures shown are representative images from n=3 patients. 
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Figure 4.10 IL28RA staining in lung tissue from a SSc-PAH patient and a healthy control 
 
 
Figure 4.10 IL28RA staining in a patient with SSc-PAH (A & B) and a healthy control (C). 
Figures shown are representative images from n=3 patients. 
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Figure 4.11 IFNAR1 staining in lung tissue from an idiopathic PAH patient and a healthy 
control 
 
 
Figure 4.11 IFNAR1 staining in lung sections from a patient with idiopathic (I)PAH (A & B) 
and a non-PAH control (C). Figures shown are representative images from n=3 patients. 
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Figure 4.12 IFNAR1 expression in 2 distinct populations of SSc-PAH patient, IPAH patients 
and healthy controls 
 
 
Figure 4.12 IFNAR1 expression (A); 1 to 3, n=3 controls; 4 to 6, n=3 patients with IPAH; 
(separate blot) 7 to 9, n=3 SSc-PAH patients with predominantly venous disease and 10 to 
12, n=3 SSc-PAH patients with predominantly arterial disease. Blot (A) quantified as 
expression relative to β actin (B). Statistical significance (*p<0.05) was determined by one-
way ANOVA with Bonferroni multiple comparison post-test. 
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Figure 4.13 IFNAR1 staining in lung sections from patients with SSc-PAH with high and low 
expression  
 
 
Figure 4.13 Lung samples from patients with SSc-PAH with high (A & B) and low (C) IFNAR1 
expression; hematoxylin and eosin and hematoxylineosin- saffron staining. (A), a small 
pulmonary artery displaying arteritis with transmural inflammatory infiltrate (arrows) and 
important intimal thickening. (B), a pulmonary artery adjacent to a small bronchiole (Br) 
showing quasiocclusive fibrosis of the intima. (C), a small pulmonary vein displaying 
important fibrotic occlusive remodeling, a feature frequently encountered in SSc-PAH; note 
the surrounding alveolar septa with capillary hemangiomatosis-like appearance (arrows).  
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Figure 4.14. TLR3 expression in patients with idiopathic (I)PAH and healthy controls
 
Figure 4.14 TLR3 expression in a patient with idiopathic (I)PAH  (A-D) and a healthy control 
(E). Figures shown are representative from n=3 patients. There is increased staining of the 
smooth muscle cells within a plexiform lesion (B) and also within interstitial and 
intravascular inflammatory cells (arrows in figure D). 
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Chapter 5: Interferon and pulmonary arterial 
hypertension in animal models 
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5.1 Rationale for Chapter 5 
In Chapter 4 I have demonstrated that there is an association between IFN activation 
and signalling and PAH and that this appears to be mediated by ET-1 and IP10. However, 
these findings do not specifically implicate IFN in the pathogenesis of the condition and 
could be potentially attributed to a generalised inflammatory state in which IFN signalling 
might be one of a number of important mediators. Of all the IFNs, the most recent guidance 
provided in the aftermath of the world symposium on pulmonary hypertension in 2013 
specifically implicates type I IFN in the pathogenesis of the disease (Simonneau et al., 2013). 
Given that almost all of the clinical evidence associating IFN with PAH and pneumonitis 
centres around type I IFN as opposed to types II or III IFN, I have chosen to investigate the 
importance of type I IFN signalling in pulmonary hypertension using the chronic hypoxic 
mouse model of PAH. It has recently been demonstrated that the 2 subunits that make up 
the type I IFN receptor (IFNAR1 and IFNAR2) have separate and independent actions in that 
IFNAR1 (and not IFNAR2) via an IFNAR1-IFN complex can independently transduce pro-
inflammatory signals under the control of type I IFN (de Weerd et al., 2013). Therefore to 
explore the effect of type I IFN signalling on the development of PAH, I investigated the 
response to chronic hypoxia of mice lacking functional IFNAR1 (IFNAR1-/-) and compared 
them to wild type C57Bl/6J mice.  
Circulating levels of ET-1 are increased in the chronic hypoxic mouse model (Li et al., 
1994)  and LPS induced endotoxaemia (Shindo et al., 1998). As mentioned above, LPS via 
TLR4 activates two adaptor proteins which activate distinct groups of genes; TRIF which is 
associated with the expression of IFNs and related genes such as IP10 and MyD88 which 
activates NF-κB regulated genes such as KC which is the mouse homologue of IL-8. To 
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explore the effect of type I IFN signalling on LPS induced ET-1 induction, I exposed IFNAR1-/- 
and control C57Bl/6J mice to LPS acutely and measured serum IFN, IP10 and cytokine levels. 
My primary hypothesis was that “Mice in whom type I IFN signalling is abolished are 
protected from the deleterious effects of hypoxia upon the pulmonary vasculature”.  
The aims of this chapter were therefore as follow: 
1) To assess the role of IFN in the development of PAH using the chronic hypoxia 
mouse model. 
2) To delineate whether any effects seen can be specifically ascribed to IFN pathways 
or non-specific inflammatory pathways. 
3) To attempt to create a novel mouse model of PAH using exogenous IFN 
administration. 
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5.2 Summary of methods for Chapter 5 
A detailed methodological description is given in Chapter 2 and is summarised 
below. 
5.2.1  Mice lacking a functional type I interferon receptor 
Mice lacking a functional type I IFN receptor, IFNAR1-/-, were kindly donated by Dr 
Nathan Bartlett from Imperial College London. Briefly, the mice were originally derived by 
Professor Michael Aguet at the University of Zurich with disruption of Exon III of IFNAR1 by 
insertion of a selection cassette (Müller et al., 1994). They were imported from David Tough 
at the Jenner institute in 2003 and were backcrossed 14 times at Imperial College London to 
generate IFNAR1 mice on a C57Bl/6J background.  
5.2.2  Chronic hypoxia-induced mouse model of pulmonary hypertension 
All animal studies were performed in accordance with UK Home Office Animals 
(Scientific Procedures) Act 1986 and institutional guidelines. Male C57Bl/6J mice (Charles 
River, Margate, UK) and male mice lacking a functional type I IFN receptor (IFNAR1-/- on a 
C57Bl/6J background)  aged 8-10 weeks old and weighing approximately 20 grams were 
exposed to normoxia or hypoxia (fiO2 10%) for 14 days (n=8-15 per group). At day 14, mice 
were anaesthetised and right ventricular systolic pressure (RVSP) was measured using direct 
cardiac puncture. Right ventricular (RV) hypertrophy was assessed as a ratio of RV weight to 
body weight (BW) as well as by Fulton’s Index which is a ratio of RV to left ventricle + septal 
weight. Blood was taken, serum obtained and levels of IP10, ET-1, IFNs and selected 
cytokines were measured by specific ELISA as detailed in Chapter 2. Lungs were fixed and 
transverse sections were stained with elastic Van Gieson and α-smooth muscle actin (Sigma, 
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UK). Pulmonary artery muscularisation was determined by the proportion of α-smooth 
muscle actin positive vessels of the total number of elastin stained vessels. 
5.2.2  Exogenous interferon treatment of mice 
Male C57Bl/6J mice (Charles River, Margate, UK) aged 8-10 weeks were injected via 
the subcutaneous route with either vehicle (0.9% NaCl) or pegylated IFNα2b (Viraferon™) at 
80 and 800μg/kg. Mice were humanely sacrificed at 24 hours or 72 hours. Blood was taken, 
serum obtained and IP10 and ET-1 levels measured by specific ELISA as detailed in Chapter 
2. The human dose of pegylated IFNα2b (Viraferon™) is 180μg administered subcutaneously 
which for a 60kg man equates to 3μg/kg. I chose to use higher doses of pegylated IFNα2b as 
I had expected cross species differences in IFN receptor pharmacology which may 
necessitate the presence of a higher concentration of drug. 
5.2.3  Mouse organ culture model 
Male C57Bl/6J mice (Charles River, Margate, UK) aged 8-10 weeks were humanely 
sacrificed. Segments of aorta or lung were removed and placed in individual wells of a 96 
well plate in 300μl of DMEM supplemented with 10% FCS, L-Glutamine (2mM), 
Streptomycin (100μg/ml), penicillin (100U/ml) and 1% vol/vol 100xMEM non-essential 
amino acids. Tissue was left to equilibrate for 24 hours before media was removed and 
replaced with media containing recombinant human IFNα2, pegylated human IFNα2b 
(Viraferon™) or mouse IFNαA – all at 10ng/ml. After 24 hours supernatant was removed and 
IP10 levels were measured by specific ELISA as per Chapter 2. 
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5.2.4  Mouse model of acute LPS administration 
Male C57Bl/6J mice (Charles River, Margate, UK) and male mice lacking a functional 
type I IFN receptor (IFNAR1-/- on a C57Bl/6J background)  aged 8-10 weeks old and weighing 
approximately 20-30 grams were injected via the intraperitoneal route with 10mg/kg of 
either vehicle (0.9% sterile NaCl) or LPS (Sigma, UK). At 4 hours, mice were humanely 
sacrificed using terminal anaesthesia, blood was collected and serum obtained.  
5.2.5  Analysis and Statistics 
Data are presented as mean ± standard error of the mean (SEM) and were analysed 
using Graph Pad Prism 5 using statistical tests referred to in the figure legends. In all cases 
an individual “n” refers to a single animal and if experiments were run in duplicate, means 
were calculated and carried forward as a single “n”. A p value of <0.05 was taken as 
significant and denoted by either * or # and p>0.05 was considered non-significant and 
denoted by NS. 
 
5.3 Results 
5.3.1  Response of C57Bl/6J and IFNAR1-/- mice to chronic hypoxia 
In response to chronic hypoxia, C57Bl/6J mice developed pathophysiological changes 
consistent with pulmonary hypertension (Figs. 5.1 and 5.2). However, IFNAR1-/- mice 
appeared to be relatively protected from the effects of hypoxia with lower right ventricular 
systolic pressure (RVSP), fewer remodelled pulmonary arteries, no evidence of RV 
hypertrophy and a reduction in circulating ET-1 levels (Figs. 5.1 and 5.2). There was also a 
reduction in RV mass of the IFNAR1-/- mice when assessed as a ratio of the left ventricle and 
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septum (Fulton’s index) demonstrating that the protective effect observed appeared to be 
specific to the RV and not mirrored by a change in left ventricular function or size (Fig. 5.3). 
Table 5.1 which is adapted from (Tsushima et al., 2011) compares cardiovascular 
parameters of C57Bl/6J and IFNAR1-/- mice under baseline conditions and reveals no 
differences in cardiac physiology between the two strains. 
5.3.2  Response of C57Bl/6J mice to exogenous interferon administration 
The half-life of unpegylated IFNα is approximately 8-12 hours and declines rapidly 
thereafter whereas pegylated IFNα retains maximal serum concentrations for up to 72 hours 
(Glue et al., 2000). To date there is no commercially available pegylated mouse IFNα. Given 
the short half-life of unpegylated IFNα, for a 14-day study, it was necessary to use pegylated 
IFNα. In the absence of mouse pegylated IFNα, I therefore wished to assess whether human 
pegylated IFNα was active in mice with a view to performing chronic IFN dosing 
experiments. I have previously demonstrated that patients with HCV respond to pegylated 
IFNα to release IP10 into the circulation in high concentrations 24 hours after dosing (Table 
4.1). However even at the highest dose of human pegylated IFNα (800μg/kg), mice did not 
respond by producing elevated levels of IP10 (Fig. 5.4 A). Unexpectedly, treatment with 
human pegylated IFNα reduced circulating levels of ET-1 (Fig. 5.4 B). The same patterns 
were observed at the 72 hour time point (Fig. 5.5). In order to identify whether the apparent 
insensitivity of mice to human pegylated IFNα was due to species differences and an 
inability of mice to sense human IFNα and/or due to the effect of pegylation, I performed 
organ culture experiments where mouse aorta and lung were explanted and exposed to 
unpegylated human IFNα, pegylated human IFNα or (unpegylated) mouse IFNα. Mouse 
tissue did not respond to human IFNα (neither pegylated nor unpegylated) (Fig. 5.6A) but 
responded strongly in a dose dependent fashion to mouse IFNα (Fig. 5.6B). 
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5.3.3 Response of C57Bl/6J and IFNAR1-/- mice to LPS 
In order to establish if the role of IFNα in hypoxia induced PAH and ET-1 serum levels 
was due to a non-specific inflammatory effect, I performed experiments using mice treated 
with LPS. Serum levels of the IFN associated markers IP10 and ET-1 were elevated in 
C57Bl/6J mice after exposure to LPS but were significantly attenuated in IFNAR1-/- mice (Fig. 
5.7). LPS induced increases in IFNα and IFNγ in serum of C57Bl/6J mice but again these 
responses were similarly abrogated in IFNAR1-/- mice (Fig. 5.8 A & B). Serum IFNλ levels 
were not altered by LPS administration (Fig. 5.8 C). Importantly, keratinocyte-derived 
chemokine (KC), the mouse homologue of IL-8, which is elevated by LPS independently of 
IFN signalling, was induced equally in both C57Bl/6J and IFNAR1-/- mice (Fig. 5.8 D). 
 
5.4 Summary and Limitations 
5.4.1  Summary 
In this chapter, using genetically modified mice lacking a functional type I IFN 
receptor, I have demonstrated a causal relationship for type I IFN in PAH. I have shown that 
type I IFN signalling drives the harmful effects of hypoxia on the pulmonary vasculature, on 
the RV and on increased serum ET-1 levels. I have shown that the development of PAH in 
mice exposed to chronic hypoxia occurs via the type I IFN receptor IFNAR1 and that this may 
be mediated by IP10 and ET-1.  
Through previous in vitro work, ET-1 has been shown to be an IFN stimulated gene 
(Wort et al., 2009). However this has never been demonstrated in an in vivo model. I 
therefore wished to explore whether the reduction in serum ET-1 observed in the IFNAR1-/- 
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mice exposed to hypoxia was due to an amelioration in pulmonary vascular pathology or 
due to a diminution in type I IFN signalling and hence ET-1 production. As predicted, I found 
that IP10 but not KC release induced by LPS was mediated by IFNAR1. KC which is the mouse 
homologue of IL-8 was released in response to LPS exposure independently of IFN as 
evidenced by serum levels that were unaffected by a lack of type I IFN signalling. 
Importantly, much like IP10, ET-1 release was dependent on IFNAR1 implicating IFN 
pathways and not more generalised non-specific inflammatory pathways. As well as 
supporting my hypothesis linking type I IFN with PAH, this is the first in vivo demonstration 
of ET-1 as an IFN dependent gene. 
As mice were insensitive to human IFNs and because there is no pegylated mouse 
IFN available, I was unable to create a novel model of IFN induced PAH in mice. Given the 
short half-life of unpegylated IFN, it proved impractical to carry out a chronic IFN dosage 
protocol. The finding that high concentrations of human pegylated IFNα2b actually reduced 
ET-1 levels in mice might be explained by the effects of using doses that are 25x and 250x 
those used in humans on a weight basis.     
5.4.2  Limitations 
While the chronic hypoxia mouse model of PAH is well established given its 
predictability and reproducibility, it is not without its limitations. The histopathological 
pulmonary vascular changes observed in mice exposed to chronic hypoxia show no evidence 
of the non-reversible intimal fibrosis or plexogenic lesions that are the hallmarks of human 
disease (Stenmark et al., 2009). Furthermore, the responses to chronic hypoxia are 
significantly affected by the strain and age of the animal. I attempted to control for this by 
strictly only including mice that were between 8 and 10 weeks old. Furthermore, there were 
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no differences in baseline pulmonary haemodynamics of the C57Bl/67 and the IFNAR1-/- 
suggesting that at least under normoxic conditions the animals were well matched. Mice 
unlike rats develop relatively small changes in pulmonary vascular muscularisation after 
exposure to chronic hypoxia. While the changes observed in my experiments were indeed 
small, there were clear and significant differences between the two strains of mouse under 
hypoxic conditions. It was not possible to repeat the experiments in rats as there does not 
exist a genetically modified rat lacking a functioning type I IFN receptor. This also meant that 
the monocrotaline model of PAH (which has similar limitations to chronic hypoxia but is only 
applicable to rats) was not available to me. There exists an alternative mouse model of PAH 
developed by Taraseviciene-Stewart and colleagues (Taraseviciene-Stewart et al., 2001); the 
Sugen Hypoxia model in which mice are injected with the VEGF inhibitor Sugen 5416 and 
exposed to chronic hypoxia. This model is considered by some to be more representative of 
human disease in that there is a florid obstructive vasculopathy with plexiform lesions, a 
more severe PAH phenotype and RV failure. It also provides a more “inflammatory” milieu 
and so it is reasonable to speculate that the improvement in RVSP, mean pulmonary artery 
pressure and RV hypertrophy observed in the IFNAR1-/- mice exposed to chronic hypoxia 
would be even more marked in the Sugen hypoxia model. 
I was unable to create an IFN induced model of PAH which was a consequence of the 
insensitivity of mice to pegylated human IFN. This is a limitation that could have been 
overcome with three times a day dosing of native mouse IFNα. Although impractical, it 
would have been interesting to assess the effect on the pulmonary vasculature and RV of 
chronic IFN administration with and without hypoxia. A strategy to overcome this would 
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have been to create a pegylated mouse IFNα although this fell outside the scope of my 
thesis. 
It was an interesting finding that high concentrations of human pegylated IFNα2b 
reduced serum ET-1 levels in mice. This was an interesting phenomenon which I did not 
have the opportunity to investigate further through broader dose response experiments 
and assessments of animals to rule out toxicity associated with such high doses. Viraferon® 
consists of IFNα2b covalently conjugated to a 12kDa monomethoxy polyethylene glycol 
chain. In humans the 12kDa pegylated IFNα2b breaks down soon after subcutaneous 
injection to release free IFNα2b. While clearance mechanisms have not yet been fully 
elucidated, renal elimination in humans is thought to account for approximately 30% of 
apparent clearance. There is no published literature on the pharmacokinetics of human 
pegylated IFNα2b in mice. Furthermore the pre-clinical data available on the FDA website as 
provided by Schering-Plough; 
(http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelo
pedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm094485.pdf) 
was obtained in cynomolgus monkeys (and in fewer experiments, rats) injected 
intravenously or subcutaneously. ET-1 readily dissolves in ethylene glycol (Janes et al., 1994; 
Krystek et al., 1991). As high concentrations of pegylated IFNα2b were used with a 
consequent large volume of ethylene glycol released, it is feasible to speculate that this 
dissolved circulating ET-1. This may have resulted in decreased serum levels and the 
hypothesis could have been tested in vitro by adding pegylated IFNα2b to an ET-1 standard 
curve and measuring ET-1 levels. Importantly, IP10 is not thought to dissolve in ethylene 
glycol. Given that the effect observed was selective for ET-1 with no effect on IP10, another 
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possible explanation could be that polyethylene glycol exerts an effect on endothelial cell 
production of ET-1. This could be tested using in vitro cell culture and organ culture models 
in both human and mouse tissue.  
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5.5 Chapter 5: Data 
Figure 5.1 Effect of abolishing type I IFN signalling on murine responses to chronic hypoxia 
 
Figure 5.1 Mice lacking a functional type I IFN receptor (IFNAR1−/−) exposed to hypoxia (10% 
O2) or normoxia (room air) compared with wild-type (C57Bl/6J) mice exposed to the same 
conditions. Data presented as mean ± standard error of the mean (SEM) from n=4 to 15 
mice. Right ventricular systolic pressure (RVSP; mm Hg; (A)), percentage of muscularized 
pulmonary vessels over total number of vessels (B), ratio of right ventricular (RV) mass to 
body weight (BW) (RV/BW; mg/g; (C)), and serum endothelin (ET)-1 levels (pg/mL; (D)) were 
measured. Statistical significance was determined by 1-way ANOVA followed by Bonferroni 
multiple comparison post-test (###P<0.0001 and ##P<0.005 for normoxic vs hypoxic 
conditions) and (***P<0.0001, **P<0.005, and *P<0.05 for IFNAR1−/− vs C57Bl/6J mice). 
 
 
 
C57BL/6J IFNAR1 -/- C57BL/6J IFNAR1 -/-
10
20
30
40
# # #
# # #
2 weeks Hypoxia - 10%O 2Normoxia
*
R
V
S
P
 (
m
m
H
g
)
C57BL/6J IFNAR1 -/- C57BL/6J IFNAR1 -/-
0.50
0.75
1.00
1.25
2 weeks Hypoxia - 10%O 2Normoxia
*
# # #
R
V
/B
W
 (
m
g
/g
)
C57BL/6J IFNAR1 -/- C57BL/6J IFNAR1 -/-
0
1
2
3
4
***
2 weeks Hypoxia - 10%O 2Normoxia
# #
E
T
-1
 (
p
g
/m
l)
C57BL/6J IFNAR1 -/- C57BL/6J IFNAR1 -/-
0
20
40
60
80
100
***
2 weeks Hypoxia - 10%O 2Normoxia
# # #
# # #
***
%
 M
u
s
c
u
la
ri
z
e
d
 v
e
s
s
e
ls
 (
o
v
e
r 
to
ta
l 
n
u
m
b
e
r)
A B 
D C 
 191 
 
Figure 5.2 Histological examples of pulmonary arteries from a C57Bl/6J mouse and an 
IFNAR1-/- mouse after exposure to chronic hypoxia. Tissue stained with elastic Van Gieson 
and α-smooth muscle actin.  
 
Figure 5.2 Histological example of a remodelled pulmonary artery taken from a C57Bl/6J 
mouse exposed to hypoxia (A) and of a normal pulmonary artery taken from an IFNAR1-/- 
mouse exposed to chronic hypoxia (B). 
 
 
B 
A 
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Figure 5.3 Effect of abolishing type I IFN signalling on murine right ventricular responses to 
chronic hypoxia 
 
Figure 5.3 Right ventricular hypertrophy as measured by Fulton’s Index (RV/(LV+Septum)) in 
C57Bl/6J and IFNAR1-/- mice exposed to chronic hypoxia for 14 days. Data expressed as 
mean ± standard error of the mean (SEM) from n=6-8 mice. Statistical significance was 
determined by t-test (*p<0.05).  
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Table 5.1 Baseline cardiovascular physiology comparing wild type and IFNAR1-/- mice taken 
from Tsushima K et al (Tsushima et al., 2011) 
 
C57Bl/6J IFNAR1-/- 
Mean Systemic Blood 
Pressure (mmHg) 
79.6 ± 4.0 82.9 ± 2.8 
Ventricular Weight 
(mg) / Body Weight (g) 
4.45 ± 0.17 4.61 ± 0.12 
Perivascular fibrosis 0.32 ± 0.05 0.14 ± 0.07 
Interstitial fibrosis (%) 0.10 ± 0.03 0.36 ± 0.21 
 
Table 5.1 Table taken from (Tsushima et al., 2011). Quantitative analysis of mean blood 
pressure, ventricular hypertrophy, area of perivascular fibrosis (fibrosis area/lumen area) 
and interstitial fibrosis. Data expressed as mean ± standard error of the mean (SEM) from 
n=3-6 mice and statistical significance (*p<0.05) was determined by one-way ANOVA 
followed by Dunnett’s multiple post-test comparison adjustment. No significant differences 
detected. 
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Figure 5.4 C57Bl/6J murine serum IP10 and ET-1 levels in response to treatment with human 
pegylated IFNα2b (Viraferon™) at 24 hours 
 
Figure 5.4 Mice injected subcutaneously with vehicle control (0.9% NaCl) or human 
pegylated IFNα2b (Viraferon™) at doses of 80 or 800 μg/kg. Serum taken at 24 hours and 
assayed for IP10 (A) and ET-1 (B). Data is presented as mean ± standard error of the mean 
(SEM) from n=4 experiments and statistical significance (*p<0.05) was determined by one-
way ANOVA followed by Dunnett’s multiple comparison post-test adjustment. 
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Figure 5.5 C57Bl/6J murine serum IP10 and ET-1 levels in response to treatment with human 
pegylated IFNα2b (Viraferon™) at 72 hours 
 
Figure 5.5 Mice injected subcutaneously with vehicle control (0.9% NaCl) or human 
pegylated IFNα2b (Viraferon™) at doses of 80 or 800 μg/kg. Serum taken at 72 hours and 
assayed for IP10 (A) and ET-1 (B). Data is presented as mean ± standard error of the mean 
(SEM) from n=4 experiments and statistical significance (*p<0.05) was determined by one-
way ANOVA followed by Dunnett’s multiple comparison post-test adjustment. 
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Figure 5.6 Mouse aorta and lung tissue treated with human and mouse IFNα in organ culture 
experiments  
 
Figure 5.6 IP10 release from mouse aorta (A) after treatment with Human IFNα2 (10ng/ml), 
mouse IFNαA (10ng/ml) and Human Pegylated IFNα2b (Viraferon™) (10ng/ml) and mouse 
lung (B) after variable concentrations of mouse and human IFNα. Data are presented as 
mean ± standard error of the mean (SEM) from n=5 mice. Statistical significance for (A) 
(*p<0.05) was determined using one-way ANOVA followed by Dunnett’s multiple comparison 
post-test adjustment. Statistical significance for (B) (*p<0.05) was determined using two-
way ANOVA followed by Bonferroni’s post-test multiple comparison post-test adjustment. 
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Figure 5.7 Influence of type I IFN signalling on LPS induced ET-1 and IP10 release 
 
Figure 5.7 Mice lacking a functional type I IFN receptor (IFNAR1−/−) injected with either LPS 
or vehicle control for 4 hours and compared with wild-type (C57Bl/6J) mice. Data presented 
as mean ± standard error of the mean (SEM) from n=6 mice. Serum levels of IP10 (A) and ET-
1 (B) were measured. Statistical significance determined by 1-way ANOVA followed by 
Bonferroni multiple comparison post-test (###P<0.0001 for LPS vs Vehicle) and (***P<0.0001 
for IFNAR1−/− vs C57Bl/6J mice). 
C57Bl/6J IFNAR1 -/- C57Bl/6J IFNAR1 -/-
0
5000
10000
15000
20000
Vehicle LPS
***
###
IP
1
0
 (
p
g
/m
l)
C57/BL6J IFNAR1 -/- C57/BL6J IFNAR1 -/-
0
50
100
150
Vehicle LPS
***
###
E
T
-1
 (
p
g
/m
l)
A 
B 
 198 
 
Figure 5.8 Influence of type I IFN signalling on LPS induced IFN and KC release 
 
Figure 5.8 Mice lacking a functional type I IFN receptor (IFNAR1−/−) injected with either LPS 
or vehicle control for 4 hours and compared with wild-type (C57Bl/6J) mice. Data presented 
as mean ± standard error of the mean (SEM) from n=6 mice. Serum levels of IFNα (A), IFNγ 
(B), IFNλ (C), and keratinocyte-derived chemokine (KC) (D) were measured. Statistical 
significance determined by 1-way ANOVA followed by Bonferroni multiple comparison post-
test (###P<0.0001 for LPS vs Vehicle) and (***P<0.0001 for IFNAR1−/− vs C57Bl/6J mice).  
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Chapter 6: General Discussion 
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Exogenous IFN administration and clinical relevance 
In this thesis I have demonstrated that cells of the pulmonary vasculature and 
respiratory epithelium sense and respond to types I and II IFN to release important 
inflammatory and vasoactive mediators. Conversely, type III IFNλ is inactive in all vascular 
and respiratory epithelial cell types but, importantly, displays activity in hepatocytes. These 
findings can be explained by the pattern of types I, II and III receptor expression given that 
the IL-28RA subunit of the type III IFN receptor was found only on hepatocytes and to a 
lesser degree on A549 cells. As previously discussed, the type III IFN receptor is composed of 
a short IL-10Rβ chain that is ubiquitously expressed and is a receptor component of other 
cytokines such as IL-10 and an IL-28RA long chain which is unique to IFNλ.  The insensitivity 
of pulmonary epithelial cells to IFNλ was somewhat unexpected given that conventional 
thinking up until now has dictated that the only tissue types expressing both subunits of the 
type III IFN receptor are hepatocytes and epithelial cells (Sommereyns et al., 2008). 
However in the study by Sommereyns and colleagues, receptor expression in brain and not 
respiratory epithelial cells was investigated. While other studies have shown that mice 
lacking the IL-28RA receptor display increased susceptibility to respiratory syncytial virus 
(Mordstein et al., 2010), to date no study in human respiratory epithelial cells has directly 
demonstrated the presence of IL-28RA. Furthermore, there are species differences in terms 
of responsiveness to IFNλ – for example human and not mouse hepatocytes respond to IFNλ 
in vivo (Hermant et al., 2014) suggesting that receptor expression and IFN activity in mice 
does not always accurately model that in humans. My finding that A549 cells had detectable 
levels of IL-28RA mRNA and yet were unresponsive to IFNλ was interesting. It may suggest 
that a threshold level of the receptor (which is not reached in this cell type) is required for 
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cytokine sensing or that the gene alone and not the protein is expressed. This could have 
been further investigated by assessing protein quantification through the use of Western 
blotting. Another possibility is that receptor expression in pulmonary epithelium is lost in 
culture. It is therefore a further limitation of this thesis that I did not address this using 
primary lung epithelial cells and/or lung parenchyma in organ culture such as I did for 
pulmonary artery segments. 
 The in vitro data described above and more fully in Chapter 3 of this thesis have 
potentially important clinical relevance and may help to explain why therapeutic 
preparations of type I IFN are associated with severe and at times life threatening 
respiratory and cardiovascular side effects. Although differing in their signalling pathways, 
given the parallels between types I and II IFN in terms of in vitro activity on pulmonary cells 
and vessels in culture, I suggest that type II IFNs are likely to display similar pulmonary toxic 
effects to that seen with type I IFN – these may be under recognised given how limited the 
indications are for its clinical use. As there is little clinical information regarding the side 
effects of IFNγ, I will largely focus this part of the discussion on type I IFN and the clinical 
relevance of my in vitro findings.  
As previously discussed, ET-1 is a critical mediator and therapeutic target in PAH and 
IP10 has been implicated in lung inflammation. I have shown that type I IFN can induce both 
IP10 and ET-1 from cells of the pulmonary vasculature and respiratory epithelium. 
Furthermore, in Chapter 4 I have shown that in a cohort of patients infected with HCV, 
exposure to subcutaneously administered pegylated IFNα2a results in raised circulating IP10 
levels, and to a lesser degree, ET-1. As these were archived samples, it was not possible to 
look for any correlation between IP10, ET-1 and respiratory or cardiovascular parameters. 
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However a large recent prospective study has found that almost 50% of patients exposed to 
pegylated IFNα suffer a decline in lung function (Foster et al., 2013) and that this might be 
due to undiagnosed pulmonary vascular disease (George and Mitchell, 2013). Hence it is 
reasonable to speculate that there might be an association between IP10, ET-1 and IFN 
induced pulmonary dysfunction. It is clear that clinically apparent IFN-induced pulmonary 
toxicity/PAH is a severe but rare phenomenon. As demonstrated by Foster and colleagues 
(Foster et al., 2013), it is largely subclinical. The challenge presented therefore is to identify 
which patients will go on to develop the severe manifestations of therapy, which patients 
will suffer with subclinical (although relevant) deteriorations in lung function and which 
patients will be unaffected. Answering this critical question may also help inform us 
regarding mechanisms linking endogenously produced IFNs and PAH although this will be 
discussed more extensively later. In order to answer this question, through the course of my 
PhD I have attempted to initiate a prospective clinical study of patients due to commence 
IFNα therapy for HCV in collaboration with Professor Graham Foster’s group at Queen Mary, 
University of London. I designed the study with a view to longitudinal assessment of serum 
for IP10, ET-1 and other inflammatory cytokines as well as periodic measurement of 
respiratory and cardiovascular parameters. This may have informed as to the true burden of 
IFN induced pulmonary toxicity and would have allowed me to phenotype patients in terms 
of risk stratification for respiratory complications of IFN therapy. I was successful in 
obtaining ethical approval for such a study and submitted the idea for funding to both the 
Medical Research Council and the British Heart Foundation. Although the grant was scored 
highly (by the MRC) and passed initial review by the BHF, at the time of writing I have been 
ultimately unsuccessful in gaining the necessary funding to take this forward.  
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In phase Ib clinical trials pegylated IFNλ-1 has been shown to possess good antiviral 
activity against HCV in chronically infected individuals and is proposed to have an improved 
side effect profile compared to IFNα due to the limited distribution of its receptor  (Muir et 
al., 2010).  In my hands, IFNλ-1 appeared to be essentially inert when applied to lung cells in 
vitro and pulmonary vessels in culture. Recently published work has confirmed my findings 
that while human hepatocytes respond to IFNλ to release IP10, other cell types (in this study 
monocytes and lymphocytes) could not be activated (Dickensheets et al., 2013). In this study 
and my own work, IP10 release stimulated by IFNλ was lower than that by IFNα although 
this does not appear to have a detrimental effect on the antiviral capacity of IFNλ which 
appears equivalent to that of IFNα (Muir et al., 2010). This would suggest that IFNλ may well 
have a propensity to an improved side effect profile than IFNα, potentially sparing the lungs 
making it an attractive therapeutic option; the results of Phase II and III clinical trials are 
eagerly awaited. The most recent update in the treatment of HCV is the advent of two new 
class of drugs. There are three protease inhibitors – boceprevir, telapravir and simeprevir   
with US FDA approval for the treatment of genotype I HCV in combination with IFNα and 
ribavirin. There is one HCV NS5B polymerase inhibitor, sofosbuvir which has been recently 
shown to have efficacy in patients with HCV genotypes 2 or 3. As the pulmonary side effects 
of the IFNs are relatively rare and in many cases subclinical, it would be prudent to test the 
effects of these drugs in vitro in combination with IFNα so as to be able to predict their 
potential for toxicity. 
In this thesis, I have focussed upon the effects of IFNs on the lungs and the 
pulmonary circulation but it would be remiss to ignore the systemic circulation. The ability 
for extra-pulmonary vascular cells to sense IFNs was beyond the scope of my studies and in 
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truth is not yet fully characterised. It is known that endothelial cells (Indraccolo et al., 2007) 
and vascular smooth muscle cells (Woods et al., 1998) from systemic vessels do respond to 
IFNs. Although these observations illustrate that IFNs may not discriminate between 
pulmonary and systemic vessels, particularly in healthy individuals, it is known that vessels 
that are primed for proliferation and remodelling such as those in the hypertensive lung, 
respond profoundly to inflammatory stimuli (Stenmark et al., 2006). In addition, as the 
pulmonary circulation is a low pressure system, small changes to vascular resistance convey 
far greater clinical significance than they would do in the higher pressure systemic 
circulation.  
Endogenous IFNs and clinical relevance 
 I have established that exogenously administered IFNs induce ET-1 and IP10 in cells 
and in patients and I have speculated that this might underpin the mechanisms behind IFN 
induced PAH. Given that SSc and HIV are two conditions which are strongly associated with 
PAH and that both are typified by continued type I IFN activation, I went on to form the 
hypothesis that chronic endogenously raised type I IFNs may play a pathological role in the 
development of PAH and that this might be mediated by IP10 and/or ET-1. Using IP10 as a 
surrogate marker of IFN activation, I found that there exists a strong relationship between 
IP10 and ET-1 in patients with SSc-PAH as well as IP10 and a number of clinical and 
haemodynamic parameters. It was necessary to use IP10 as a marker of IFN activity as 
serum IFN levels were generally low (although higher in the PAH group than in controls). 
This was not unexpected as it is well established that serum IFN levels may not accurately 
represent cytokine activity at the tissue level and that only a fraction of the total amount of 
IFNα is in steady state in the circulation (Prinz et al., 2008). The half-life of IFNα is 
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approximately 10 minutes and levels in the circulation are low due to dilution in bodily 
fluids, diffusion from plasma to extracellular fluid compartments, binding to receptors and 
prompt catabolism by the kidneys, liver, muscle and lungs (Bocci, 1981). Notwithstanding 
this, IFNα levels in the SSc-PAH group were detectable in a proportion of patients but none 
of the healthy controls. Detectable circulating levels reflect increased tissue activity and so 
serum levels can only provide a representative impression of the dynamic ongoing balance 
between production and excretion. 
 As discussed above, the biological consequences of increased IFN levels are not only 
governed by circulating levels and tissue concentrations but also by the degree of receptor 
expression. Of the three IFN receptors examined (IFNAR1, IFNGR1 and IL28RA), the most 
marked increase observed in the level of staining between SSc-PAH patients and controls 
was with the type I IFN receptor IFNAR1. This suggests that type I IFN is the dominant IFN in 
the pathogenesis of SSc-PAH and may be responsible for driving the raised IP10 response 
observed in serum. Unexpectedly, IFNAR1 expression was also raised in patients with IPAH 
and not solely those with SSc-PAH. Although there is a school of thought that IPAH may 
have an autoimmune component, this has not been definitively proven and so the notion 
that IFN signalling may play a pathological role in this condition is a novel concept. IFNAR1 
protein quantification from total lung homogenate revealed that while all IPAH patients had 
significantly raised levels, there exists heterogeneity in the levels observed in SSc-PAH 
patients. It is known that all patients with SSc-PAH display histological features of 
pulmonary arterial inflammation with varying degrees of pulmonary venous occlusive 
disease. It is also established that those patients with a greater degree of venous disease as 
opposed to arterial disease are less responsive to targeted PAH therapies. This observation 
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led me to hypothesise that those SSc-PAH patients with higher IFNAR1 levels might be those 
whose pulmonary vascular disease more closely resembles an IPAH morphology with 
transmural inflammatory infiltrates and intimal thickening whereas those with lower total 
lung IFNAR1 levels may have a greater burden of venous disease. This did indeed appear to 
be the case in the six lung samples examined; the three SSc-PAH patients with high gross 
lung IFNAR1 expression displayed profound arterial inflammation and intimal fibrosis 
(features consistent with IPAH) and the three with low IFNAR1 expression had a 
predominance of venous involvement with fibrotic occlusive remodelling. It would have 
been very interesting to measure IP10 levels in the serum of the patients whose lung 
samples were examined for IFN receptor expression. If serum IP10 values are found to 
corroborate with lung IFNAR1 expression, the prospect that serum IP10 could be a marker 
of pulmonary arterial inflammation and remodelling is potentially clinically exciting. At the 
moment there is no means by which clinicians can identify which SSc-PAH patients will 
respond positively to PAH therapies and indeed which will deteriorate as a direct result of 
treatment. If IP10 could be shown to be a serum marker of lung IFNAR1 expression, it could 
potentially be measured to assess which patients should receive targeted therapies. 
Furthermore, if serum IP10 levels fall in line with treatment response and an improvement 
in pulmonary vascular resistance, it could have potential as a biomarker of disease.   
 The question as to whether IP10 is a direct mediator of disease with pathogenic 
potential or is solely an indicator of IFN activation was not tested in this thesis. If time had 
permitted, I could have addressed this question through a number of means. In vitro, it 
would have been interesting to measure the effect of exogenous IP10 administration on 
vascular smooth muscle and endothelial cell proliferation. The receptor for IP10 is CXCR3 
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and there exists a selective receptor blocker SCH 546738. This antagonist has recently been 
shown to reduce disease severity in mouse models of autoimmune disease as well as reduce 
CXCR3 mediated chemotaxis in vitro (Jenh et al., 2012). Using a similar strategy,  it would 
have been possible to investigate the direct role of IP10 in animal models of pulmonary 
hypertension by administering SCH 546738 to mice exposed to chronic hypoxia. Another 
approach could have been to assess the response of CXCR3 knockout mice to chronic 
hypoxia and it has previously been demonstrated that CXCR3 knockout mice are protected 
from smoke-induced pulmonary inflammation and that CXCR3 mediates the recruitment of 
inflammatory cells into the airways and lungs (Nie et al., 2008). In lung sections of patients 
with PAH (both SSc-PAH and IPAH), it would have been interesting look for CXCR3 staining 
using immunohistochemistry and also to quantify protein with Western blotting. Indeed 
lung CXCR3 expression at both the gene and protein level has been shown to be increased in 
patients with PAH and it has been demonstrated that IP10 mediates endothelial dysfunction 
by disrupting calcium homeostasis (Zabini et al., 2012). This leads me to conclude that with 
the caveat that such an approach does not predispose to an increased incidence of sepsis, 
therapeutic blockade of the IP10 receptor, CXCR3, may have potential in the treatment of 
inflammatory diseases of the lung including pulmonary vascular inflammation.  
 The in vitro and clinical data presented in Chapters 3 and 4 is consistent with the 
hypothesis that IFN has a role in driving pulmonary vascular inflammation and PAH. 
However, in order to provide more conclusive proof for a direct association between IFN 
and PAH, and to allow further investigation of the mechanisms involved, I employed the use 
of an animal model of disease. Of the six IFN receptor subunits examined through 
immunohistochemistry, IFNAR1 demonstrated the most marked difference between PAH 
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patients and controls. Furthermore, a recent study has found that the two type I IFN 
receptor subunits have differing functions and that IFNAR1 (and not IFNAR2) via an IFNAR1-
IFN complex can independently transduce pro-inflammatory signals under the control of 
type I IFN (de Weerd et al., 2013). I therefore chose to explore the effect of type I IFN 
signalling on the development of PAH by investigating the response to chronic hypoxia of 
genetically modified mice lacking functional IFNAR1. I found that type I IFN signalling 
mediates the deleterious effects of hypoxia on the pulmonary vasculature, on the right 
ventricle and on increased serum ET-1 levels. In Chapter 3, I have demonstrated that ET-1 
can be driven by type I IFN in vitro and in Chapter 4, I suggest that IFN can drive the release 
of ET-1 in some individuals. However, it has never previously been proven in vivo that IFN 
can drive ET-1 production. The data generated from the chronic hypoxia mouse model of 
pulmonary hypertension in Chapter 5 suggests that this might be the case but does not 
provide definitive proof. An alternative explanation could be that the amelioration in 
pulmonary vascular pathology and right ventricular dysfunction observed in the IFNAR1-/- 
mice exposed to hypoxia might in itself cause a reduction in ET-1 release. I therefore wished 
to prove a causal relationship between type I IFN and ET-1 production in vivo. Given the lack 
of a pegylated mouse IFNα and the insensitivity of human IFNα in mice, I was unable to 
create a novel mouse model of exogenously administered IFN induced ET-1 release in vivo. I 
therefore addressed this hypothesis using an LPS model of ET-1 release. As discussed earlier, 
LPS via TLR4 activates TRIF and MyD88. I found that IP10 and not KC induced by LPS was 
mediated by IFNAR1. Importantly, LPS-induced ET-1 release, like IP10, was dependent on 
IFNAR1. This data implicates TRIF pathways and IFN signalling in the generation of ET-1, 
adds weight to the body of evidence demonstrated in this thesis implicating type I IFN in 
PAH and is also the first in vivo demonstration of ET-1 as an IFN dependent hormone.  
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 Despite being inactive in all cell types tested except for hepatocytes, it was an 
unexpected finding that IFNλ was the most readily measured IFN in the serum of patients 
with SSc-PAH. This led me to consider whether IFNλ could in some way play a pathological 
role in PAH. Having demonstrated a lack of effect for IFNλ in all cells in culture barring 
hepatocytes and explained this finding through a relative absence of IL-28RA, I wished to 
exclude the possibility that cells in culture might display an altered phenotype and 
experience down regulation of IL-28RA. I therefore assessed the activity of all three IFN 
classes on segments of freshly harvested pulmonary artery. These data corroborated the 
data from cultured cells in that only IFNs –α and –γ induced IP10 release from whole vessel 
while IFNλ remained inactive. Immunohistochemistry on lung sections from patients with 
SSc-PAH revealed a predominance of IL-28RA within the lung epithelium and not within 
remodelled pulmonary arteries. Furthermore, despite the relative presence of IL-28RA 
mRNA in A549 cells, neither this cell type nor a further two lung epithelial cell types 
responded to IFNλ even in the presence of TNFα. In mice, LPS induced release of IFNα, IFNγ, 
ET-1, IP10 and KC but not IFNλ. Importantly, in mice lacking type I IFN signalling, LPS-
induced release of IFNα, IFNγ, ET-1 and IP10 was significantly abrogated. This suggests that 
ET-1 production is mediated by type I IFN via IFNAR1 but is independent of IFNλ. In 
conclusion, I suggest that although IFNλ is raised in the serum of SSc-PAH patients, it does 
not play a pathological role. Elevated systemic type I IFN induces the expression of many 
IFN-stimulated genes including IFNλ. Some such as ET-1 (and possibly IP10) play an 
important immunopathological role while others such as IFNλ are not involved in the 
disease process and it might be that their upregulation reflects ongoing type I IFN activation. 
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Innate immune dysfunction and PAH 
 Ligation of TLR3 induced ET-1 from cells of the pulmonary vasculature and using 
immunohistochemistry, TLR3 was shown to be upregulated in the lungs of patients with 
PAH. In vivo, TLR3 activation recognises double stranded and single stranded RNA viruses to 
activate TRIF pathways and induce the production of type I IFN. I found that TLR3 induced 
ET-1 release in vitro appeared to be independent of IFN since other than IFNλ release from 
HLFS, none of the IFNs could be measured in cell culture supernatant after Poly(I:C) 
treatment. I suggest that this does not conclusively rule out the possibility that ET-1 release 
in this circumstance is indeed related to type I IFN. It is possible for example that the 
concentration of IFNs released into the cell culture is too low to be measured but sufficient 
to exert an effect. Another explanation is that all of the type I IFN produced by the cell acts 
upon its receptor and is then internalised so that by the 24 hour time point of supernatant 
collection, there is none left in the conditioned medium. This could have been investigated 
by measuring IFN levels in supernatant at earlier time points.   
Viruses such as HHV-8 and possibly EBV have long been implicated in the 
pathogenesis of PAH although much of the evidence for this is circumstantial and the case is 
far from proven  (Cool et al., 2011).  However HIV is definitely associated with PAH (Sitbon 
et al., 2008), and there is evidence emerging that HIV is sensed by TLR3 to result in ISG 
induction and IP10 release (Miyauchi et al., 2012). This represents a plausible means by 
which HIV infection is associated with the development of PAH. In addition, as well as 
sensing and responding to pathogens, TLRs can be activated when they bind to non-
infectious activating proteins– DAMPs. Autoimmune diseases such as SSc and maybe even 
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IPAH are typified by circulating material of this nature and I hypothesise that TLR3 activation 
within the pulmonary vasculature may play a role in the pathogenesis of PAH in this way. 
Dendritic cells and in particular PDCs are the major source of type I IFN and have 
long been implicated in autoimmune conditions which have a type I IFN signature. CXCL4 is 
also produced primarily by PDCs and so the finding that CXCL4 augments IFNα activity in the 
production of ET-1 from pulmonary artery smooth muscle cells is intriguing and highlights 
dendritic cells as a central immune cell in PAH. Furthermore, CXCL4 also potentiated the 
activity of the TLR3 agonist Poly(I:C) and so although I have not demonstrated this, I 
hypothesise that continued TLR3 activation by DAMPs or autoantibodies results in ongoing 
type I IFN and CXCL4 production. There may then exist an amplification mechanism by 
which type I IFN and CXCL4 responses are augmented to release ET-1 from the pulmonary 
vasculature leading to a smooth muscle proliferation, vasoconstriction and a PAH disease 
phenotype. In this way I consider that continued dysregulated innate immunity leads to 
pulmonary vascular inflammation and in some individuals, PAH (Fig. 6.1). 
Future direction of research 
 I have shown that activation of key players in the innate immune response to viruses 
might have an important role to play in the pathology of PAH (Fig. 6.1). Whilst I have been 
able to explore the interplay between IFNs and the pulmonary vasculature, had time 
allowed, I would have liked to also focus on the effects of TLR3 and CXCL4 on pulmonary 
vascular pathology using further experimental models. It would have been interesting to 
treat cells with Poly(I:C) and IFNAR1 antagonists to establish whether the ET-1 induction 
seen with TLR3 ligation is truly IFN independent. It would also have been fascinating to 
explore the response to chronic hypoxia of genetically modified mice lacking TLR3 and in 
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separate experiments those lacking CXCL4 with the hypothesis that these would be 
protected from developing PAH. 
As a result of data presented in this thesis, there are a number of clinically relevant 
and potentially beneficial therapeutic strategies that could be employed in future. A number 
of companies are in the early stages of development of anti-IFNα therapies for the 
treatment of systemic lupus erythematosus (SLE) and these take the form of either anti-
IFNα neutralising antibodies or type I IFN receptor antagonists (Kirou and Gkrouzman, 
2013). Many of these have now passed safety studies and the most developed of these 
drugs is Sifalimumab (a human anti-IFNα monoclonal antibody) which binds to and 
specifically neutralises most IFNα subtypes preventing signalling through IFNAR1; in dose 
escalation studies this drug has been tolerated well with no safety concerns (Petri et al., 
2013). Thus far, targeting type I IFN therapeutically has been limited to trials in SLE. The data 
presented in this thesis provides the rationale for clinical trials of such drugs in the 
treatment of SSc-PAH and possibly IPAH. 
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Figure 6.1 Summary of thesis findings providing a link between innate immunity and PAH 
 
Figure 6.1 Presented here is a hypothesised schematic showing the link between innate 
immunity and PAH. The process is initiated by activation of toll like receptor 3 (TLR) by 
pathogens or circulating non-infectious immune proteins such as autoantibodies; danger 
associated molecular patterns (DAMPs). Although I have not formally demonstrated this, it is 
known that TLR3 activation on immune cells such as dendritic cells results in the generation 
of type I IFN and CXCL4. Type I IFN signals via the type I IFN receptor which comprises 
IFNAR1 and IFNAR2 subunits. TNFα is mainly produced by macrophages and together with 
type I IFN and potentially CXCL4, stimulate cells of the pulmonary vasculature to generate 
IP10 and ET-1. IP10 can mediate endothelial dysfunction and ET-1 is a promitogen and 
vasoconstrictor acting primarily on the vascular smooth muscle to cause cellular 
proliferation resulting in intimal muscularisation and pulmonary vascular remodelling. As the 
smooth muscle layer expands and cell numbers increase, the main source of ET-1 becomes 
the smooth muscle which acts in an autocrine fashion to respond to IFN stimulation. In situ 
thrombosis follows and this aberrant process of cellular hyperproliferation leads to the 
characteristic plexiform lesions. With time, pulmonary vascular resistance increases with 
consequent effects on the right ventricle. Patients start to become symptomatic at this point 
and report breathlessness and a reduced capacity for exercise. As the disease progresses the 
right ventricle starts to fail and eventually death occurs from heart failure. On the basis of 
the work performed in this thesis, suggested future therapeutic targets and/or biomarkers of 
disease are contained within light blue circles.   
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Conclusion: 
Through a variety of in vitro and in vivo models, in this thesis I have been able to 
demonstrate that types I and II but not type III IFN activate human pulmonary cells and 
whole pulmonary artery to release vasoactive mediators. I have hypothesised that this may 
be of relevance to IFN drug induced pulmonary toxicity. I have then proven that endogenous 
type I IFN signalling and activation drives the development of PAH associated with systemic 
sclerosis and may have a role to play in other forms of the disease such as in IPAH. In 
associated experiments I have shown that TLR3 is upregulated in the lungs of patients with 
PAH and activation of pulmonary cells with a TLR3 agonist induces ET-1 release. Finally I 
have shown that CXCL4 augments IFN and TLR3 agonist responses highlighting the 
importance of innate immunity and dendritic cells in the pathogenesis of this devastating 
condition. These data lead me to hypothesise that modulation of type I IFN signalling 
pathways may be of therapeutic benefit in the treatment of PAH and allow me to conclude 
that type I IFN drives the pathogenesis of PAH. 
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